var title_f12_29_12752="Pathogenesis of SBP";
var content_f12_29_12752=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F52311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F52311&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 484px\">",
"   <div class=\"ttl\">",
"    Mechanisms that may be involved in the pathogenesis of spontaneous bacterial peritonitis",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 464px; height: 577px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     BA: bactericidal activity; CNNA: culture-negative neutrocytic ascites; SBP: spontaneous bacterial peritonitis.",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from Such J. Clin Infect Dis 1998; 27:669. Copyright &copy; 1998 University of Chicago Press.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12752=[""].join("\n");
var outline_f12_29_12752=null;
var title_f12_29_12753="FAST hepatorenal right flank probe position";
var content_f12_29_12753=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=EM%2F62976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=EM%2F62976&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 524px\">",
"   <div class=\"ttl\">",
"    FAST: Hepatorenal (right flank) probe position",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 504px; height: 334px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This image shows proper probe position for obtaining a view of Morisons pouch (hepatorenal interface).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Manoj Pariyadath, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12753=[""].join("\n");
var outline_f12_29_12753=null;
var title_f12_29_12754="Patient information: Community-acquired pneumonia in adults (The Basics)";
var content_f12_29_12754=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"1\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16993\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"         Pneumonia",
"        </a>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?32/47/33522\">",
"         Patient information: Flu (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?35/18/36130\">",
"         Patient information: Pneumonia in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?6/46/6883\">",
"         Patient information: Shortness of breath (dyspnea) (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?11/48/12035\">",
"         Patient information: Vaccines (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?29/38/30308\">",
"         Patient information: Pneumonia in adults (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?13/57/14225\">",
"         Patient information: Pneumonia prevention (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: Community-acquired pneumonia in adults (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/community-acquired-pneumonia-in-adults-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H10513233\">",
"      <span class=\"h1\">",
"       What is pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Pneumonia is a lung infection that can cause coughing, fever, and trouble breathing (",
"      <a class=\"graphic graphic_figure graphicRef55943 \" href=\"UTD.htm?10/3/10294\">",
"       figure 1",
"      </a>",
"      ). The lung infection is usually caused by bacteria, but it can also be caused by viruses or other germs.",
"     </p>",
"     <p>",
"      Doctors use the term &ldquo;community-acquired&rdquo; when a person catches an infection in their daily life, and not from being in the hospital. Doctors call it &ldquo;hospital-acquired&rdquo; when people catch an infection from being in the hospital.",
"     </p>",
"     <p>",
"      Community-acquired pneumonia can be mild or severe. A mild infection is sometimes called &ldquo;walking pneumonia.&rdquo; That&rsquo;s because most people with walking pneumonia are not very sick and can still walk around and do their daily activities.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513248\">",
"      <span class=\"h1\">",
"       What are the symptoms of community-acquired pneumonia?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Common symptoms include:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Cough &ndash; People sometimes cough up mucus (sputum).",
"       </li>",
"       <li>",
"        Fever",
"       </li>",
"       <li>",
"        Chest pain, especially when taking a deep breath",
"       </li>",
"       <li>",
"        A fast heartbeat",
"       </li>",
"       <li>",
"        Shaking chills",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513263\">",
"      <span class=\"h1\">",
"       Should I see a doctor or nurse?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. If you have the symptoms listed above, see a doctor or nurse as soon as possible.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513278\">",
"      <span class=\"h1\">",
"       Will I need tests?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Probably. Your doctor or nurse will ask about your symptoms and do an exam. He or she will probably do a chest X-ray to look for an infection in your lungs.",
"     </p>",
"     <p>",
"      Depending on your individual situation, you might need other tests. These can include blood tests or lab tests on a sample of mucus that you cough up.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513293\">",
"      <span class=\"h1\">",
"       How is community-acquired pneumonia treated?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Doctors treat community-acquired pneumonia with antibiotic medicines. These medicines kill the germs that are causing the infection. Most people can take antibiotic pills at home, but some people need to be treated in the hospital. People who are treated in the hospital get antibiotics into their vein through a tube called an &ldquo;IV.&rdquo;",
"     </p>",
"     <p>",
"      Some people also get extra oxygen to help them breathe more easily.",
"     </p>",
"     <p>",
"      Most people start to feel better within 3 to 5 days of taking their medicine. But a cough from pneumonia can last weeks or months after treatment.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513308\">",
"      <span class=\"h1\">",
"       Is there anything else I can do to take care of myself?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Yes. You can:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        Get plenty of rest",
"       </li>",
"       <li>",
"        Drink plenty of fluids",
"       </li>",
"       <li>",
"        Take a fever-reducing medicine, if you have a fever",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513323\">",
"      <span class=\"h1\">",
"       What can I do to keep from getting pneumonia again?",
"      </span>",
"      &nbsp;&mdash;&nbsp;To avoid germs, you can wash your hands often with soap and water, or use alcohol hand rubs.",
"     </p>",
"     <p>",
"      You can also get certain vaccines to help keep you from getting pneumonia again. Vaccines are treatments that can prevent serious infections. Depending on your individual situation, your doctor might recommend that you get the pneumococcal vaccine. This can help keep you from getting an infection from the kind of bacteria that most commonly causes pneumonia.",
"     </p>",
"     <p>",
"      Most adults should also get the flu vaccine every year.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H10513338\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=see_link\">",
"       Patient information: Pneumonia in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=see_link\">",
"       Patient information: Shortness of breath (dyspnea) (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=see_link\">",
"       Patient information: Flu (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=see_link\">",
"       Patient information: Vaccines (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=see_link\">",
"       Patient information: Pneumonia in adults (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=see_link\">",
"       Patient information: Pneumonia prevention (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?12/29/12754?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16993 Version 1.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-203.80.222.8-558F5CFEDC-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12754=[""].join("\n");
var outline_f12_29_12754=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513233\">",
"      What is pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513248\">",
"      What are the symptoms of community-acquired pneumonia?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513263\">",
"      Should I see a doctor or nurse?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513278\">",
"      Will I need tests?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513293\">",
"      How is community-acquired pneumonia treated?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513308\">",
"      Is there anything else I can do to take care of myself?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513323\">",
"      What can I do to keep from getting pneumonia again?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10513338\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16993\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/3/10294\">",
"      Pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?32/47/33522?source=related_link\">",
"      Patient information: Flu (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?29/38/30308?source=related_link\">",
"      Patient information: Pneumonia in adults (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?35/18/36130?source=related_link\">",
"      Patient information: Pneumonia in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?13/57/14225?source=related_link\">",
"      Patient information: Pneumonia prevention (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?6/46/6883?source=related_link\">",
"      Patient information: Shortness of breath (dyspnea) (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?11/48/12035?source=related_link\">",
"      Patient information: Vaccines (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12755="Inguinal syndrome in LGV";
var content_f12_29_12755=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F61366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F61366&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Inguinal syndrome in lymphogranuloma venereum",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 270px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The characteristic \"groove\" sign is seen in this man with inflammed superficial and deep inguinal lymph nodes. These may go on to rupture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced from the Centers for Disease Control and Prevention.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12755=[""].join("\n");
var outline_f12_29_12755=null;
var title_f12_29_12756="Aluminum hydroxide: Patient drug information";
var content_f12_29_12756=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Aluminum hydroxide: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=see_link\">",
"     see \"Aluminum hydroxide: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=see_link\">",
"     see \"Aluminum hydroxide: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F132475\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      ALternaGel&reg; [OTC];",
"     </li>",
"     <li>",
"      Dermagran&reg; [OTC]",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F132476\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Amphojel&reg;;",
"     </li>",
"     <li>",
"      Basaljel&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10013914\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700602",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sometimes drugs are not safe when you take them with certain other drugs. Taking them together can cause bad side effects. This is one of those drugs. Be sure to talk to your doctor about all the drugs you take.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10013916\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691408",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower high phosphate levels.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691873",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to treat heartburn and upset stomach.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10013915\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701477",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to aluminum or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10013920\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696895",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take other drugs within 1 hour of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697636",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are breast-feeding. You will need to talk about any risks to your baby.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10013921\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696432",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Bad taste in your mouth. This most often goes back to normal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697978",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Hard stools (constipation). Drinking more liquids, working out, or adding fiber to your diet may help. Talk with your doctor about a stool softener or laxative.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10013923\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699014",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very hard stools (constipation).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699105",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any bruising or bleeding.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10013918\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695733",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take 1 to 3 hours after meals as an antacid.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694329",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a liquid (suspension) if you cannot swallow pills. Shake well before use.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696107",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Those who have feeding tubes may also use the liquid. Flush the feeding tube before and after this drug is given.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694818",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Drink lots of noncaffeine liquids unless told to drink less liquid by your doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10013919\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696563",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696540",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Many times this drug is taken on an as needed basis.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10013924\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10013925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11414 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-89.32.226.102-21F53BA666-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12756=[""].join("\n");
var outline_f12_29_12756=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132475\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F132476\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013914\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013916\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013915\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013920\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013921\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013923\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013918\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013919\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013924\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10013925\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?27/16/27910?source=related_link\">",
"      Aluminum hydroxide: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/36/21062?source=related_link\">",
"      Aluminum hydroxide: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12757="DCM anatomy PI";
var content_f12_29_12757=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F58474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F58474&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 588px\">",
"   <div class=\"ttl\">",
"    Heart with dilated cardiomyopathy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 568px; height: 398px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The heart on the left is normal. The heart on the right has dilated cardiomyopathy. In people with the condition, the chambers of the heart become enlarged (especially the left ventricle). In some cases, the walls of heart also become thin.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12757=[""].join("\n");
var outline_f12_29_12757=null;
var title_f12_29_12758="Nail surgery";
var content_f12_29_12758=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Nail surgery",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Barbara M Mathes, MD, FACP, FAAD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Russell S Berman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Robert P Dellavalle, MD, PhD, MSPH",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12758/contributors\">",
"     Rosamaria Corona, MD, DSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/29/12758/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 3, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail disorders, particularly ingrown, incurved, pincer, hypertrophic, infected, and painful nails, are common conditions in adults (",
"    <a class=\"graphic graphic_picture graphicRef60056 graphicRef59295 graphicRef67968 \" href=\"UTD.htm?3/4/3146\">",
"     picture 1A-C",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/1\">",
"     1",
"    </a>",
"    ]. Although abnormalities of nails can be disfiguring, it is usually pain that brings the patient to the physician. Most asymptomatic nail disorders affect the toenails, but the fingernails can be affected as well. A variety of relatively simple approaches to nail problems can prevent or alleviate symptoms, and others may correct or cure the underlying problem.",
"   </p>",
"   <p>",
"    Nail anatomy and common office procedures performed on the nails are described here. The routine treatment of ingrown toenails is reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=see_link\">",
"     \"Paronychia and ingrown toenails\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     NAIL ANATOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;A basic knowledge of nail anatomy is helpful in understanding nail disorders and their surgical treatment. The nail is an anatomic unit comprising the nail plate, nail bed, and matrix (",
"    <a class=\"graphic graphic_figure graphicRef76994 \" href=\"UTD.htm?24/43/25267\">",
"     figure 1",
"    </a>",
"    ). The nail plate is the hard, keratinized portion of nail (fingernail or toenail) that is typically convex or flat and sits on top the distal phalanx. It is the \"growing\" portion of the nail unit and the cause of most symptomatic problems. Toenails are more convex than fingernails.",
"   </p>",
"   <p>",
"    The nail plate is firmly attached to the underlying nail bed and is bordered laterally by the lateral nail folds. Proximally, the nail is bordered by the proximal nail fold and a contiguous eponychium known as a cuticle.",
"   </p>",
"   <p>",
"    Proximal to the nail bed is the matrix, the portion of the unit from which most of the nail plate originates. The distal portion of the matrix can be seen under the nail plate as the lunula or \"half-moon\" of the nail.",
"   </p>",
"   <p>",
"    The vascular supply to the nail unit is provided by an anastomosing, arching network of arterioles extending from the digital arteries; venous drainage is through bilateral, proximal nail fold veins. The nail unit is richly innervated by nerves coursing alongside the digital arteries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/2,3\">",
"     2,3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The entire nail unit lies atop the distal phalanx; thus, bony changes including degenerative, inflammatory, and traumatic can affect the growth and appearance of the nail. Because the nail is an epidermal appendage, conditions that affect the epidermis, including psoriasis, lichen planus, dermatitis, and superficial fungal infections, can also affect the nail unit, thereby altering the appearance of the nail plate and bed. Nail plate growth is faster in fingernails than toenails, averaging 0.1 mm per day or 1.0 cm per three months. Nail growth slows with age and with vascular insufficiency and can be interrupted partially or completely by systemic processes including fever, surgery, significant illness, and medications.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PARING, TRIMMING, AND GRINDING",
"    </span>",
"    &nbsp;&mdash;&nbsp;Toenail paring, trimming, and grinding are commonly performed by physicians and podiatrists on patients with diabetes or those who have physical limitations that prevent their ability to perform routine nail care. Paring and trimming can be performed with regular nail clippers, but heavy duty nail nippers are recommended because the slow-growing nails of older patients result in a very thick, tough nail plate requiring the anvil-handled device for satisfactory trimming (",
"    <a class=\"graphic graphic_picture graphicRef86021 \" href=\"UTD.htm?31/15/31984\">",
"     picture 2A",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Over the years, a variety of techniques including cutting the distal nail square, angling the edges, or creating a \"V\" in the center, have been advocated. After trying many techniques, I prefer to customize the shape of the nail trim to its problems, most often shaping the distal edge to the toe shape. The nails are trimmed to leave 2 to 3 mm of free nail plate, then an emery board is used to file down sharp edges that may accidentally catch on stockings and lift the nail plate from the bed.",
"   </p>",
"   <p>",
"    An ingrown portion of a nail plate deeply embedded into the lateral soft tissue can be removed by placing the tip of the nipper under the \"ingrown\" edge and cutting it free. This simple procedure can temporarily provide pain relief for several weeks.",
"   </p>",
"   <p>",
"    Sometimes nails are too thick and too dystrophic for nippers alone (",
"    <a class=\"graphic graphic_picture graphicRef76809 \" href=\"UTD.htm?4/33/4626\">",
"     picture 3",
"    </a>",
"    ); in this case, nail grinders are essential (",
"    <a class=\"graphic graphic_picture graphicRef86022 \" href=\"UTD.htm?31/61/32735\">",
"     picture 2B",
"    </a>",
"    ). Grinders are drills with specially designed bits that grind and sand down the hyperkeratotic material. Grinding and sanding can eliminate a considerable amount of thick keratin, which often substantially reduces pain by removing the hard, inflexible keratin driving into the underlying soft tissue.",
"   </p>",
"   <p>",
"    Eye protection and a surgical mask or plastic face shield covering the entire face are advised when paring and grinding nails; bits of nail may fly off when cut, and the powdery nail, often infected with fungal elements, is aerosolized.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no specific care advised after simple trimming, paring, or grinding, although applying a cream or lotion containing 20 percent to 25 percent urea (eg, Ultramide, Baker Cummins Dermatology, Miami, FL, and Carmol, Doak Dermatologics, Fairfield, NJ) daily to the nail plate helps prevent excessive thickening. If, while removing an imbedded portion of nail, the skin is broken by the nail, a topical antibiotic covered with an adhesive bandage and washing of the site daily are recommended until there is complete healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     NAIL AVULSION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail avulsion is a procedure whereby all or a portion of the nail plate is removed from the nail bed. Avulsions are done for diagnostic and therapeutic purposes. Avulsing the nail plate allows examination and visualization of lesions in the underlying nail bed and matrix. Nail avulsions are sometimes performed when treating onychomycosis, because some physicians believe topical application of antifungal agents along with systemic therapy enhances therapeutic response, although good supportive data are lacking. Avulsions are most frequently done for ingrown and incurved nails.",
"   </p>",
"   <p>",
"    Sometimes nails are avulsed traumatically. When there is partial traumatic avulsion, the nail can be trimmed short and covered with an adhesive bandage to prevent \"catching\" and further traumatic avulsion. An effort should be made to maintain as much of the remaining adherent nail plate as possible so as to prevent further damage to, and keratinization of, the nail bed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Nail avulsion is extremely painful and requires adequate anesthesia for optimal results. To begin, the patient should be in a recumbent position. Anesthesia is provided by a digital block or wing block, supplemented with local injections. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    While waiting for the anesthesia to take effect, the digit can be soaked in an antiseptic bath (povidone-iodine or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?12/36/12870?source=see_link\">",
"     chlorhexidine",
"    </a>",
"    ). Before beginning the procedure, test for adequacy of anesthesia by inserting a needle into the digital tip and under the nail.",
"   </p>",
"   <p>",
"    To begin, the operator holds the digit to keep it stable during the procedure. A narrow dental spatula, a thin small elevator (Freer septum elevator) (",
"    <a class=\"graphic graphic_picture graphicRef86023 \" href=\"UTD.htm?36/61/37855\">",
"     picture 4",
"    </a>",
"    ), or a straight mosquito hemostat is then placed under the distal edge of the plate (",
"    <a class=\"graphic graphic_picture graphicRef86024 \" href=\"UTD.htm?40/6/41063\">",
"     picture 5",
"    </a>",
"    ). Advance the instrument longitudinally toward the matrix in the natural cleavage plane, stopping in the area of the proximal nail groove (the tissue forming the proximal wall of the nail matrix). Some force is initially required to advance the instrument, but then it becomes relatively easy to advance until the proximal nail groove is reached. When performing a complete avulsion, the maneuver is repeated under a new section of nail plate, and the instrument is also moved in a side-to-side fashion, until the entire plate is freed from underlying nail bed and adjacent nail folds. The same instrument is then placed on top of the nail plate under the lateral and proximal nail folds to break these attachments. The free distal edge of the nail is then grasped with a hemostat and pulled out with a side-to-side or twisting motion. Any strands of epithelium can be snipped with small scissors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/2-4\">",
"     2-4",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    With partial avulsions, the instrument is advanced as before under the nail plate longitudinally until the nail groove is reached; however, the separation of the nail plate from the nail bed is confined to the width of the plate that needs to be removed. After this is accomplished, the surface nail attachments at the lateral fold are lysed as before. A nail splitter (",
"    <a class=\"graphic graphic_picture graphicRef86025 \" href=\"UTD.htm?43/25/44432\">",
"     picture 6",
"    </a>",
"    ) is placed under the plate, advanced the entire length of the plate, then closed to cut the nail (",
"    <a class=\"graphic graphic_picture graphicRef77818 \" href=\"UTD.htm?5/30/5601\">",
"     picture 7",
"    </a>",
"    ). The free edge of the avulsed portion of nail is then grasped with a hemostat and pulled out.",
"   </p>",
"   <p>",
"    Having removed the nail, a thin film of petrolatum (eg, Vaseline Petroleum Jelly or Aquaphor) or antimicrobial ointment (polysporin or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?6/20/6469?source=see_link\">",
"     bacitracin",
"    </a>",
"    ) is placed on the exposed nail bed and then is covered with a small nonadherent dressing (eg, Telfa). The entire digit is then wrapped securely, but not too tightly, with 1- or 2-inch rolled gauze (eg, Conform). Bleeding is usually minimal if only avulsion is performed.",
"   </p>",
"   <p>",
"    When operating on the toenail, advise the patient to bring an open-toed shoe or slipper to wear home after the procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Wound care",
"    </span>",
"    &nbsp;&mdash;&nbsp;Simple avulsions and chemical matricectomies (see below) should be soaked in warm water 24 to 48 hours after the procedure. Before removal of the dressing, I recommend that patients soak their digit in the shower or in a bowl to avoid bleeding and pain when the dressing is removed. A gelatinous film of epithelium is likely to appear over the exposed nail bed and can be gently removed with dilute",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/41/41617?source=see_link\">",
"     hydrogen peroxide",
"    </a>",
"    on a cotton-tipped applicator. The cotton tip should be rolled over the site gently, avoiding rubbing or vigorous attempts at tissue removal. A small amount of petrolatum or antibiotic ointment is placed on the tissue, then it is covered with an adhesive bandage for a simple avulsion or roller gauze if a matricectomy was performed. This dressing change should be repeated daily.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     CHEMICAL MATRICECTOMY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Chemical matricectomy is the chemical ablation of all or part of the nail matrix. The rationale for chemical matricectomy is to destroy the matrix to prevent the nail from growing. Typical indications are recurrent or chronically ingrown, or incurved, nails with frequent pain or infection. Previously, surgical resections of the nail matrix also involved amputation of underlying bone and were associated with long healing times and disfigurement. The current procedure of chemical ablation is relatively easy to perform, has minimal bleeding, allows the patient to return to normal activities after a few days, is not significantly disfiguring, and compares favorably to surgical approaches with recurrence rates of less than 5 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=see_link&amp;anchor=H11#H11\">",
"     \"Paronychia and ingrown toenails\", section on 'Recurrent ingrown toenail'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The procedure below describes the use of phenol in performing the chemical matricectomy. One study described more rapid healing with the use of sodium hydroxide [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/7\">",
"     7",
"    </a>",
"    ], but until additional studies are performed demonstrating efficacy, safety, and ease of use, we continue to use phenol.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Procedure",
"    </span>",
"    &nbsp;&mdash;&nbsp;Supplies needed for chemical matricectomy include a preoperative antiseptic solution, anesthesia supplies, sterile drapes, sterile gloves, elevating instrument (dental spatula, Freer elevator (",
"    <a class=\"graphic graphic_picture graphicRef86023 \" href=\"UTD.htm?36/61/37855\">",
"     picture 4",
"    </a>",
"    ), straight mosquito forceps), nail splitter (",
"    <a class=\"graphic graphic_picture graphicRef86025 \" href=\"UTD.htm?43/25/44432\">",
"     picture 6",
"    </a>",
"    ) (for partial matricectomy), scissors, forceps, small curette (an ear curette or other 1- to 2-mm curette), tourniquet, cotton-tipped applicators, petroleum jelly, fully saturated (88 percent) liquefied phenol, isopropyl alcohol in 20-mL syringes, petrolatum or antibiotic ointment, nonadherent gauze (Telfa), and roller gauze (Conform). An electrocautery device is optional, as are a long-acting anesthesia (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) and a corticosteroid (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    ) for injection.",
"   </p>",
"   <p>",
"    To perform the procedure, the digit must be well anesthetized with a digital block and soaked in the antiseptic solution (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"     \"Digital nerve block\"",
"    </a>",
"    ). Place the patient in a recumbent position on the operating table and apply sterile drapes to expose the operative site. The nail plate is partially avulsed if just a portion of the matrix is to be ablated or completely avulsed if the entire matrix is to be ablated. Any exuberant tissue should be curetted or excised with scissors and forceps. The area of matrix to be treated is then curetted sharply. Electrocautery may be performed on this area of matrix to control bleeding using a thin, fine tip to avoid damage to the overlying proximal nail fold tissue. A tourniquet is then placed at the base of the digit to prevent blood from diluting the phenol. The overlying proximal nail fold, adjacent nail bed, and lateral nail folds are then coated with petroleum jelly to prevent phenol from damaging these tissues.",
"   </p>",
"   <p>",
"    Cotton-tipped applicators are stripped of all but a small wisp of cotton, or alternatively, the bare end of the stick is covered with a small wisp of cotton, which is then saturated with phenol solution. The cotton wisp should be held against the inside mouth of the phenol bottle to drain the excess phenol to prevent dripping. The phenol-soaked wisp is then applied to the matrix and vigorously rubbed into the treatment area for 30 seconds. One to two subsequent phenol applications are made in a similar fashion. The tissue will denature quickly and turn white or gray. The denaturation by phenol is self-limiting, and no irrigation is necessary. However, some surgeons irrigate the treated area with 30 to 50 mL of isopropyl alcohol or water. The tourniquet is then removed [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/8\">",
"     8",
"    </a>",
"    ]. The tourniquet should never be left in place for longer than 10 to 15 minutes.",
"   </p>",
"   <p>",
"    After completing a chemical ablation, many physicians inject either a long acting anesthetic (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/60/34758?source=see_link\">",
"     bupivacaine",
"    </a>",
"    ) or a combination of 0.6 mL of long-acting anesthetic and 0.4 mL of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    into the proximal nail fold (total volume of injection is approximately 0.5 mL) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12758/abstract/4\">",
"     4",
"    </a>",
"    ]. The anesthetic provides an extended period of comfort, allowing the patient to get any needed prescription medication, get home, and elevate the treated foot or hand. I have found that patients require less pain medication, few, if any, opioids, and are able to walk comfortably more quickly when using this technique. Some surgeons find the addition of steroids to be helpful in preventing postoperative chemical lymphangitis, which can occur.",
"   </p>",
"   <p>",
"    Petrolatum or an antibiotic ointment is placed on the nail bed, the site covered with a nonadherent dressing (Telfa), and then the entire digit is wrapped with 1- or 2-inch roller gauze (Conform). The wrapping should be secure but not so tight as to be uncomfortable. Dressings wrapped too tightly may increase postoperative pain.",
"   </p>",
"   <p>",
"    The patient is then advised to go home and elevate the affected foot or hand for 12 to 24 hours. Adequate elevation requires the limb be held above the level of the heart. Ice packs applied to the dorsal foot in the case of toenails or dorsal hand or wrist for fingernails seems to diminish pain and slow the clearing of anesthesia.",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     Acetaminophen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/38/15978?source=see_link\">",
"     ibuprofen",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/0/35848?source=see_link\">",
"     codeine",
"    </a>",
"    , or hydrocodone are appropriate analgesics when used in combination with, but not as a substitute for, elevation. Most pain occurs in the first 24 to 48 hours and the majority of patients can return to normal activities while wearing an open-toed shoe after 48 hours. Persistent pain or increasing pain after two days suggests an infection or chemical cellulitis. Infections should be cultured and treated with antistaphylococcal antibiotics; chemical cellulitis is treated with elevation, ice, and nonsteroidal antiinflammatory drugs.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Wound care and complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;The wound care for chemical matricectomy is the same as that for simple avulsion (see above).",
"   </p>",
"   <p>",
"    After a partial matricectomy, the affected nail bed begins to keratinize or harden, producing a \"pseudonail\", and the lateral nail fold epithelium grows toward the remaining nail plate, eventually producing a normal-appearing nail, albeit slightly narrower. With complete matricectomy, the nail bed keratinizes and forms a pseudonail that appears similar to a nail plate. Gauze coverings should be used postmatricectomy for one week, then adhesive bandages should be used for an additional two to three weeks.",
"   </p>",
"   <p>",
"    A chemical cellulitis can occur secondary to the denaturing of tissue by phenol. Although some degree of chemical cellulitis occurs in many cases, it usually is not enough to warrant a visit to the physician. Important chemical cellulitis is recognized when the swelling not only involves the digit but the entire foot or hand or extends proximal to the foot or hand. Associated erythema and pain are variable. Most cases can be managed with continued elevation of the foot or hand to above the level of the heart, alternating cold and warm compresses and nonsteroidal antiinflammatory drugs.",
"   </p>",
"   <p>",
"    Occasionally, chemical matricectomy does not completely prevent nail plate regrowth. When the regrown nail is a small spicule, it can be grasped with a hemostat and pulled out, a procedure that is associated with little discomfort. If a portion of the nail or the entire nail regrows, consider repeating the procedure, performing another ablative procedure, or referral.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pain is the most common complication following nail surgery and is more likely to occur when infection is present before the procedure. Permanent procedures should be avoided in the presence of infection, and infection should be treated prior to operating whenever possible.",
"   </p>",
"   <p>",
"    In my experience, most patients with persistent pain after the procedure were noncompliant with postoperative instructions regarding elevation and ice, so I stress these aspects of wound care with my patients.",
"   </p>",
"   <p>",
"    Infection is always a possibility, even when one has been meticulous with patient preparation and technique. I ask patients to contact me for the following situations:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The pain worsens rather than improves over 24 hours",
"     </li>",
"     <li>",
"      There is increasing redness of the area",
"     </li>",
"     <li>",
"      A red streak develops",
"     </li>",
"     <li>",
"      Pus is present",
"     </li>",
"     <li>",
"      There is fever",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the first few postoperative days, bacterial infection, usually with Staphylococcus aureus, is most likely, but after one week, infections with Candida, which tend to remain localized, are increasingly prevalent. Candidal infections usually can be treated by discontinuing the antibiotic ointment and applying a topical antifungal agent (Lotrimin [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/18/33056?source=see_link\">",
"     Clotrimazole",
"    </a>",
"    ], Nizoral [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/34/33312?source=see_link\">",
"     Ketoconazole",
"    </a>",
"    ], Spectazole [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?4/56/4995?source=see_link\">",
"     econazole",
"    </a>",
"    nitrate], Naftin [naftidine hydrochloride], Loprox [",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/40/44676?source=see_link\">",
"     ciclopirox",
"    </a>",
"    olamine]). Do not use the combination of clotrimazole and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/5/44120?source=see_link\">",
"     betamethasone",
"    </a>",
"    (Lotrisone) cream, because the potent steroid may exacerbate the fungal infection and retard healing.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     CONTRAINDICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Diminished vascular supply to the digit is a relative but not absolute contraindication to nail surgery. It is common for patients with significant peripheral vascular disease, including diabetes, to have painful disorders of the nail, and surgical intervention may be indicated. Avoiding epinephrine in the anesthetic, using digital rather than local blocks, minimizing or eliminating a tourniquet, and using palliative rather than permanent procedures help reduce risk in these patients.",
"   </p>",
"   <p>",
"    Overt bacterial infection of the operative site is a relative contraindication to chemical matricectomy, and temporizing procedures often need to be performed. These patients should be treated with a systemic antibiotic for two to three weeks before performing a permanent procedure.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H57923056\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nail disorders, particularly ingrown, incurved, pincer, hypertrophic, infected, and painful nails, are common conditions in adults (",
"      <a class=\"graphic graphic_picture graphicRef60056 graphicRef59295 graphicRef67968 \" href=\"UTD.htm?3/4/3146\">",
"       picture 1A-C",
"      </a>",
"      ). A variety of surgical techniques are used to correct or cure the underlying condition or to prevent or alleviate symptoms. These include paring, trimming and grinding, nail avulsion, and chemical matricectomy. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Toenail paring, trimming, and grinding are commonly performed by physicians and podiatrists on patients with diabetes or those who have physical limitations that prevent their ability to perform routine nail care. Regular nail clippers, heavy duty nail nippers, or nail grinders may be used (",
"      <a class=\"graphic graphic_picture graphicRef86021 graphicRef86022 \" href=\"UTD.htm?38/33/39444\">",
"       picture 2A-B",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Paring, trimming, and grinding'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nail avulsion is a procedure whereby all or a portion of the nail plate is removed from the nail bed (",
"      <a class=\"graphic graphic_picture graphicRef77818 \" href=\"UTD.htm?5/30/5601\">",
"       picture 7",
"      </a>",
"      ). Nail avulsion is extremely painful and requires adequate anesthesia by digital or wing block. Avulsion is done for diagnostic and therapeutic purposes, most frequently for ingrown and incurved nails. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Nail avulsion'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=see_link\">",
"       \"Digital nerve block\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Chemical matricectomy is the chemical ablation of all or part of the nail matrix. Typical indications are recurrent or chronically ingrown or incurved nails with frequent pain or infection. After complete or partial nail avulsion, phenol is applied to the matrix portion to be treated. (See",
"      <a class=\"local\" href=\"#H9\">",
"       'Chemical matricectomy'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Pain is the most common complication following nail surgery. Pain may be controlled by elevation of the affected foot or hand for 12 to 24 hours, application of ice packs to the dorsal foot or hand, and oral analgesics. (See",
"      <a class=\"local\" href=\"#H12\">",
"       'Complications'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Nail surgery may be contraindicated in patients with peripheral vascular disease and reduced vascular supply to the digits. When surgery is necessary, avoiding epinephrine in the anesthetic, using digital rather than local blocks, minimizing or eliminating a tourniquet, and using palliative rather than permanent procedures help reduce risk in these patients. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Contraindications'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     Mathes BM, Alguire PC. Nail Surgery. In: Dermatologic Procedures in Atlas of  Office Procedures, Alguire PC, Mathes BM (Eds), WB Saunders, Philadelphia 1999. Vol 2, p.97.",
"    </li>",
"    <li>",
"     Clark RE, Trope WD. Nail surgery. In: Cutaneous Surgery, 1st ed, Wheeland RG (Ed), WB Saunders, Philadelphia 1994. p.375.",
"    </li>",
"    <li>",
"     Krull EA. Surgery of the nail. In: Dermatology, Moschella S, Hurley HH (Eds), WB Saunders, Philadelphia 1992. p.2403.",
"    </li>",
"    <li>",
"     Salashe SJ. Nail unit surgery. In: Atlas of Cutaneous Surgery, Robinson JK, Arndt KA, LeBoit PE, et al (Eds), WB Saunders, Philadelphia 1996. p.189.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12758/abstract/5\">",
"      Bostanci S, Ekmek&ccedil;i P, G&uuml;rgey E. Chemical matricectomy with phenol for the treatment of ingrowing toenail: a review of the literature and follow-up of 172 treated patients. Acta Derm Venereol 2001; 81:181.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12758/abstract/6\">",
"      Andreassi A, Grimaldi L, D'Aniello C, et al. Segmental phenolization for the treatment of ingrowing toenails: a review of 6 years experience. J Dermatolog Treat 2004; 15:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12758/abstract/7\">",
"      Bostanci S, Kocyigit P, G&uuml;rgey E. Comparison of phenol and sodium hydroxide chemical matricectomies for the treatment of ingrowing toenails. Dermatol Surg 2007; 33:680.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12758/abstract/8\">",
"      Siegle RJ, Harkness J, Swanson NA. Phenol alcohol technique for permanent matricectomy. Arch Dermatol 1984; 120:348.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1735 Version 4.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-41.78.124.10-00EF7A87C0-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12758=[""].join("\n");
var outline_f12_29_12758=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H57923056\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      NAIL ANATOMY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PARING, TRIMMING, AND GRINDING",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      NAIL AVULSION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Wound care",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      CHEMICAL MATRICECTOMY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Procedure",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Wound care and complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      CONTRAINDICATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H57923056\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DERM/1735\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1735|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?24/43/25267\" title=\"figure 1\">",
"      Nail anatomy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DERM/1735|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?19/25/19857\" title=\"picture 1A\">",
"      Ingrown toenail 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?14/21/14676\" title=\"picture 1B\">",
"      Pincer nails 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?9/24/9602\" title=\"picture 1C\">",
"      Pincer nails 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/15/31984\" title=\"picture 2A\">",
"      Nail nipper",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?31/61/32735\" title=\"picture 2B\">",
"      Nail grinder 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?4/33/4626\" title=\"picture 3\">",
"      Rams horn toenails",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/61/37855\" title=\"picture 4\">",
"      Nail elevator and spatula",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?40/6/41063\" title=\"picture 5\">",
"      Elevator under nail",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?43/25/44432\" title=\"picture 6\">",
"      Nail splitter",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?5/30/5601\" title=\"picture 7\">",
"      Partial nail avulsion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/9/23703?source=related_link\">",
"      Digital nerve block",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/61/37846?source=related_link\">",
"      Paronychia and ingrown toenails",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12759="Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction";
var content_f12_29_12759=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Dose modification of antiretroviral agents in adults with renal or hepatic dysfunction",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12759/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12759/contributors\">",
"     Amy L Graziani, PharmD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12759/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12759/contributors\">",
"     John G Bartlett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12759/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12759/contributors\">",
"     Allyson Bloom, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/29/12759/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 4, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The introduction of antiretroviral agents, especially highly active antiretroviral therapy (HAART), has markedly altered the natural history of human immunodeficiency virus (HIV) infection (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=see_link\">",
"     \"The stages and natural history of HIV infection\"",
"    </a>",
"    ). These regimens have greatly extended life expectancy and reduced the incidence of most acquired immunodeficiency syndrome (AIDS)-defining conditions. However, the drug regimens are complex, costly, and are accompanied by a number of significant side effects, many of which are dose-related. Because organ dysfunction can result in slowed elimination and accumulation of these agents, it is important to dose-reduce select antiretroviral medications to avert dose-related side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL DOSING RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite the fact that many HIV-infected patients also have renal or hepatic dysfunction, most antiretroviral agents have not been well studied in HIV-infected patients with renal or hepatic insufficiency, including those receiving hemodialysis or peritoneal dialysis. Thus, dosing recommendations for such patients are often extrapolated from information about the structure, chemical characteristics, metabolism, and elimination of the drug in patients with normal organ function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/1\">",
"     1",
"    </a>",
"    ]. The table summarizes recommendations from United States guidelines that have been based upon these limited data (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the limited data and empiric nature of many of the recommendations, patients with organ dysfunction should be monitored closely for drug toxicity and efficacy. It is important to note that the available data are from patients with either renal or hepatic dysfunction but not from those with impairment of both organ systems. If patients do have both significant hepatic and renal dysfunction, it is even more difficult to predict the effects on parent drug and metabolites, drug efficacy, and safety. Although not currently performed routinely in most centers, the increasing availability and evolving database of antiretroviral drug serum concentration monitoring may prove helpful to these patients in the future.",
"   </p>",
"   <p>",
"    Drug-specific dosing recommendations are listed in the comprehensive",
"    <a class=\"external\" href=\"file://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdf\">",
"     DHHS Antiretroviral Guidelines",
"    </a>",
"    Table. A summary of renal and hepatic considerations for these classes of drugs will be reviewed here.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     NUCLEOSIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most NRTIs, including",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    (ddI),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    (D4T),",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (3TC) are eliminated primarily unchanged in the urine. These drugs require dose reduction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    extension of the dosing interval in patients with renal insufficiency [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. Two exceptions are",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"     abacavir",
"    </a>",
"    , which undergo substantial extra-renal (hepatic) biotransformation, and therefore may require less significant or no dose reductions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Coformulations",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fixed-dose combination drugs (",
"    <a class=\"graphic graphic_table graphicRef60927 \" href=\"UTD.htm?24/25/24989\">",
"     table 2",
"    </a>",
"    ) can be problematic in patients with significant renal dysfunction because the renal excretion of the components is not identical and several of these coformulated drugs contain the potentially nephrotoxic and renally eliminated drug",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    . Therefore, these coformulations are not recommended in patients with advanced renal dysfunction. The DHHS guidelines recommend avoiding Atripla, Complera, Epzicom, Trizivir, and Combivir at a creatinine clearance (CrCl) &lt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    and Truvada at a CrCl &lt;30",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    Stribild should not be initiated if the estimated CrCl &lt;70",
"    <span class=\"nowrap\">",
"     mL/min,",
"    </span>",
"    and it should be discontinued if the CrCl drops to 50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    during treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/5\">",
"     5",
"    </a>",
"    ]. However, the component drugs may be prescribed separately in some cases (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Lactic acidosis/severe hepatomegaly with steatosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several of the NRTIs have been associated with the disorder of lactic",
"    <span class=\"nowrap\">",
"     acidosis/severe",
"    </span>",
"    hepatomegaly with steatosis. The majority of cases have been in patients who received the older NRTIs",
"    <a class=\"drug drug_general\" href=\"UTD.htm?14/38/14952?source=see_link\">",
"     didanosine",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    . The clinical manifestations of diagnosis of this complication are discussed elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=see_link\">",
"     \"Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Tenofovir and nephrotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     Tenofovir",
"    </a>",
"    has been associated with a low incidence of proximal renal tubular dysfunction or Fanconi's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Signs of proximal renal tubular dysfunction include proteinuria, glucosuria, hypophosphatemia, hypouricemia, hypokalemia, low serum bicarbonate,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    elevated serum creatinine. Risk factors for tenofovir-associated nephrotoxicity include low body weight, advanced HIV, and perhaps concomitant use of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    . Clinicians need to be aware that proteinuria, glucosuria, hypophosphatemia, hypouricemia,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    hypokalemia may develop before the serum creatinine increases. In addition, tenofovir is eliminated renally and, like the hepatitis B drug,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    , the nephrotoxicity may be dose- or cumulative dose-related. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=see_link&amp;anchor=H14340801#H14340801\">",
"     \"Pharmacology of nucleoside reverse transcriptase inhibitors\", section on 'Tenofovir'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The quandary is that patients with HIV nephropathy require effective HAART to recover their renal function and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is a very effective and easy to administer component of many HAART regimens [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/8\">",
"     8",
"    </a>",
"    ]. Therefore, the clinician is left with the difficult task of assessing the benefit versus risks of prescribing tenofovir to patients with renal dysfunction. If tenofovir is prescribed, the dose should be reduced according to the creatinine clearance and the patient should be monitored closely for signs of proximal renal tubular dysfunction. Specific dose reductions are listed in the DHHS guidelines [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In patients with end-stage renal disease (ESRD) on hemodialysis in whom recovery of renal function is not anticipated,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    is a convenient choice since it can be dosed once weekly, thus decreasing pill burden and reducing the annual cost substantially.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NNRTIs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     rilpivirine",
"    </a>",
"    ) undergo hepatic metabolism.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     Nevirapine",
"    </a>",
"    should be avoided in patients with moderate to severe liver disease (Child-Pugh Class B or C) since data on its use in this population is limited and nevirapine has been associated with hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ]. However, the pharmacokinetics of nevirapine appear to be similar in patients with and without chronic viral hepatitis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"     nevirapine",
"    </a>",
"    product labeling (but not the DHHS guidelines) recommends that hemodialysis patients receive an additional 200 mg dose after each dialysis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/10\">",
"     10",
"    </a>",
"    ]. This recommendation is based on a pharmacokinetic study that showed a decrease in the area under the curve of 44 percent over a one-week period among patients on dialysis with typical dosing. An accumulation of nevirapine hydroxy-metabolites was also observed in dialysis patients, although the clinical significance of this is unknown.",
"   </p>",
"   <p>",
"    There are no specific guidelines for",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/42/29353?source=see_link\">",
"     efavirenz",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?27/10/27816?source=see_link\">",
"     delavirdine",
"    </a>",
"    in patients with significant hepatic dysfunction. The DHHS guidelines state that they should be used with caution in that setting [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/0/13320?source=see_link\">",
"     Etravirine",
"    </a>",
"    is the least dependent on hepatic metabolism; 81 to 86 percent of a dose is eliminated unchanged in the feces. Etravirine does not require dose adjustment for patients with Child-Pugh Class A or B liver dysfunction; there are no data available for patients with Child-Pugh Class C [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2,11\">",
"     2,11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15798?source=see_link\">",
"     Rilpivirine",
"    </a>",
"    does not require dose adjustment in patients with Child-Pugh Class A or B hepatic dysfunction. There are no data available in severe, Child-Pugh Class C dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ]. Drug-associated hepatitis has been reported.",
"   </p>",
"   <p>",
"    Since the NNRTIs are not primarily eliminated unchanged in the urine, dose modifications for the non-coformulated drugs have not been recommended for patients with renal insufficiency. However, this recommendation assumes that any metabolites, which may be eliminated renally, do not accumulate or contribute to drug toxicity. There are no data published to confirm this assumption for most of these agents. &nbsp;",
"   </p>",
"   <p>",
"    In contrast, the fixed-drug combination products containing NNRTIs (Atripla and Complera) should not be used if the creatinine clearance (CrCl) &lt;50",
"    <span class=\"nowrap\">",
"     mL/min.",
"    </span>",
"    (See",
"    <a class=\"local\" href=\"#H4\">",
"     'Coformulations'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PROTEASE INHIBITORS (PIs)",
"    </span>",
"    &nbsp;&mdash;&nbsp;Like the NNRTIs, the currently available PIs (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     atazanavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?43/11/44217?source=see_link\">",
"     fosamprenavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/36/25161?source=see_link\">",
"     indinavir",
"    </a>",
"    ,",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"     ,",
"    </span>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/62/19433?source=see_link\">",
"     nelfinavir",
"    </a>",
"    , ritonavir,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/25/3482?source=see_link\">",
"     saquinavir",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    ) are highly metabolized. Dose modification has been recommended for some of these agents including atazanavir, fosamprenavir and indinavir in patients with significant hepatic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Renal excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;PIs are not primarily eliminated unchanged in the urine. Thus, dose adjustment has not been recommended for most of these drugs in patients with renal insufficiency. As with the NNRTIs, the untested assumption is that possible renally-excreted metabolites do not accumulate or contribute to drug toxicity.",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    is the only protease inhibitor that has a specific warning against use in experienced patients on hemodialysis (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2,12\">",
"     2,12",
"    </a>",
"    ]. This recommendation stems from a pharmacokinetic study in hemodialysis patients that showed that dialysis patients had 40 percent lower atazanavir AUC's compared with controls. In this study, the atazanavir dose was 400 mg, unboosted (eg, without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    ). The mechanism for the reduction of levels is unclear because dialysis does not remove much atazanavir. The authors postulated that the decreased atazanavir exposure may be related to the potentially lower gastric pH that has been described in dialysis patients. Because the study was done with unboosted atazanavir, they recommend considering boosting atazanavir with ritonavir in hemodialysis patients, although the PK in that situation has not yet been studied. Thus, the DHHS guidelines recommend that antiretroviral-experienced patients on hemodialysis not receive atazanavir at all (even if boosted with ritonavir) and that antiretroviral-naive patients always receive the ritonavir-boosted atazanavir dose, 300 mg atazanavir and 100 mg ritonavir once daily [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?0/31/506?source=see_link\">",
"     Atazanavir",
"    </a>",
"    has also been associated with nephrolithiasis and renal dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/13\">",
"     13",
"    </a>",
"    ]. This should be considered when prescribing it to patients with underlying renal dysfunction. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=see_link\">",
"     \"Crystal-induced acute kidney injury (acute renal failure)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In patients with normal renal function,",
"    <span class=\"nowrap\">",
"     lopinavir/",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"      ritonavir",
"     </a>",
"    </span>",
"    can be dosed once daily (800",
"    <span class=\"nowrap\">",
"     mg/200",
"    </span>",
"    mg) or twice daily (400",
"    <span class=\"nowrap\">",
"     mg/100",
"    </span>",
"    mg). However, lower levels of both lopinavir and ritonavir have been observed in dialysis patients compared with historical controls with normal renal function [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/14\">",
"     14",
"    </a>",
"    ]. Thus, the DHHS guidelines recommend not using once-daily dosing in dialysis patients; there is a theoretical risk that dialysis patients with protease inhibitor mutations may not achieve high enough",
"    <span class=\"nowrap\">",
"     lopinavir/ritonavir",
"    </span>",
"    levels to achieve virologic control [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2,14\">",
"     2,14",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Hepatotoxicity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although hepatic dysfunction has been reported with the protease inhibitors as a class,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"     darunavir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"     tipranavir",
"    </a>",
"    have specific warnings related to potential hepatotoxicity and fatalities have been reported. For that reason, the DHHS guidelines state that darunavir is not recommended in patients with severe liver dysfunction; the tipranavir section states that it should be used with caution in patients with hepatic dysfunction and that it is contraindicated in patients with moderate to severe, Child-Pugh Class B or C hepatic dysfunction (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Advanced liver disease is associated with impairment of cytochrome (CYP) 3A activity and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"     ritonavir",
"    </a>",
"    is a powerful inhibitor of this isoenzyme. One study examined the effect of ritonavir on CYP3A activity in 26 HIV-positive men (13 with chronic viral hepatitis [CVH]; 13 controls without viral hepatitis) by using",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/60/4042?source=see_link\">",
"     midazolam",
"    </a>",
"    , a probe for CYP3A phenotypic activity [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/15\">",
"     15",
"    </a>",
"    ]. In patients not taking ritonavir, CYP3A activity was similar in CVH and non-CVH patients. However, in the patients taking ritonavir without CVH, CYP3A activity was reduced dramatically to 7 percent of controls. The presence of CVH along with ritonavir further reduced CYP3A activity to 4 percent. These results remind us that patients taking drugs that depend on CYP3A for metabolism should be monitored closely for toxicity if they are taking ritonavir and that CVH may have an additive effect on CYP3A.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CCR5 INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Maraviroc",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are no specific recommendations for dosing the drug in hepatic dysfunction, but caution that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    concentrations will likely be elevated since it is metabolized by CYP3A; this may predispose patients to drug-related side effects (eg, orthostatic hypotension) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ]. In addition, severe hepatotoxicity has been reported, and there is a black box warning concerning this in the product labeling (",
"    <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"     table 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Twenty-five percent of a",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"     maraviroc",
"    </a>",
"    dose is eliminated renally. Dosing adjustments for patients with renal impairments must also take into account the interactions between maraviroc and medications metabolized by CYP3A as well as its association with postural hypotension. Both the product label and DHHS guidelines state that maraviroc is not recommended in patients with creatinine clearance (CrCl) &lt;30",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    or patients on dialysis if they are also receiving potent CYP3A inducers or inhibitors [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2,16\">",
"     2,16",
"    </a>",
"    ]. If patients with such renal impairment are not on potent CYP3A inducers or inhibitors, the typical dose of 300 mg twice daily can be used unless they develop postural hypotension, in which case the dose should be reduced to 150 mg twice daily [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2,16\">",
"     2,16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h1\">",
"     FUSION INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Enfuvirtide",
"    </span>",
"    &nbsp;&mdash;&nbsp;No dosage changes are recommended for patients with renal or hepatic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     INTEGRASE INHIBITORS",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Raltegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"     Raltegravir",
"    </a>",
"    is metabolized via UGT1A1 glucuronidation. There are no dosing adjustments recommended for patients with renal or hepatic dysfunction [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19838796\">",
"    <span class=\"h2\">",
"     Elvitegravir",
"    </span>",
"    &nbsp;&mdash;&nbsp;Elvitegravir is available as a fixed-drug combination product with cobicistat,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    , and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    (Stribild). There are no dosing adjustments recommended for patients with mild to moderate hepatic dysfunction (Child-Pugh class A, B) and no data on patients with severe, Child-Pugh Class C hepatic dysfunction. Although the elvitegravir itself does not require dose reduction in the setting of renal dysfunction, there are creatinine clearance (CrCl) cutoffs for administration of the coformulated tablet to patients with renal dysfunction due to the renally-eliminated and potentially nephrotoxic tenofovir and emtricitabine components: it should be avoided in patients with CrCl &lt;70",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    at initiation and discontinued in those who develop CrCl &lt;50",
"    <span class=\"nowrap\">",
"     mL/min",
"    </span>",
"    while on therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/5\">",
"     5",
"    </a>",
"    ]. The cobicistat component can increase serum creatinine slightly and decrease creatinine clearance, but not glomerular filtration, due to inhibition of the tubular secretion of creatinine [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/5\">",
"     5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     TIMING OF DOSES FOR PATIENTS ON HEMODIALYSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;For patients undergoing hemodialysis (HD), we recommend scheduling medications so that at least one of the daily doses is taken soon after dialysis on dialysis days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/17\">",
"     17",
"    </a>",
"    ]. Although a number of antiretroviral agents are probably not dialyzed, the logic behind the recommendation is to guarantee therapeutic serum concentrations in case dialysis removes some of the drug or an important metabolite. The DHHS guidelines recommend that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/45/43734?source=see_link\">",
"     stavudine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"     zidovudine",
"    </a>",
"    specifically be taken after dialysis on dialysis days [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12759/abstract/2\">",
"     2",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11567238\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most antiretroviral agents have not been well studied in HIV-infected patients with renal or hepatic insufficiency. Thus, dosing recommendations for such patients (",
"      <a class=\"graphic graphic_table graphicRef64250 \" href=\"UTD.htm?28/12/28866\">",
"       table 1",
"      </a>",
"      ) are often extrapolated from information about the structure, chemical characteristics, metabolism, and elimination of the drug in patients with normal organ function. Because of the limited data and empiric nature of many of the recommendations, patients with organ dysfunction should be monitored closely for drug toxicity and efficacy. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General dosing recommendations'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most nucleoside reverse transcriptase inhibitors (NRTIs) are eliminated unchanged in the urine and thus require dose reduction",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      dosing interval extension in patients with renal insufficiency. The two exceptions to this are",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/28/24008?source=see_link\">",
"       zidovudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?30/63/31734?source=see_link\">",
"       abacavir",
"      </a>",
"      , which require less significant or no dose reductions. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Nucleoside/tide reverse transcriptase inhibitors (NRTIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       Tenofovir",
"      </a>",
"      has been associated with proximal renal tubular dysfunction, particularly in patients with low body weight, advanced HIV, and possibly concomitant use of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?11/58/12202?source=see_link\">",
"       ritonavir",
"      </a>",
"      . Proteinuria, glucosuria, hypophosphatemia, hypouricemia,",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hypokalemia may develop before the serum creatinine increases. Tenofovir is included in many fixed-drug combinations including Truvada, Atripla, Complera, and Stribild. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Tenofovir and nephrotoxicity'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The non-nucleoside reverse transcriptase inhibitors (NNRTIs) undergo hepatic metabolism, and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/12/18633?source=see_link\">",
"       nevirapine",
"      </a>",
"      specifically should be avoided in patients with moderate to severe liver disease. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Non-nucleoside reverse transcriptase inhibitors (NNRTIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Protease inhibitors are highly metabolized in the liver.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?35/39/36473?source=see_link\">",
"       Darunavir",
"      </a>",
"      is not recommended in patients with severe liver dysfunction.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/33/19992?source=see_link\">",
"       Tipranavir",
"      </a>",
"      is contraindicated in patients with moderate to severe hepatic dysfunction. Dose adjustment has not been recommended for most protease inhibitors in patients with renal insufficiency. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Protease inhibitors (PIs)'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/45/20182?source=see_link\">",
"       Maraviroc",
"      </a>",
"      should be used with caution in patients with hepatic dysfunction as levels may be elevated and it has been associated with hepatic failure. Dosing in patients with renal dysfunction is complicated because potential interacting drugs and orthostatic hypotension must be taken into account. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CCR5 inhibitors'",
"      </a>",
"      above.) No dosage adjustments in the setting of renal or hepatic dysfunction are indicated for",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/27/10678?source=see_link\">",
"       raltegravir",
"      </a>",
"      or fusion inhibitors. Elvitegravir is available as part of a fixed-drug combination (Stribild) that does require modification in patients with renal dysfunction. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'CCR5 inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H13\">",
"       'Fusion inhibitors'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H15\">",
"       'Integrase inhibitors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For patients on hemodialysis, in the absence of good data on the clearance by dialysis, at least one of the daily doses of the antiretroviral agent should be taken soon after dialysis. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Timing of doses for patients on hemodialysis'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/1\">",
"      Izzedine H, Launay-Vacher V, Baumelou A, Deray G. An appraisal of antiretroviral drugs in hemodialysis. Kidney Int 2001; 60:821.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.aidsinfo.nih.gov/guidelines/GuidelineDetail.aspx?MenuItem=Guidelines&amp;Search=Off&amp;GuidelineID=7&amp;ClassID=1 (Accessed on March 31, 2012).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/3\">",
"      Jayasekara D, Aweeka FT, Rodriguez R, et al. Antiviral therapy for HIV patients with renal insufficiency. J Acquir Immune Defic Syndr 1999; 21:384.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/4\">",
"      Ostrop NJ, Burgess E, Gill MJ. The use of antiretroviral agents in patients with renal insufficiency. AIDS Patient Care STDS 1999; 13:517.",
"     </a>",
"    </li>",
"    <li>",
"     Stribild Product Labeling, Gilead Sciences, 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/6\">",
"      Gupta SK. Tenofovir-associated Fanconi syndrome: review of the FDA adverse event reporting system. AIDS Patient Care STDS 2008; 22:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/7\">",
"      Gallant JE, Parish MA, Keruly JC, Moore RD. Changes in renal function associated with tenofovir disoproxil fumarate treatment, compared with nucleoside reverse-transcriptase inhibitor treatment. Clin Infect Dis 2005; 40:1194.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/8\">",
"      Longenecker CT, Scherzer R, Bacchetti P, et al. HIV viremia and changes in kidney function. AIDS 2009; 23:1089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/9\">",
"      Vogel M, Bertram N, Wasmuth JC, et al. Nevirapine pharmacokinetics in HIV-infected and HIV/HCV-coinfected individuals. J Antimicrob Chemother 2009; 63:988.",
"     </a>",
"    </li>",
"    <li>",
"     Viramune Product labeling, Boehringer Ingelheim Pharmaceuticals, Inc. November 2012.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/11\">",
"      Sch&ouml;ller-Gy&uuml;re M, Kakuda TN, De Smedt G, et al. Effects of hepatic impairment on the steady-state pharmacokinetics of etravirine 200 mg BID: an open-label, multiple-dose, controlled Phase I study in adults. Clin Ther 2010; 32:328.",
"     </a>",
"    </li>",
"    <li>",
"     Agarwala S, et al. Pharmacokinetics of atazanavir in severely renally impaired subjects including those on hemodialysis. 4th IAS Conference on HIV Pathogenesis, Treatment and Prevention. In: Program and abstracts of the 8th International Workshop on Clinical Pharmacology of HIV Therapy. April 16-18, 2007; Budapest. Abstract 2.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/13\">",
"      Islam FM, Wu J, Jansson J, Wilson DP. Relative risk of renal disease among people living with HIV: a systematic review and meta-analysis. BMC Public Health 2012; 12:234.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/14\">",
"      Gupta SK, Rosenkranz SL, Cramer YS, et al. The pharmacokinetics and pharmacogenomics of efavirenz and lopinavir/ritonavir in HIV-infected persons requiring hemodialysis. AIDS 2008; 22:1919.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12759/abstract/15\">",
"      Knox TA, Oleson L, von Moltke LL, et al. Ritonavir greatly impairs CYP3A activity in HIV infection with chronic viral hepatitis. J Acquir Immune Defic Syndr 2008; 49:358.",
"     </a>",
"    </li>",
"    <li>",
"     Selzentry product label. file://www.viivhealthcare.com/~/media/Files/G/GlaxoSmithKline-Plc/pdfs/us_selzentry.pdf.",
"    </li>",
"    <li>",
"     2000-2001 Medical Management of HIV Infection, Bartlett JG, Gallant JE (Eds), Johns Hopkins University, Baltimore 2000.",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3798 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-BFB688DDA0-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12759=[""].join("\n");
var outline_f12_29_12759=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11567238\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL DOSING RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      NUCLEOSIDE/TIDE REVERSE TRANSCRIPTASE INHIBITORS (NRTIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Coformulations",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Lactic acidosis/severe hepatomegaly with steatosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Tenofovir and nephrotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS (NNRTIs)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PROTEASE INHIBITORS (PIs)",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Renal excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Hepatotoxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CCR5 INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Maraviroc",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      FUSION INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Enfuvirtide",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      INTEGRASE INHIBITORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Raltegravir",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19838796\">",
"      Elvitegravir",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      TIMING OF DOSES FOR PATIENTS ON HEMODIALYSIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11567238\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3798\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3798|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/12/28866\" title=\"table 1\">",
"      ART dosing recommendations for renal or hepatic insufficiency",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?24/25/24989\" title=\"table 2\">",
"      Antiretroviral drugs",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/2/34857?source=related_link\">",
"      Crystal-induced acute kidney injury (acute renal failure)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/40/30345?source=related_link\">",
"      Mitochondrial toxicity of HIV nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/15/41209?source=related_link\">",
"      Pharmacology of nucleoside reverse transcriptase inhibitors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/2/13353?source=related_link\">",
"      The stages and natural history of HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12760="Combination therapy for chronic hepatitis B virus infection";
var content_f12_29_12760=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Combination therapy for chronic hepatitis B virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Anna SF Lok, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Rafael Esteban, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12760/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/29/12760/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 28, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Monotherapy with a single antiviral agent or interferon is unlikely to be sufficient for the eradication of HBV infection in the majority of patients who are chronically infected. With the availability of several medications, it is now possible to contemplate combination therapy for hepatitis B [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/1\">",
"     1",
"    </a>",
"    ]. Such an approach has proven to be beneficial in patients with HIV infection and those with chronic hepatitis C. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=see_link\">",
"     \"Selecting antiretroviral regimens for the treatment naive HIV-infected patient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=see_link\">",
"     \"Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Ideally, therapeutic agents used in combination therapy should have additive or synergistic activity against HBV, delay or prevent the development of drug resistance, and have no added toxicity. The question is which agents to combine: two nucleos(t)ide analogs or one nucleos(t)ide analog plus interferon?",
"   </p>",
"   <p>",
"    This topic review will summarize experience with combination therapy for chronic hepatitis B virus infection. Most of the experience involves the addition of another agent to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=see_link\">",
"     \"Lamivudine monotherapy for chronic hepatitis B virus infection\"",
"    </a>",
"    .) None of the combination approaches has been approved for routine use.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     LAMIVUDINE PLUS STANDARD INTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The combination of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and interferon seems logical because monotherapy with each agent is effective, and lamivudine and interferon have different mechanisms of action. However, disparate results have been described in controlled trials.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Treatment-na&iuml;ve patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;There are conflicting data on the outcome after combination therapy in treatment-na&iuml;ve patients [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/2-4\">",
"     2-4",
"    </a>",
"    ]. One trial included 230 patients from Europe, Canada, and Australia who were randomly assigned to one of three treatment arms [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/2\">",
"     2",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg daily) for eight weeks followed by combination therapy with lamivudine plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (10 MU SQ three times weekly) for 16 weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg daily) for 52 weeks",
"     </li>",
"     <li>",
"      Placebo for eight weeks followed by combination therapy with placebo plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (10 MU SQ three times weekly) for 16 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    HBeAg seroconversion at week 52 was higher in patients receiving combination therapy with interferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , although the results were not statistically significant (29 versus 18 and 19 percent, respectively). More patients in the lamivudine monotherapy group had histologic improvement at 52 weeks, possibly because of the timing of the repeat liver biopsies; repeat liver biopsies were performed while the patients in the lamivudine monotherapy group were still on treatment, compared to 28 weeks after cessation of treatment in the other two groups. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=see_link\">",
"     \"Histologic scoring systems for chronic liver disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Different conclusions were reached in another study of 151 patients who were randomly assigned to combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"     interferon alfa-2b",
"    </a>",
"    (9 MU SQ three times weekly) plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg daily) for 24 weeks, or lamivudine alone for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/3\">",
"     3",
"    </a>",
"    ]. Patients were followed for a further 48 weeks. The mean histologic activity index was approximately 11, the median serum HBV DNA 160",
"    <span class=\"nowrap\">",
"     pg/mL",
"    </span>",
"    (~5 million int.",
"    <span class=\"nowrap\">",
"     units/mL),",
"    </span>",
"    and the median serum ALT 168 int.",
"    <span class=\"nowrap\">",
"     units/L",
"    </span>",
"    in both groups. Sustained HBeAg seroconversion with undetectable serum levels of HBV DNA was observed significantly more often in the combination therapy group (33 versus 15 percent). A corresponding improvement in histology was also more common in the combination therapy group (46 versus 27 percent).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Interferon nonresponders",
"    </span>",
"    &nbsp;&mdash;&nbsp;One of the largest trials focusing on interferon nonresponders involved 238 HBeAg positive patients from 63 international centers who failed to respond to interferon monotherapy and were randomly assigned to the following treatment groups in a 2:1:1 ratio [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/5\">",
"     5",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg PO once daily) for 52 weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      (100 mg PO once daily) for eight weeks followed by lamivudine (100 mg PO once daily) plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/56/29576?source=see_link\">",
"       interferon alfa-2b",
"      </a>",
"      (10 million units SQ three times weekly) for an additional 16 weeks",
"     </li>",
"     <li>",
"      Placebo",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The following observations were made:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A biochemical response (normalization of serum ALT) during treatment was observed significantly more often with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      compared with placebo or combination therapy (44 versus 15 and 18 percent, respectively).",
"     </li>",
"     <li>",
"      <span class=\"nowrap\">",
"       M204V/I",
"      </span>",
"      mutations were detected in 27 percent of the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      patients compared to none in the placebo or combination therapy groups.",
"     </li>",
"     <li>",
"      HBeAg seroconversion occurred in a similar proportion of patients in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      , placebo, and combination groups (18, 13, and 12 percent).",
"     </li>",
"     <li>",
"      HBeAg loss occurred significantly more often in the",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      group compared with placebo or combination groups (33 versus 13 and 21 percent, respectively).",
"     </li>",
"     <li>",
"      A histologic response (defined as a 2-point reduction in the HAI) was more likely with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      compared with placebo or combination therapy (52 versus 25, and 32 percent, respectively).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest that:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In treatment-na&iuml;ve patients with HBeAg positive chronic hepatitis B, a one-year course of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      monotherapy is similar in efficacy to a 16-week course of interferon monotherapy.",
"     </li>",
"     <li>",
"      Retreatment of interferon nonresponders with combination therapy of interferon plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      offers no advantage compared to retreatment with lamivudine monotherapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     HBeAg negative chronic hepatitis B",
"    </span>",
"    &nbsp;&mdash;&nbsp;The efficacy of combination therapy in patients with HBeAg negative chronic hepatitis B was evaluated in a pilot trial involving 29 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg daily) plus interferon (6 million units three times weekly) for 52 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/6\">",
"     6",
"    </a>",
"    ]. At the end of treatment, 93 percent of patients had virologic and biochemical response and 46 percent had improved liver histology but only 14 percent of patients had sustained virologic response after one year of post-treatment follow-up.",
"   </p>",
"   <p>",
"    Another report included 50 anti-HBe positive patients who were randomly assigned to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    (100 mg daily) alone or lamivudine plus interferon (5 million units three times weekly) for 12 months [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/4\">",
"     4",
"    </a>",
"    ]. While no significant differences were observed in initial response rates or relapse rates following discontinuation of therapy, fewer patients in the combination group developed",
"    <span class=\"nowrap\">",
"     M204V/I",
"    </span>",
"    mutations during therapy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     LAMIVUDINE PLUS PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;The attachment of polyethylene glycol to a protein (pegylation) reduces its rate of absorption following subcutaneous injection, reduces renal and cellular clearance, and decreases the immunogenicity of the protein. All of these effects tend to enhance the half-life of the pegylated versus the native protein. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=see_link&amp;anchor=H4#H4\">",
"     \"Standard and pegylated interferon for chronic hepatitis B virus infection\", section on 'Efficacy of peginterferon'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    At least four controlled trials in HBeAg-negative and HBeAg-positive patients have evaluated the efficacy of combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    &nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/7-9\">",
"     7-9",
"    </a>",
"    ]. Although combination therapy results in higher rate of virological and biochemical response at the end of therapy, sustained response assessed six months after treatment was similar compared to peginterferon alone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     HBeAg positive chronic HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;A growing number of studies have evaluated peginterferon with and without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    in the treatment of HBeAg positive chronic HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. Considered together these data suggest that peginterferon is more effective than lamivudine in inducing HBeAg seroconversion when response is assessed six months after withdrawal of therapy and that combination therapy offers no advantage compared with peginterferon monotherapy. However, viral suppression occurred more rapidly in the groups that received lamivudine with or without peginterferon, and lamivudine-resistant mutation was less frequently detected in those who received combination of peginterferon and lamivudine compared to lamivudine monotherapy.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A multinational study included a total of 814 patients who were randomly assigned to peginterferon alfa-2a (180 mcg once weekly) with either placebo or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) or to lamivudine monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/10\">",
"       10",
"      </a>",
"      ]. Patients were treated for 48 weeks and assessed after 24 weeks of treatment-free follow-up. The primary endpoints were HBeAg seroconversion or HBV DNA &lt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      and secondary endpoints were HBeAg loss and ALT normalization. At week 72, all endpoints were significantly more likely in the groups receiving peginterferon compared with lamivudine monotherapy (HBeAg seroconversion 32 and 27 versus 19 percent), (HBV DNA &lt;100,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      32 and 34 versus 22 percent), (HBeAg loss 34 and 28 versus 21 percent), and (ALT normalization 41 and 39 versus 28 percent) in the peginterferon monotherapy, combination therapy, or lamivudine monotherapy groups, respectively.",
"     </li>",
"     <li>",
"      Another trial included 307 patients who were randomly assigned to receive peginterferon alfa-2b with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) or placebo for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/7\">",
"       7",
"      </a>",
"      ]. The peginterferon dose was 100 mcg weekly for the first nine months followed by 50 mcg weekly for the last three months. Patients were followed until six months after stopping therapy.",
"      <br/>",
"      <br/>",
"      All patients were HBV DNA positive and had serum ALT values more than twice the upper limit of normal at baseline. The majority (77 percent) were male, 77 percent were Caucasian (21 percent Asian). The proportion of patients achieving loss of HBeAg at the end of follow-up was similar in the monotherapy and combination therapy groups (36 versus 35 percent). More patients in the combination therapy group had cleared HBeAg at the end of treatment (44 versus 29 percent), but there were more HBeAg seroreversions during follow-up. The response rates were similar when considering suppression of HBV DNA or changes in the serum aminotransferase levels. Response rates were higher in patients with HBV genotype A (47 percent) and B (44 percent) compared to genotype C (28 percent) and D (26 percent). The authors concluded that combination therapy was not superior to peginterferon monotherapy.",
"     </li>",
"     <li>",
"      Another trial included 100 Chinese patients with HBeAg positive chronic hepatitis and moderately elevated ALT levels who were randomly assigned to either peginterferon-alfa-2b (1.5",
"      <span class=\"nowrap\">",
"       mcg/kg",
"      </span>",
"      per week, maximum 100 mcg) for 32 weeks plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) for 52 weeks or lamivudine monotherapy [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/9\">",
"       9",
"      </a>",
"      ]. The study did not include a peginterferon monotherapy group. A sustained virologic response was defined as HBeAg seroconversion, and an HBV DNA level less than 500,000",
"      <span class=\"nowrap\">",
"       copies/mL",
"      </span>",
"      at least 24 weeks after the end of treatment. The rate of sustained virologic response was significantly higher in the combination therapy group (36 versus 14 percent). There were no significant differences in the proportion of patients with normalization of serum ALT or histologic improvement. Lamivudine-resistant mutations were detected more often in the monotherapy group compared with the combination therapy group (40 versus 21 percent). A follow-up report showed that the higher rate of sustained virologic response in the combination group was maintained for up to three years (29 versus 9 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Significance of ALT flares",
"    </span>",
"    &nbsp;&mdash;&nbsp;ALT flares during interferon-based treatment are sometimes associated with HBeAg seroconversion. By contrast, ALT flares after discontinuation of nucleos(t)ide analogues are related to viral relapse. A post-hoc analysis of one of the controlled trials cited above [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/10\">",
"     10",
"    </a>",
"    ] (reported as an abstract) evaluated the significance of ALT flares in 814 HBeAg-positive patients who had been randomly assigned to peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    or placebo, or to lamivudine monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/12\">",
"     12",
"    </a>",
"    ]. Marked on-treatment ALT elevations (defined as an ALT &gt;10x the upper limit of normal) were more frequent with peginterferon monotherapy and were more likely to be associated with HBeAg seroconversion (32 versus 27 and 19 percent in the peginterferon monotherapy, combination therapy, or lamivudine monotherapy groups, respectively).",
"   </p>",
"   <p>",
"    Eight patients had a flare after treatment that was considered to be a serious adverse event (four following peginterferon with or without",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and four following lamivudine monotherapy). The flare led to hepatic decompensation in two patients (both in the lamivudine monotherapy group, n=272), one of whom died and the other needing a liver transplant. The authors concluded that marked on-treatment ALT elevations were more frequent with peginterferon monotherapy and were more common in patients with HBeAg seroconversion 24 weeks after the end of treatment. In contrast, marked flares during the follow-up phase were more frequent with lamivudine and appeared to be more serious.",
"   </p>",
"   <p>",
"    In another study, ALT flares occurred in 38 (51 percent) patients who received peginterferon and",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and in 37 (49 percent) patients who received peginterferon monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/7\">",
"     7",
"    </a>",
"    ]. Overall, flares were not more common in responders. However, host induced flares (flares followed by HBV DNA decrease) were significantly more likely to be associated with HBeAg loss than virus induced flares (flares following HBV DNA increase): 58 versus 20 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/13\">",
"     13",
"    </a>",
"    ]. Furthermore, HBsAg loss was exclusively seen in patients who had a host induced flare.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     HBeAg negative chronic HBV",
"    </span>",
"    &nbsp;&mdash;&nbsp;One trial included a total of 537 patients with HBeAg negative chronic HBV infection who were randomly assigned to three groups [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      peginterferon alfa-2a (180 mcg weekly) plus placebo for 48 weeks",
"     </li>",
"     <li>",
"      peginterferon alfa-2a plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      (100 mg daily) for 48 weeks",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       Lamivudine",
"      </a>",
"      for 48 weeks",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Approximately two-thirds of patients were Asian and most (82 to 86 percent) were male. The mean serum ALT ranged from 91 to 106",
"    <span class=\"nowrap\">",
"     U/L,",
"    </span>",
"    the mean (log10) HBV DNA titer ranged from 7.1 to 7.4",
"    <span class=\"nowrap\">",
"     copies/mL,",
"    </span>",
"    22 to 31 percent had bridging fibrosis or cirrhosis.",
"   </p>",
"   <p>",
"    After 24 weeks of follow-up, the percentage of patients with normalization of serum ALT levels or HBV DNA levels below 20,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    was significantly higher with peginterferon monotherapy (59 and 43 percent, respectively) or combination therapy (60 and 44 percent, respectively) compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    monotherapy (44 and 29 percent, respectively). Rates of sustained suppression of HBV DNA to below 400",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were also significantly higher in the peginterferon monotherapy or combination therapy groups compared with lamivudine monotherapy (19 and 20 versus 7 percent, respectively). Loss of HBsAg occurred in 12 patients in the peginterferon groups compared with 0 patients in the lamivudine groups. Adverse events including pyrexia, fatigue, myalgia, and headache were less frequently observed in the lamivudine monotherapy groups.",
"   </p>",
"   <p>",
"    The authors concluded that patients with HBeAg-negative chronic HBV had significantly higher rates of response with peginterferon compared with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    and the addition of lamivudine to peginterferon did not improve response rates.",
"   </p>",
"   <p>",
"    A subsequent report described follow-up for up to three years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/14\">",
"     14",
"    </a>",
"    ]. The proportion of patients with a normal ALT was significantly higher with peginterferon monotherapy or combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    compared with lamivudine alone (31 and 31 versus 18 percent, respectively). HBV DNA levels &le;10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were also more likely in those who received peginterferon monotherapy or combination therapy compared with lamivudine (28 and 25 versus 15 percent, respectively). Of those who received peginterferon, 9 percent cleared HBsAg.",
"   </p>",
"   <p>",
"    These data indicate that 25 to 30 percent of patients with HBeAg-negative chronic hepatitis B had sustained",
"    <span class=\"nowrap\">",
"     biochemical/clinical",
"    </span>",
"    remission after a one-year course of peginterferon. However, only 59 percent of patients entered the long-term follow-up study. Intention to treat analysis including all patients in the original trial showed that ALT normalization was observed in only 20 percent of patients who received peginterferon monotherapy, 20 percent of those who received combination therapy compared with 8 percent of those who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    . Similarly, HBV DNA levels &le;10,000",
"    <span class=\"nowrap\">",
"     copies/mL",
"    </span>",
"    were observed in 18 and 16 versus 7 percent of these groups, respectively.",
"   </p>",
"   <p>",
"    Peginterferon monotherapy for 48 weeks results in a low rate of sustained response. Extension of peginterferon to 96 weeks with or without the addition of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    has also been evaluated. In a randomized controlled trial, 128 patients with HBeAg negative chronic HBV genotype D were randomly assigned to one of three treatment arms: peginterferon alpha-2a (180 &mu;g weekly) for 48 weeks, peginterferon alpha-2a (180 &mu;g weekly) for 48 weeks followed by 135 &mu;g weekly for an additional 48 weeks, or combination treatment of peginterferon alpha-2a (180 &mu;g weekly) and lamivudine (100",
"    <span class=\"nowrap\">",
"     mg/day)",
"    </span>",
"    for 48 weeks followed by peginterferon alpha-2a (135 &mu;g weekly) for 48 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/15\">",
"     15",
"    </a>",
"    ]. At 48-week post-treatment follow-up, extended treatment with peginterferon alpha-2a alone for 96 weeks as compared with 48 weeks resulted in a higher proportion of patients achieving a virological response (HBV DNA &lt;2000 int.",
"    <span class=\"nowrap\">",
"     units/mL:",
"    </span>",
"    29 versus 12 percent). However, virological response at the end of treatment or at 24 weeks after treatment was similar. Combination treatment was not associated with a higher virological response as compared with peginterferon alpha-2a alone, regardless of duration. However, only 13 patients in the combination treatment group completed follow-up. There were no significant differences in discontinuation rates in the peginterferon 96-week arms compared with the 48-week arm. Given the costs and potential for more adverse events, the clinical benefits of extended therapy with peginterferon alpha-2a need to be validated in larger studies. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=see_link&amp;anchor=H10#H10\">",
"     \"Overview of the management of hepatitis B and case examples\", section on 'Interferon'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=see_link&amp;anchor=H14#H14\">",
"     \"Clinical significance of hepatitis B virus genotypes\", section on 'Responses to interferon'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     TELBIVUDINE PLUS PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;A clinical trial examining combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    plus peginterferon was terminated early because of a high rate of peripheral neuropathy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     ADEFOVIR PLUS PEGINTERFERON",
"    </span>",
"    &nbsp;&mdash;&nbsp;An initial report of combination therapy with peginterferon plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    found a marked decrease in HBV DNA. This trial involved 24 patients who were treated with 48 weeks of combination therapy followed by 96 weeks of adefovir monotherapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/17,18\">",
"     17,18",
"    </a>",
"    ]. At week 144, 12 of 15 patients who were HBeAg positive had lost HBeAg while ALT levels normalized in 23 patients (96 percent). Histologic improvement was noted in 11 of 16 patients who had a follow-up biopsy. Two patients developed adefovir resistance. These promising results need to be confirmed in larger studies.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN PATIENTS WITH RESISTANCE TO LAMIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     Adefovir",
"    </a>",
"    dipivoxil (bis-POM PMEA) is a nucleotide analog of adenosine monophosphate, which can inhibit reverse transcriptase and DNA polymerase activity levels. It has been approved as primary monotherapy for chronic hepatitis B, in patients who developed resistance to",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    , and as combination therapy with other agents. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=see_link\">",
"     \"Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=see_link&amp;anchor=H20#H20\">",
"     \"Liver transplantation for chronic hepatitis B virus infection\", section on 'Management of recurrent HBV infection'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN PATIENTS WHO HAVE NOT PREVIOUSLY RECEIVED TREATMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    appears to reduce resistance to lamivudine when both drugs are given to patients who have never received treatment. A randomized controlled trial included 115 treatment-na&iuml;ve patients with HBeAg positive HBV who received lamivudine (100 mg daily) plus placebo or lamivudine plus adefovir (10 mg daily) for two years [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/19\">",
"     19",
"    </a>",
"    ]. The degree of reduction on HBV DNA was similar in the two arms at week 16 (the primary study endpoint). However, HBV DNA breakthrough was observed more often in the monotherapy group (44 versus 19 percent). Not all the breakthroughs were associated with genotypic resistance. Rates of HBeAg seroconversion were identical (35 percent). These results indicate that combination therapy has the potential to decrease development of resistance to lamivudine but does not result in more potent HBV DNA suppression or increase the rate of HBeAg seroconversion at two years.",
"   </p>",
"   <p>",
"    The rate of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    resistance in the de novo combination therapy group remained disappointingly high. One possible explanation for such a high rate of drug resistance in patients receiving two drugs that are not cross-resistant may be related to the weak antiviral activity of the approved dose of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    . Another limitation of the study was a high drop-out rate in year two.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     LAMIVUDINE PLUS TELBIVUDINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;A phase II trial evaluated combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"     lamivudine",
"    </a>",
"    plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"     telbivudine",
"    </a>",
"    (L-deoxythymidine, a nucleoside analogue) to lamivudine or telbivudine alone in 104 patients with compensated, HBeAg positive HBV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/20\">",
"     20",
"    </a>",
"    ]. No significant benefit of combination therapy was observed after 52 weeks compared with telbivudine alone for all parameters analyzed: HBV DNA suppression, HBeAg seroconversion, normalization of ALT, and emergence of drug resistance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     ADEFOVIR DIPIVOXIL PLUS EMTRICITABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"     adefovir",
"    </a>",
"    dipivoxil plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    was compared to adefovir monotherapy in a placebo-controlled trial involving 30 treatment naive patients with HBeAg positive HBV [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/21\">",
"     21",
"    </a>",
"    ]. Patients were randomly assigned to adefovir plus emtricitabine or adefovir alone for 96 weeks. The median decrease in HBV DNA at the end of treatment was higher in the combination group (-5.3 versus -3.98 log10",
"    <span class=\"nowrap\">",
"     copies/mL).",
"    </span>",
"    More patients in the combination group had normalization of serum ALT and a reduction in HBV DNA to &lt;300",
"    <span class=\"nowrap\">",
"     copies/mL.",
"    </span>",
"    However, HBeAg seroconversion was similar in the two groups (14 versus 25 percent). No resistance to either drug was detected at week 96. The absence of an emtricitabine monotherapy arm makes it difficult to determine whether the greater degree of viral suppression was attributable to the combination regimen or was due to emtricitabine, which is more potent than adefovir at suppressing HBV replication.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     TENOFOVIR DISOPROXIL PLUS EMTRICITABINE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    disoproxil plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/15/5366?source=see_link\">",
"     emtricitabine",
"    </a>",
"    is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H114035657\">",
"    <span class=\"h1\">",
"     TENOFOVIR DISOPROXIL PLUS ENTECAVIR",
"    </span>",
"    &nbsp;&mdash;&nbsp;Combination therapy with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"     tenofovir",
"    </a>",
"    disoproxil plus",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"     entecavir",
"    </a>",
"    in previously-treated patients who were refractory to therapy is described separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=see_link\">",
"     \"Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection\"",
"    </a>",
"    .) The largest controlled trial evaluating previously untreated patients focused on 379 patients with HBeAg positive or negative chronic HBV who were randomly assigned to entecavir monotherapy (0.5 mg daily) or combination therapy with tenofovir (300 mg daily) for 100 weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12760/abstract/22\">",
"     22",
"    </a>",
"    ]. At week 96, the proportion of patients achieving the primary endpoint (HBV DNA levels less than 50 international",
"    <span class=\"nowrap\">",
"     units/mL)",
"    </span>",
"    was similar in both groups. However, in a subgroup analysis, combination therapy was more effective (79 versus 62 percent) in HBeAg positive patients who had baseline HBV DNA levels of &ge;10(8) int.",
"    <span class=\"nowrap\">",
"     units/mL.",
"    </span>",
"    None of the patients in either group had evidence of antiviral resistance at the end of the study. Although the rate of ALT normalization was higher in the patients that received entecavir monotherapy as compared with combination therapy, there was no significant difference in the rates of HBeAg seroconversion and HBeAg loss. These data suggest that de novo combination of tenofovir disoproxil plus entecavir does not offer any benefit compared with entecavir monotherapy in most patients; whether accelerated viral suppression in patients with high baseline HBV DNA is clinically relevant remains to be determined.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=see_link\">",
"       \"Patient information: Hepatitis B (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=see_link\">",
"       \"Patient information: Hepatitis B (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Combination therapy offers the potential to achieve three important goals in the treatment of HBV: increasing the rate of HBeAg seroconversion or viral clearance, and (in those in whom this cannot be accomplished) achieving long-term viral suppression while avoiding drug resistance. Unfortunately, none of these goals has been achieved convincingly to an extent greater than with currently available monotherapies. This may be because all nucleos(t)ide analogs for HBV have the same viral target. Most studies on combination therapy have focused on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and the main advantage observed is a reduction in incidence of lamivudine resistance. Given the low rate of antiviral resistance associated with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      monotherapy, it would be difficult to demonstrate that combination therapy will provide additional benefit.",
"     </li>",
"     <li>",
"      Clinical trials comparing peginterferon and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      to peginterferon alone suggest that while initial response rate is higher in the combination therapy group, sustained response after stopping treatment is not increased. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Lamivudine plus peginterferon'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Studies comparing two antiviral agents (",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/7/38007?source=see_link\">",
"       lamivudine",
"      </a>",
"      and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?10/44/10949?source=see_link\">",
"       adefovir",
"      </a>",
"      or lamivudine and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?3/15/3317?source=see_link\">",
"       telbivudine",
"      </a>",
"      ) to single antiviral agent suggest that virological response rate is not increased but drug-resistance is reduced.",
"     </li>",
"     <li>",
"      One trial comparing combination of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?18/47/19191?source=see_link\">",
"       tenofovir",
"      </a>",
"      disoproxil plus",
"      <a class=\"drug drug_general\" href=\"UTD.htm?28/55/29557?source=see_link\">",
"       entecavir",
"      </a>",
"      to entecavir monotherapy in treatment na&iuml;ve patients found that overall responses were similar but combination therapy resulted in more rapid viral suppression in HBeAg-positive patients with high baseline HBV DNA. Whether this difference is clinically relevant is not clear. (See",
"      <a class=\"local\" href=\"#H114035657\">",
"       'Tenofovir disoproxil plus entecavir'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/1\">",
"      Richman DD. The impact of drug resistance on the effectiveness of chemotherapy for chronic hepatitis B. Hepatology 2000; 32:866.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/2\">",
"      Schalm SW, Heathcote J, Cianciara J, et al. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46:562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/3\">",
"      Barbaro G, Zechini F, Pellicelli AM, et al. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35:406.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/4\">",
"      Santantonio T, Niro GA, Sinisi E, et al. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/5\">",
"      Schiff ER, Dienstag JL, Karayalcin S, et al. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38:818.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/6\">",
"      Tatulli I, Francavilla R, Rizzo GL, et al. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/7\">",
"      Janssen HL, van Zonneveld M, Senturk H, et al. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365:123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/8\">",
"      Marcellin P, Lau GK, Bonino F, et al. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351:1206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/9\">",
"      Chan HL, Leung NW, Hui AY, et al. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/10\">",
"      Lau G, Luo KX, Marcellin P et al. Peginterferon alfa-2A monotherapy and in combination with lamivudine is more effective than lamivudine monotherapy in HBeAg-positive chronic hepatitis B: results from a large, multinational study (abstract). Hepatology 2004; 40 (Suppl 1):171A.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/11\">",
"      Chan HL, Hui AY, Wong VW, et al. Long-term follow-up of peginterferon and lamivudine combination treatment in HBeAg-positive chronic hepatitis B. Hepatology 2005; 41:1357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/12\">",
"      Piratvisuth T, Luo KX, Marcellin P, et al. Effect of ALT flares on efficacy and safety of peginterferon alfa-2a, peginterferon alfa-2a plus lamivudine and lamivudine in HBeAg-positive chronic hepatitis B (abstract). J Hepatol 2005; :(Suppl).",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/13\">",
"      Flink HJ, Sprengers D, Hansen BE, et al. Flares in chronic hepatitis B patients induced by the host or the virus? Relation to treatment response during Peg-interferon {alpha}-2b therapy. Gut 2005; 54:1604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/14\">",
"      Marcellin P, Bonino F, Lau GK, et al. Sustained response of hepatitis B e antigen-negative patients 3 years after treatment with peginterferon alpha-2a. Gastroenterology 2009; 136:2169.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/15\">",
"      Lampertico P, Vigan&ograve; M, Di Costanzo GG, et al. Randomised study comparing 48 and 96 weeks peginterferon &alpha;-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut 2013; 62:290.",
"     </a>",
"    </li>",
"    <li>",
"     file://www.clinicaltrials.gov/ct2/show/NCT00412750?term=telbivudine&amp;rank=2 (Accessed on July 08, 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/17\">",
"      Wursthorn K, Lutgehetmann M, Dandri M, et al. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/18\">",
"      Lutgehetmann M, Volzt T, Quaas A, et al. Sequential combination therapy leads to biochemical and histological improvement despite low ongoing intrahepatic hepatitis B virus replication. Antivir Ther 2008; 13:57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/19\">",
"      Sung JJ, Lai JY, Zeuzem S, et al. Lamivudine compared with lamivudine and adefovir dipivoxil for the treatment of HBeAg-positive chronic hepatitis B. J Hepatol 2008; 48:728.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/20\">",
"      Lai CL, Leung N, Teo EK, et al. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 2005; 129:528.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/21\">",
"      Hui CK, Zhang HY, Bowden S, et al. 96 weeks combination of adefovir dipivoxil plus emtricitabine vs. adefovir dipivoxil monotherapy in the treatment of chronic hepatitis B. J Hepatol 2008; 48:714.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12760/abstract/22\">",
"      Lok AS, Trinh H, Carosi G, et al. Efficacy of entecavir with or without tenofovir disoproxil fumarate for nucleos(t)ide-na&iuml;ve patients with chronic hepatitis B. Gastroenterology 2012; 143:619.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3646 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-118.195.65.247-9CA6F9C4F1-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12760=[""].join("\n");
var outline_f12_29_12760=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H20\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      LAMIVUDINE PLUS STANDARD INTERFERON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Treatment-na&iuml;ve patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Interferon nonresponders",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      HBeAg negative chronic hepatitis B",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      LAMIVUDINE PLUS PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      HBeAg positive chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Significance of ALT flares",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      HBeAg negative chronic HBV",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      TELBIVUDINE PLUS PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      ADEFOVIR PLUS PEGINTERFERON",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN PATIENTS WITH RESISTANCE TO LAMIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LAMIVUDINE PLUS ADEFOVIR DIPIVOXIL IN PATIENTS WHO HAVE NOT PREVIOUSLY RECEIVED TREATMENT",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      LAMIVUDINE PLUS TELBIVUDINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      ADEFOVIR DIPIVOXIL PLUS EMTRICITABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      TENOFOVIR DISOPROXIL PLUS EMTRICITABINE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H114035657\">",
"      TENOFOVIR DISOPROXIL PLUS ENTECAVIR",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/59/36792?source=related_link\">",
"      Adefovir dipivoxil in the treatment of chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/52/36681?source=related_link\">",
"      Clinical significance of hepatitis B virus genotypes",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?38/30/39398?source=related_link\">",
"      Histologic scoring systems for chronic liver disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/24/6538?source=related_link\">",
"      Lamivudine monotherapy for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/2/15402?source=related_link\">",
"      Liver transplantation for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/33/28184?source=related_link\">",
"      Mechanism of action and efficacy of ribavirin for the treatment of chronic hepatitis C virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/51/24378?source=related_link\">",
"      Overview of the management of hepatitis B and case examples",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?30/45/31447?source=related_link\">",
"      Patient information: Hepatitis B (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?25/41/26258?source=related_link\">",
"      Patient information: Hepatitis B (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/24/36234?source=related_link\">",
"      Selecting antiretroviral regimens for the treatment naive HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/60/14281?source=related_link\">",
"      Standard and pegylated interferon for chronic hepatitis B virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/9/28822?source=related_link\">",
"      Tenofovir disoproxil fumarate in the treatment of adults with chronic HBV infection who do not have HIV infection",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12761="Classification and epidemiology of anal cancer";
var content_f12_29_12761=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Classification and epidemiology of anal cancer",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12761/contributors\">",
"     David P Ryan, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Christopher G Willett, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Richard M Goldberg, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12761/contributors\">",
"     Diane MF Savarese, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/29/12761/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Anal cancer is uncommon. It comprises only 2.4 percent of all digestive system malignancies in the United States; only 7060 new cases are diagnosed annually [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The incidence of anal cancer in the general population has increased over the last 30 years, both in the United States and elsewhere [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/2-6\">",
"     2-6",
"    </a>",
"    ]. An increased incidence has been associated with female gender, infection with human papillomavirus (HPV), lifetime number of sexual partners, genital warts, cigarette smoking, receptive anal intercourse, and infection with human immunodeficiency virus (HIV) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/7\">",
"     7",
"    </a>",
"    ]. Thus, from an etiologic standpoint, anal cancer is more similar to genital malignancies than it is to gastrointestinal tract cancers.",
"   </p>",
"   <p>",
"    Substantial progress has been made in the pathophysiology and treatment of anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/8\">",
"     8",
"    </a>",
"    ]. In the 1960s, this malignancy was thought to be due to chronic perianal inflammation, and was treated routinely by abdominoperineal resection, necessitating a permanent colostomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/9\">",
"     9",
"    </a>",
"    ]. As a result of carefully conducted epidemiologic and clinical studies, it is now known that anal cancer is associated with HPV infection and that cure of anal cancer is possible in the majority of patients with preservation of the anal sphincter.",
"   </p>",
"   <p>",
"    The pathology and epidemiology of anal cancer will be reviewed here. The clinical features, diagnosis, and treatment are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=see_link\">",
"     \"Clinical features, staging, and treatment of anal cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     ANATOMY AND HISTOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;The proximal end of the anal canal begins anatomically where the rectum enters the puborectalis sling at the apex of the anal sphincter complex (palpable as the anorectal ring on digital rectal examination, and approximately 1 to 2 cm above the dentate line); it extends distally to the point where the squamous mucosa blends with the perianal skin, which roughly coincides with the palpable intersphincteric groove or the outermost boundary of the internal sphincter muscle, a distance of approximately 4 cm (",
"    <a class=\"graphic graphic_figure graphicRef62539 \" href=\"UTD.htm?14/30/14819\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/10\">",
"     10",
"    </a>",
"    ]. The anal canal is divided by the dentate line, a macroscopically visible landmark that overlies the transition from glandular to squamous mucosa; immediately proximal to the dentate line, a narrow zone of transitional mucosa that is similar to urothelium, is variably present.",
"   </p>",
"   <p>",
"    The proximal region of the anus encompasses mucosa of three different histologic types: glandular, transitional, and nonkeratinizing squamous (proximal to distal, respectively). Distally, the squamous mucosa (which is devoid of epidermal appendages such as hair follicles, apocrine glands and sweat glands) merges with the perianal skin (true epidermis). This mucocutaneous junction has been referred to as the anal \"verge\" or margin. This boundary is indistinct on macroscopic examination, and anatomically, its location may vary with the patient's body habitus.",
"   </p>",
"   <p>",
"    Thus, two categories of tumors arise in the anal region. Tumors that develop from mucosa (any of the three types) are termed anal canal cancers while those that arise within the skin at or distal to the squamous mucocutaneous junction are termed perianal or anal margin cancers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Histology",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several histologic types of malignancy arise within the anus, including squamous cell cancer (SCC), which is most common, adenocarcinoma, melanoma, and rarely, sarcoma (",
"    <a class=\"graphic graphic_table graphicRef76078 \" href=\"UTD.htm?27/56/28555\">",
"     table 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/11\">",
"     11",
"    </a>",
"    ]. Due to the variation in anatomy (particularly the transition zone), the anal canal can be quite short in length in some individuals, and the anatomical location as determined by a surgeon or endoscopist should not determine the classification of a tumor. Rather, the histology and location of tumors in the anal region guide the appropriate diagnosis and treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Anal canal tumors",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is no easily identifiable landmark between the rectum and the anus; in addition, the transition zone has a widely variable histologic appearance. As a result, the pathologic classification of tumors arising in this area may be difficult.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Squamous cell cancers &mdash; Tumors arising in the transitional or squamous mucosa are squamous cell cancers and appear to behave similarly, despite their sometimes variable morphologic appearance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/12,13\">",
"       12,13",
"      </a>",
"      ]. By convention, most series that report outcomes of \"anal cancer\" refer exclusively to these tumors. The term \"anal cancer\" by common definition refers to squamous cell cancers arising within the mucosa of the anus, and the two terms will be used interchangeably throughout this review.",
"      <br/>",
"      <br/>",
"      Basaloid features are identified in approximately 25 percent of squamous cell cancers of the anal canal and must be distinguished from basal cell carcinomas of the perianal skin, which as noted below, are classified as skin cancers. Basaloid (also termed junctional or cloacogenic) carcinoma is a variant of SCC that arises from epithelial transitional zone. However, these terms have largely been abandoned because these tumors are now recognized as nonkeratinizing types of squamous cell carcinoma. Tumors arising within the anal canal above the dentate line are termed nonkeratinizing SCCs, while those arising within the anal canal distal to the dentate line are termed keratinizing SCCs.",
"     </li>",
"     <li>",
"      Adenocarcinomas &mdash; Adenocarcinomas arising from glandular elements within the anal canal are rare, but appear to share a similar natural history to rectal adenocarcinomas, and are treated similarly.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Determination of the anatomic site of origin of carcinomas that overlap the anorectal junction can be problematic. For staging purposes, such tumors are classified as rectal cancers if their epicenter is located more than 2 cm proximal to the dentate line or proximal to the anorectal ring on digital examination, and as anal canal cancers if their epicenter is 2 cm or less from the dentate line [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Perianal skin cancers",
"    </span>",
"    &nbsp;&mdash;&nbsp;The clinical distinction between tumors of the anal canal and those that involve the anal \"margin\" or perianal skin can also be difficult. As noted above, SCCs that arise on any mucosal surface of the anus are treated as anal canal cancers, even if they are located distally at the perianal margin. In contrast, tumors arising within the hair-bearing skin at or distal to the squamous mucocutaneous junction have been termed anal margin cancers. However, the preferred term is perianal skin cancers, since, with the exception of melanomas, tumors arising within the perianal skin behave biologically like skin cancers. Although there are essentially no prospective data validating this practice, these tumors are classified, staged (",
"    <a class=\"graphic graphic_table graphicRef78140 \" href=\"UTD.htm?5/0/5134\">",
"     table 2",
"    </a>",
"    ), and treated as skin cancers rather than anal canal cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/14\">",
"     14",
"    </a>",
"    ]. However, the regional nodal drainage (relevant to the N category) is specific to this anatomic site (",
"    <a class=\"graphic graphic_table graphicRef72273 \" href=\"UTD.htm?15/60/16333\">",
"     table 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Tumors of the perianal skin are most often SCCs but other types of cutaneous malignancies (eg, basal cell carcinoma, melanoma, Bowen's disease, extramammary Paget disease) can arise within this region.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Bowen's disease (SCC in situ) can occur within the perianal skin as it can in other areas of non sun-exposed skin. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=see_link\">",
"       \"Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Melanomas that arise in either the anal canal or perianal skin should be treated according to the same principles commonly applied to this tumor at other sites. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=see_link\">",
"       \"Initial surgical management of melanoma of the skin and unusual sites\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Paget disease of the anus, an intraepithelial adenocarcinoma, can be one of two types: a primary cutaneous malignancy in which the tumor cells show sweat gland differentiation, and a lesion in which there is involvement of adjacent squamous epithelium by lateral",
"      <span class=\"nowrap\">",
"       intramucosal/intraepithelial",
"      </span>",
"      spread from an underlying adenocarcinoma of the rectum or perianal glands.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Lymphatic drainage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Lymphatic drainage of anal cancers is dependent upon the anatomic site of origin [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/15-17\">",
"     15-17",
"    </a>",
"    ]. Tumors originating above the dentate line, similar to rectal cancers, drain to the perirectal and paravertebral nodes. In contrast, tumors arising below the dentate line spread primarily to the superficial inguinal and femoral nodes, areas that are rarely involved by rectal cancer.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK FACTORS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although it remains an uncommon cancer, the incidence of anal cancer is increasing in the United States and other countries [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/2,18-20\">",
"     2,18-20",
"    </a>",
"    ]. In data from the Surveillance, Epidemiology and End Results program of the National Cancer Institute, between 1975-1984 and 1995-2004, US incidence rates increased by 57 percent in men (from 0.79 to 1.24 per 100,000 person-years) and by 41 percent in women (from 1.04-1.47 per 100,000 person-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In certain populations, such as men who have sex with other men (MSM) and HIV-infected patients, there is an especially high incidence of anal cancer. The rate of anal cancer was estimated to be as high as 37 per 100,000 among MSM prior to the HIV epidemic [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/21\">",
"     21",
"    </a>",
"    ], rendering its incidence in this population similar to that of cervical cancer in women prior to the introduction of cervical Papanicolaou (Pap) smear screening [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/13\">",
"     13",
"    </a>",
"    ]. The incidence of anal cancer among HIV-positive MSM has been estimated to be approximately twice that of HIV-negative MSM [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/22,23\">",
"     22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to other common malignancies affecting HIV-positive individuals (eg, Kaposi's sarcoma and non-Hodgkin lymphoma), the incidence of anal cancer has not declined in incidence in the era of potent antiretroviral therapy (formerly referred to as highly active antiretroviral therapy, HAART) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/24,25\">",
"     24,25",
"    </a>",
"    ]. This was demonstrated in a study in San Francisco County, in which the age-adjusted incidence of anal cancer in men aged 40 to 64 years of age (regardless of sexual orientation) more than quadrupled from the pre-HIV period (1973 to 1978) to the present era (1996 to 1999), following the widespread availability of potent antiretroviral therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/26\">",
"     26",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"     \"HIV infection and malignancy: Management considerations\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Risk factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the past, anal cancer was thought to develop in areas of chronic local inflammation or irritation associated with benign anal and perianal conditions such as hemorrhoids, fissures, and fistulae [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/27,28\">",
"     27,28",
"    </a>",
"    ]. Case reports of anal cancer developing in the setting of inflammatory bowel disease (IBD) led to the conclusion that this tumor resulted from chronic inflammation, in a manner similar to the development of colorectal neoplasia in patients with underlying IBD [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/29,30\">",
"     29,30",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=see_link\">",
"     \"Colorectal cancer surveillance in inflammatory bowel disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    However, subsequent case-control studies found little to no impact of a history of hemorrhoids, fistulae, and fissures on the development of anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/31,32\">",
"     31,32",
"    </a>",
"    ]. Furthermore, in a large Danish series, none of the 1160 patients with IBD developed anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/33\">",
"     33",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Sexual activity",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial reports suggesting an increased incidence of the disease in homosexual men provided a link between sexual activity and the development of anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/21,34\">",
"     21,34",
"    </a>",
"    ]. This relationship has been confirmed in subsequent reports as illustrated by the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a population-based, case control study of anal cancer, women with anal cancer were more likely than controls to have a history of genital warts (relative risk [RR] 32.5), herpes simplex 2 (RR 4.1), or chlamydia trachomatis (RR 2.3), while men with anal cancer were more likely than controls to have never been married (RR 8.6), to have engaged in homosexual sexual activity (RR 50), to have practiced receptive anal intercourse (RR 33), and to have a history of genital warts (RR 27) or gonorrhea (RR 17) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/35\">",
"       35",
"      </a>",
"      ]. Subsequent studies confirmed the relationship between anal cancer and receptive anal intercourse in men [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/31,32,36-38\">",
"       31,32,36-38",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      A second case-control study in heterosexuals compared 417 patients with anal cancer, 534 patients with rectal cancer, and 554 normal controls [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/39\">",
"       39",
"      </a>",
"      ]. In multivariate analysis, the strongest risk factors for anal cancer in women were ten or more lifetime sexual partners (RR 4.5) and a history of anal warts (RR 11.7), genital warts (RR 4.6), gonorrhea (RR 3.3), cervical dysplasia (RR 2.3), or sexual partners with a history of a sexually transmitted disease (RR 2.4). A history of engaging in receptive anal intercourse before the age of 30 and at least two anal intercourse partners were also significant risk factors in women. Among heterosexual men, multivariate analysis revealed significantly elevated risks of anal cancer with ten or more lifetime sexual partners (RR 2.5), a history of anal warts (RR 4.9) or a history of syphilis or hepatitis (RR 4.0).",
"     </li>",
"     <li>",
"      Anal cancer and cervical cancer in women &mdash; Further support for the role of sexual activity in the development of anal cancers derive from reports demonstrating a strong relationship between cervical cancer and anal cancer in women [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/40-43\">",
"       40-43",
"      </a>",
"      ]. In data from the Danish Cancer Registry, the odds ratio for developing anal cancer following a diagnosis of cervical cancer was significantly higher than the risk of developing either stomach or colon cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/41\">",
"       41",
"      </a>",
"      ]. In addition, women with anal cancer had a greater likelihood of prior vulvar, vaginal, or cervical cancers [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/42\">",
"       42",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In the Surveillance, Epidemiology and End Results Program (SEER) data base in the United States, the relative risks of developing anal or vaginal cancer following a diagnosis of invasive cervical cancer were 4.6 and 5.6, respectively [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/43\">",
"       43",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Human papillomavirus infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Human papillomavirus (HPV) infection is the most commonly diagnosed sexually transmitted disease in the United States and provides as least part of the link between sexual activity and anal cancer. A close association exists between infection by oncogenic HPV strains and many premalignant and malignant lesions of the genital tract, anus, and rectum [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/39,44\">",
"     39,44",
"    </a>",
"    ]. Furthermore, HPV infection is the common link that explains the association between index and second primary anogenital cancers and oral",
"    <span class=\"nowrap\">",
"     cavity/pharyngeal",
"    </span>",
"    cancers. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=see_link&amp;anchor=H13763970#H13763970\">",
"     \"Human papillomavirus associated head and neck cancer\", section on 'Epidemiology'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=see_link&amp;anchor=H345501696#H345501696\">",
"     \"Second primary malignancies in patients with head and neck cancers\", section on 'Incidence'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV DNA has been isolated from 46 to 100 percent of in situ and invasive SCCs of the anus [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/39,45-47\">",
"     39,45-47",
"    </a>",
"    ], and epidemiologic studies have shown that up to 93 percent of anal SCCs are associated with HPV infection. Women are more likely to have HPV associated anal cancer than are men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    While a number of HPV types can be found in the anogenital tract, only a few have been associated with cancer. The spectrum of HPV types in the anal canal is similar to that described in the cervix and is associated with the same \"risk\" phenotypes. As in cervical cancer, HPV 16 is the most frequently isolated type in anal malignancies [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/39,47,49,50\">",
"     39,47,49,50",
"    </a>",
"    ] and its presence predicts for preinvasive as well as invasive cancer. In contrast, low grade in situ lesions frequently are associated with other HPV subtypes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/38,50,51\">",
"     38,50,51",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The premalignant condition of cervical intraepithelial neoplasia associated with HPV infection (CIN or squamous intraepithelial lesions) also occurs with HPV infections involving the anus (termed anal intraepithelial neoplasia [AIN], also known as anal squamous intraepithelial lesions, ASIL). As in CIN, AIN can be morphologically low grade or high grade. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    HPV infection in the anal canal and perianal region may be subclinical, or clinically apparent as condylomata. AIN, particularly high grade AIN, is considered to be the precursor of anal cancer. Progression of AIN to invasive anal SCC is related to many factors, including HIV seropositivity, a lower CD4 count, the type of HPV infection, and higher levels of DNA of high-risk HPV types in the anal canal [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/52\">",
"     52",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prevalence of HPV infection in men who have sex with men (MSM), a group at high risk for both AIN and invasive anal cancer, is higher in the presence of HIV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/53\">",
"     53",
"    </a>",
"    ]. (see",
"    <a class=\"local\" href=\"#H11\">",
"     'HIV infection'",
"    </a>",
"    below).",
"   </p>",
"   <p>",
"    A substantial minority of anal cancers are not associated with HPV infection. No difference has been noted between HPV positive and HPV negative tumors in regards to patient age, the presence of adjacent dysplasia, ductal differentiation, or prognosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/54\">",
"     54",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Vaccines directed against the HPV types associated with cervical and anal neoplasia in women and anal lesions in males have been developed, and their utility for prevention of anal neoplasia is beginning to be studied. As an example, in a randomized trial involving 4065 males, a quadrivalent HPV vaccine was effective in preventing infection with HPV types 6, 11, 16, and 18 and preventing the development of external genital lesions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=see_link&amp;anchor=H19#H19\">",
"     \"Clinical trials of human papillomavirus vaccines\", section on 'Clinical trials of HPV vaccine in males'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In a planned substudy of that trial evaluating the impact of the quadrivalent vaccine on the development of AIN in 602 men having sex with men (MSM), there was a 78 percent decrease in the incidence of AIN associated with HPV types 6, 11, 16, and 18 among men who received all three vaccine doses compared to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/55\">",
"     55",
"    </a>",
"    ]. The results of this trial and recommendations for the use of HPV vaccines are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=see_link&amp;anchor=H445943593#H445943593\">",
"     \"Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment\", section on 'Prevention'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=see_link\">",
"     \"Recommendations for the use of human papillomavirus vaccines\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     HIV infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is unclear whether HIV infection itself has a direct effect on the development of anal cancer or if this is mediated through HPV. The data supporting a relationship between HIV, HPV, and anal cancer includes the following observations:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Epidemiologic data indicate that the increasing anal cancer rates in the United States between 1980 and 2005 were strongly influenced by the HIV epidemic in males but were independent of HIV infection in females [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/19\">",
"       19",
"      </a>",
"      ]. Among men, the incidence rates increased by 3.4 percent annually overall and by 1.7 percent annually in men without HIV infection. Among women, incidence rates of anal cancer increased 3.3 percent annually overall and by 3.3 percent annually in those without HIV infection.",
"     </li>",
"     <li>",
"      There is a markedly higher incidence of AIN and anal cancer in HIV-infected men, particularly those who have sex with men (MSM) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/53,56-59\">",
"       53,56-59",
"      </a>",
"      ]. In a report of data from 13 cohorts (11 clinic-based, including 34,189 HIV-infected and 114,260 HIV uninfected individuals) that were included in the North American AIDS Cohort Collaboration on Research and Design (NA-ACCORD) for the years 1996 to 2007, the unadjusted anal cancer incidence rates per 100,000 person years were 131 for HIV-infected MSM, 46 for other HIV-infected men, and 2 for HIV-uninfected men [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/59\">",
"       59",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The incidence of HPV infection and HPV associated preinvasive and invasive malignancy is increased in HIV-infected patients, regardless of sexual practice [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/38,60-64\">",
"       38,60-64",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Among HPV infected individuals, the prevalence of high grade AIN and anal carcinoma is higher in those with concomitant HIV infection compared to those who are HIV-negative [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/65\">",
"       65",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a meta-analysis of 53 studies, the prevalence of both high-risk anal HPV subtypes (74 versus 34 percent) and anal cancer (45.9 versus 5.1 per 100,000 men) was significantly higher among HIV-positive as compared to HIV-negative MSM [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/53\">",
"       53",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Despite these observations, the overall impact of HIV infection on incidence rates of anal cancer remains unclear since population-based studies have produced conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/4,19,22,23,66,67\">",
"     4,19,22,23,66,67",
"    </a>",
"    ]. The following observations illustrate the range of findings:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An increased incidence of anal cancer was noted in some reports during the peak of the AIDS epidemic [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/66\">",
"       66",
"      </a>",
"      ]. In New York City, for example, there was a 10-fold increase in the incidence of anal cancer among men aged 20 to 49 from 1979 to 1985, concurrent with the onset of the AIDS epidemic and a marked rise in Kaposi's sarcoma and non-Hodgkin lymphoma in this population [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/66\">",
"       66",
"      </a>",
"      ]. In contrast, case-control studies of single men living in San Francisco did not find a significant rise in the incidence of anal cancer from before the appearance of AIDS in about 1980 to the late 1980s, a period in which there was an increased incidence of both Kaposi's sarcoma and non-Hodgkin lymphoma [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/37,68,69\">",
"       37,68,69",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=see_link\">",
"       \"HIV infection and malignancy: Management considerations\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=see_link\">",
"       \"HIV infection and malignancy: Epidemiology and pathogenesis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In an American series linking registries reporting both AIDS and cancer, the relative risk of developing anal cancer at and after the diagnosis of AIDS was 84 (95% CI 46.4-152) among homosexual patients compared with the general population and 38 (95% CI 9.4-151) among non homosexual patients [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/22\">",
"       22",
"      </a>",
"      ]. However, a second report that linked cancer and AIDS registries across both the United States and Puerto Rico noted only a nonsignificant trend toward an increased risk of anal cancer with the acquisition of AIDS [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/23\">",
"       23",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Patients with a longer duration of HIV infection have a substantially higher rate of anal cancer, but in contrast to other AIDS-associated cancers, the use of potent antiretroviral therapy has not led to a decline in the incidence of anal cancer [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/70,71\">",
"       70,71",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Without controlling for receptive anal intercourse and prior HPV infection, it is difficult to discern the true effect of HIV on the incidence of anal cancer. It is possible that HIV infection interacts with HPV to predispose to anal cancer. In a cohort of 346 HIV-infected and 262 HIV-negative homosexual men, infection with multiple anal HPV types was more common in the HIV-infected patients (73 versus 23 percent), and was associated with significant immunosuppression (CD4 count below",
"    <span class=\"nowrap\">",
"     200/microL)",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/72\">",
"     72",
"    </a>",
"    ]. This finding could reflect increased HPV replication in patients with AIDS, which would allow more HPV types to reach a detectable concentration. Infection with more than one type of HPV is associated with an increased risk of abnormal anal cytology [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/56,73\">",
"     56,73",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=see_link\">",
"     \"Virology of human papillomavirus infections and the link to cancer\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Chronic immunosuppression in HIV infection is also associated with a greater risk of progression from low grade AIN to high grade AIN or invasive cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/38,52\">",
"     38,52",
"    </a>",
"    ]. This was illustrated in a cohort study in which HIV-positive men with a CD4 count below",
"    <span class=\"nowrap\">",
"     500/microL",
"    </span>",
"    were 7.5 times more likely to develop high grade AIN than HIV-negative men [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Chronic immunosuppression not due to HIV",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other causes of chronic immunosuppression, such as solid organ transplantation, also may be associated with the development of high grade AIN and invasive anal carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/74\">",
"     74",
"    </a>",
"    ]. Among renal transplant recipients, for example, the risk of anogenital cancer may be increased as much as 100-fold; this risk has been associated with persistent HPV infection [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/75,76\">",
"     75,76",
"    </a>",
"    ]. Similarly, chronic glucocorticoid therapy for the treatment of autoimmune disease may predispose to both HPV infection and HPV related invasive anal cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/77,78\">",
"     77,78",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=see_link\">",
"     \"Major side effects of systemic glucocorticoids\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Cigarette smoking",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several case-control studies have noted a statistically significant risk of anal cancer in smokers, especially current smokers [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/31,43,47,79-81\">",
"     31,43,47,79-81",
"    </a>",
"    ]. In one series, compared to controls without anal cancer, cigarette smoking was associated with a significantly increased risk of anal cancer (RR 1.9 for 20 pack-years, RR 5.2 for 50 pack-years) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/31\">",
"     31",
"    </a>",
"    ]. Cigarette smoking is highly associated with cervical neoplasia and is thought to act as a co-carcinogen [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12761/abstract/82\">",
"     82",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=see_link\">",
"     \"Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/32/22018?source=see_link\">",
"       \"Patient information: Anal cancer (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18017504\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Anatomically, two categories of tumors arise in the anal region. Tumors that develop from mucosa (any of the three types) are termed anal canal cancers while those that arise within the skin at or distal to the squamous mucocutaneous junction are termed perianal or anal margin cancers. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Anatomy and histology'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Historically, the medical community has distinguished between tumors arising in the perianal hair-bearing skin and tumors in the anal canal in terms of treatment. The former are felt to be biologically similar to squamous cell carcinomas of the skin rather than squamous cell carcinomas of the aerodigestive tract, and have been staged and treated as skin rather than anal canal cancers. However, it is not clear that there are any true differences in the natural history or response to treatment for these two types of squamous cell cancers. Nevertheless, when a squamous cell cancer is identified as arising from the perianal skin rather than the anal canal (which in our experience is very uncommon), it is classified, staged, and treated as skin cancers rather than anal canal cancers. There are essentially no prospective data validating this practice. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Perianal skin cancers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The majority of tumors arising in the transitional or squamous mucosa of the anal canal are squamous cell cancers. The term \"anal cancer\" by common definition refers to squamous cell cancers arising within the mucosa of the anal canal. In contrast, adenocarcinomas arising from glandular elements within the anal canal are rare, but appear to share a similar natural history to rectal adenocarcinomas. They are treated in a manner that is similar to rectal carcinoma rather than anal cancer. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Anal canal tumors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Although it remains an uncommon cancer, the incidence of anal cancer is increasing in the United States and other countries. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Epidemiology and risk factors'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      An increased incidence has been associated with female gender, infection with human papillomavirus (HPV), lifetime number of sexual partners, genital warts, cigarette smoking, receptive anal intercourse, infection with human immunodeficiency virus (HIV) and other causes of chronic immunosuppression. Thus, from an etiologic standpoint, anal cancer is more similar to genital malignancies than it is to gastrointestinal tract cancers. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Risk factors'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/1\">",
"      Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA Cancer J Clin 2013; 63:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/2\">",
"      Johnson LG, Madeleine MM, Newcomer LM, et al. Anal cancer incidence and survival: the surveillance, epidemiology, and end results experience, 1973-2000. Cancer 2004; 101:281.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/3\">",
"      Chiao EY, Krown SE, Stier EA, Schrag D. A population-based analysis of temporal trends in the incidence of squamous anal canal cancer in relation to the HIV epidemic. J Acquir Immune Defic Syndr 2005; 40:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/4\">",
"      Frisch M, Melbye M, M&oslash;ller H. Trends in incidence of anal cancer in Denmark. BMJ 1993; 306:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/5\">",
"      Brewster DH, Bhatti LA. Increasing incidence of squamous cell carcinoma of the anus in Scotland, 1975-2002. Br J Cancer 2006; 95:87.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/6\">",
"      Goldman S, Glimelius B, Nilsson B, P&aring;hlman L. Incidence of anal epidermoid carcinoma in Sweden 1970-1984. Acta Chir Scand 1989; 155:191.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/7\">",
"      Palefsky JM. Anal human papillomavirus infection and anal cancer in HIV-positive individuals: an emerging problem. AIDS 1994; 8:283.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/8\">",
"      Myerson RJ, Karnell LH, Menck HR. The National Cancer Data Base report on carcinoma of the anus. Cancer 1997; 80:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/9\">",
"      Klotz RG Jr, Pamukcoglu T, Souilliard DH. Transitional cloacogenic carcinoma of the anal canal. Clinicopathologic study of three hundred seventy-three cases. Cancer 1967; 20:1727.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.165.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/11\">",
"      Klas JV, Rothenberger DA, Wong WD, Madoff RD. Malignant tumors of the anal canal: the spectrum of disease, treatment, and outcomes. Cancer 1999; 85:1686.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/12\">",
"      Flam M, John M, Pajak TF, et al. Role of mitomycin in combination with fluorouracil and radiotherapy, and of salvage chemoradiation in the definitive nonsurgical treatment of epidermoid carcinoma of the anal canal: results of a phase III randomized intergroup study. J Clin Oncol 1996; 14:2527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/13\">",
"      Bartelink H, Roelofsen F, Eschwege F, et al. Concomitant radiotherapy and chemotherapy is superior to radiotherapy alone in the treatment of locally advanced anal cancer: results of a phase III randomized trial of the European Organization for Research and Treatment of Cancer Radiotherapy and Gastrointestinal Cooperative Groups. J Clin Oncol 1997; 15:2040.",
"     </a>",
"    </li>",
"    <li>",
"     American Joint Committee on Cancer Staging Manual, 7th, Edge SB, Byrd DR, Compton CC, et al (Eds), Springer, New York 2010. p.301.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/15\">",
"      Frost DB, Richards PC, Montague ED, et al. Epidermoid cancer of the anorectum. Cancer 1984; 53:1285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/16\">",
"      Greenall MJ, Quan SH, Stearns MW, et al. Epidermoid cancer of the anal margin. Pathologic features, treatment, and clinical results. Am J Surg 1985; 149:95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/17\">",
"      Pintor MP, Northover JM, Nicholls RJ. Squamous cell carcinoma of the anus at one hospital from 1948 to 1984. Br J Surg 1989; 76:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/18\">",
"      Robinson D, Coupland V, M&oslash;ller H. An analysis of temporal and generational trends in the incidence of anal and other HPV-related cancers in Southeast England. Br J Cancer 2009; 100:527.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/19\">",
"      Shiels MS, Pfeiffer RM, Chaturvedi AK, et al. Impact of the HIV epidemic on the incidence rates of anal cancer in the United States. J Natl Cancer Inst 2012; 104:1591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/20\">",
"      Cook MB, Dawsey SM, Freedman ND, et al. Sex disparities in cancer incidence by period and age. Cancer Epidemiol Biomarkers Prev 2009; 18:1174.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/21\">",
"      Daling JR, Weiss NS, Klopfenstein LL, et al. Correlates of homosexual behavior and the incidence of anal cancer. JAMA 1982; 247:1988.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/22\">",
"      Melbye M, Cot&eacute; TR, Kessler L, et al. High incidence of anal cancer among AIDS patients. The AIDS/Cancer Working Group. Lancet 1994; 343:636.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/23\">",
"      Goedert JJ, Cot&eacute; TR, Virgo P, et al. Spectrum of AIDS-associated malignant disorders. Lancet 1998; 351:1833.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/24\">",
"      Bower M, Powles T, Newsom-Davis T, et al. HIV-associated anal cancer: has highly active antiretroviral therapy reduced the incidence or improved the outcome? J Acquir Immune Defic Syndr 2004; 37:1563.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/25\">",
"      Diamond C, Taylor TH, Aboumrad T, et al. Increased incidence of squamous cell anal cancer among men with AIDS in the era of highly active antiretroviral therapy. Sex Transm Dis 2005; 32:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/26\">",
"      Cress RD, Holly EA. Incidence of anal cancer in California: increased incidence among men in San Francisco, 1973-1999. Prev Med 2003; 36:555.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/27\">",
"      KLINE RJ, SPENCER RJ, HARRISON EG Jr. CARCINOMA ASSOCIATED WITH FISTULA-IN-ANO. Arch Surg 1964; 89:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/28\">",
"      BUCKWALTER JA, JURAYJ MN. Relationship of chronic anorectal disease to carcinoma. AMA Arch Surg 1957; 75:352.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/29\">",
"      Slater G, Greenstein A, Aufses AH Jr. Anal carcinoma in patients with Crohn's disease. Ann Surg 1984; 199:348.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/30\">",
"      Daly JJ, Madrazo A. Anal Crohn's disease with carcinoma in situ. Dig Dis Sci 1980; 25:464.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/31\">",
"      Holly EA, Whittemore AS, Aston DA, et al. Anal cancer incidence: genital warts, anal fissure or fistula, hemorrhoids, and smoking. J Natl Cancer Inst 1989; 81:1726.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/32\">",
"      Frisch M, Olsen JH, Bautz A, Melbye M. Benign anal lesions and the risk of anal cancer. N Engl J Med 1994; 331:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/33\">",
"      Frisch M, Johansen C. Anal carcinoma in inflammatory bowel disease. Br J Cancer 2000; 83:89.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/34\">",
"      Peters RK, Mack TM. Patterns of anal carcinoma by gender and marital status in Los Angeles County. Br J Cancer 1983; 48:629.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/35\">",
"      Daling JR, Weiss NS, Hislop TG, et al. Sexual practices, sexually transmitted diseases, and the incidence of anal cancer. N Engl J Med 1987; 317:973.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/36\">",
"      Melbye M, Rabkin C, Frisch M, Biggar RJ. Changing patterns of anal cancer incidence in the United States, 1940-1989. Am J Epidemiol 1994; 139:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/37\">",
"      Rabkin CS, Yellin F. Cancer incidence in a population with a high prevalence of infection with human immunodeficiency virus type 1. J Natl Cancer Inst 1994; 86:1711.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/38\">",
"      Critchlow CW, Surawicz CM, Holmes KK, et al. Prospective study of high grade anal squamous intraepithelial neoplasia in a cohort of homosexual men: influence of HIV infection, immunosuppression and human papillomavirus infection. AIDS 1995; 9:1255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/39\">",
"      Frisch M, Glimelius B, van den Brule AJ, et al. Sexually transmitted infection as a cause of anal cancer. N Engl J Med 1997; 337:1350.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/40\">",
"      Peters RK, Mack TM, Bernstein L. Parallels in the epidemiology of selected anogenital carcinomas. J Natl Cancer Inst 1984; 72:609.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/41\">",
"      Melbye M, Spr&oslash;gel P. Aetiological parallel between anal cancer and cervical cancer. Lancet 1991; 338:657.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/42\">",
"      Frisch M, Olsen JH, Melbye M. Malignancies that occur before and after anal cancer: clues to their etiology. Am J Epidemiol 1994; 140:12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/43\">",
"      Rabkin CS, Biggar RJ, Melbye M, Curtis RE. Second primary cancers following anal and cervical carcinoma: evidence of shared etiologic factors. Am J Epidemiol 1992; 136:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/44\">",
"      Northfelt DW, Swift PS, Palefsky JM. Anal neoplasia. Pathogenesis, diagnosis, and management. Hematol Oncol Clin North Am 1996; 10:1177.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/45\">",
"      Tilston P. Anal human papillomavirus and anal cancer. J Clin Pathol 1997; 50:625.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/46\">",
"      Bj&oslash;rge T, Engeland A, Luostarinen T, et al. Human papillomavirus infection as a risk factor for anal and perianal skin cancer in a prospective study. Br J Cancer 2002; 87:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/47\">",
"      Daling JR, Madeleine MM, Johnson LG, et al. Human papillomavirus, smoking, and sexual practices in the etiology of anal cancer. Cancer 2004; 101:270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/48\">",
"      Joseph DA, Miller JW, Wu X, et al. Understanding the burden of human papillomavirus-associated anal cancers in the US. Cancer 2008; 113:2892.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/49\">",
"      Zaki SR, Judd R, Coffield LM, et al. Human papillomavirus infection and anal carcinoma. Retrospective analysis by in situ hybridization and the polymerase chain reaction. Am J Pathol 1992; 140:1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/50\">",
"      Palefsky JM, Holly EA, Gonzales J, et al. Detection of human papillomavirus DNA in anal intraepithelial neoplasia and anal cancer. Cancer Res 1991; 51:1014.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/51\">",
"      Duggan MA, Boras VF, Inoue M, et al. Human papillomavirus DNA determination of anal condylomata, dysplasias, and squamous carcinomas with in situ hybridization. Am J Clin Pathol 1989; 92:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/52\">",
"      Palefsky JM, Holly EA, Hogeboom CJ, et al. Virologic, immunologic, and clinical parameters in the incidence and progression of anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual men. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:314.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/53\">",
"      Machalek DA, Poynten M, Jin F, et al. Anal human papillomavirus infection and associated neoplastic lesions in men who have sex with men: a systematic review and meta-analysis. Lancet Oncol 2012; 13:487.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/54\">",
"      Williams GR, Lu QL, Love SB, et al. Properties of HPV-positive and HPV-negative anal carcinomas. J Pathol 1996; 180:378.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/55\">",
"      Palefsky JM, Giuliano AR, Goldstone S, et al. HPV vaccine against anal HPV infection and anal intraepithelial neoplasia. N Engl J Med 2011; 365:1576.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/56\">",
"      Palefsky JM, Gonzales J, Greenblatt RM, et al. Anal intraepithelial neoplasia and anal papillomavirus infection among homosexual males with group IV HIV disease. JAMA 1990; 263:2911.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/57\">",
"      Palefsky JM, Holly EA, Ralston ML, et al. Anal squamous intraepithelial lesions in HIV-positive and HIV-negative homosexual and bisexual men: prevalence and risk factors. J Acquir Immune Defic Syndr Hum Retrovirol 1998; 17:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/58\">",
"      Palefsky JM, Holly EA, Ralston ML, et al. High incidence of anal high-grade squamous intra-epithelial lesions among HIV-positive and HIV-negative homosexual and bisexual men. AIDS 1998; 12:495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/59\">",
"      Silverberg MJ, Lau B, Justice AC, et al. Risk of anal cancer in HIV-infected and HIV-uninfected individuals in North America. Clin Infect Dis 2012; 54:1026.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/60\">",
"      Frisch M, Biggar RJ, Goedert JJ. Human papillomavirus-associated cancers in patients with human immunodeficiency virus infection and acquired immunodeficiency syndrome. J Natl Cancer Inst 2000; 92:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/61\">",
"      Caussy D, Goedert JJ, Palefsky J, et al. Interaction of human immunodeficiency and papilloma viruses: association with anal epithelial abnormality in homosexual men. Int J Cancer 1990; 46:214.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/62\">",
"      Kiviat N, Rompalo A, Bowden R, et al. Anal human papillomavirus infection among human immunodeficiency virus-seropositive and -seronegative men. J Infect Dis 1990; 162:358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/63\">",
"      Williams AB, Darragh TM, Vranizan K, et al. Anal and cervical human papillomavirus infection and risk of anal and cervical epithelial abnormalities in human immunodeficiency virus-infected women. Obstet Gynecol 1994; 83:205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/64\">",
"      Sun XW, Kuhn L, Ellerbrock TV, et al. Human papillomavirus infection in women infected with the human immunodeficiency virus. N Engl J Med 1997; 337:1343.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/65\">",
"      Sobhani I, Vuagnat A, Walker F, et al. Prevalence of high-grade dysplasia and cancer in the anal canal in human papillomavirus-infected individuals. Gastroenterology 2001; 120:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/66\">",
"      Biggar RJ, Burnett W, Mikl J, Nasca P. Cancer among New York men at risk of acquired immunodeficiency syndrome. Int J Cancer 1989; 43:979.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/67\">",
"      Selik RM, Rabkin CS. Cancer death rates associated with human immunodeficiency virus infection in the United States. J Natl Cancer Inst 1998; 90:1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/68\">",
"      Biggar RJ, Horm J, Goedert JJ, Melbye M. Cancer in a group at risk of acquired immunodeficiency syndrome (AIDS) through 1984. Am J Epidemiol 1987; 126:578.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/69\">",
"      Harnly ME, Swan SH, Holly EA, et al. Temporal trends in the incidence of non-Hodgkin's lymphoma and selected malignancies in a population with a high incidence of acquired immunodeficiency syndrome (AIDS). Am J Epidemiol 1988; 128:261.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/70\">",
"      Crum-Cianflone NF, Hullsiek KH, Marconi VC, et al. Anal cancers among HIV-infected persons: HAART is not slowing rising incidence. AIDS 2010; 24:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/71\">",
"      Piketty C, Selinger-Leneman H, Bouvier AM, et al. Incidence of HIV-related anal cancer remains increased despite long-term combined antiretroviral treatment: results from the french hospital database on HIV. J Clin Oncol 2012; 30:4360.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/72\">",
"      Palefsky JM, Holly EA, Ralston ML, Jay N. Prevalence and risk factors for human papillomavirus infection of the anal canal in human immunodeficiency virus (HIV)-positive and HIV-negative homosexual men. J Infect Dis 1998; 177:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/73\">",
"      Unger ER, Vernon SD, Lee DR, et al. Human papillomavirus type in anal epithelial lesions is influenced by human immunodeficiency virus. Arch Pathol Lab Med 1997; 121:820.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/74\">",
"      Penn I. Incidence and treatment of neoplasia after transplantation. J Heart Lung Transplant 1993; 12:S328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/75\">",
"      Penn I. Cancers of the anogenital region in renal transplant recipients. Analysis of 65 cases. Cancer 1986; 58:611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/76\">",
"      Arends MJ, Benton EC, McLaren KM, et al. Renal allograft recipients with high susceptibility to cutaneous malignancy have an increased prevalence of human papillomavirus DNA in skin tumours and a greater risk of anogenital malignancy. Br J Cancer 1997; 75:722.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/77\">",
"      Sillman F, Stanek A, Sedlis A, et al. The relationship between human papillomavirus and lower genital intraepithelial neoplasia in immunosuppressed women. Am J Obstet Gynecol 1984; 150:300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/78\">",
"      Sillman FH, Sedlis A. Anogenital papillomavirus infection and neoplasia in immunodeficient women: an update. Dermatol Clin 1991; 9:353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/79\">",
"      Holmes F, Borek D, Owen-Kummer M, et al. Anal cancer in women. Gastroenterology 1988; 95:107.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/80\">",
"      Daling JR, Sherman KJ, Hislop TG, et al. Cigarette smoking and the risk of anogenital cancer. Am J Epidemiol 1992; 135:180.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/81\">",
"      Frisch M, Glimelius B, Wohlfahrt J, et al. Tobacco smoking as a risk factor in anal carcinoma: an antiestrogenic mechanism? J Natl Cancer Inst 1999; 91:708.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12761/abstract/82\">",
"      Sood AK. Cigarette smoking and cervical cancer: meta-analysis and critical review of recent studies. Am J Prev Med 1991; 7:208.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2474 Version 19.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-122.72.76.133-3453397B85-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12761=[""].join("\n");
var outline_f12_29_12761=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H18017504\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      ANATOMY AND HISTOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Histology",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Anal canal tumors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Perianal skin cancers",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Lymphatic drainage",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      EPIDEMIOLOGY AND RISK FACTORS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Risk factors",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Sexual activity",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Human papillomavirus infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - HIV infection",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Chronic immunosuppression not due to HIV",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Cigarette smoking",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18017504\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ONC/2474\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2474|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?14/30/14819\" title=\"figure 1\">",
"      Anatomy of the anus",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ONC/2474|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?27/56/28555\" title=\"table 1\">",
"      WHO classification anal cancer",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?5/0/5134\" title=\"table 2\">",
"      TNM stage cutaneous SCC",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?15/60/16333\" title=\"table 3\">",
"      Anal cancer TNM stage",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?1/33/1562?source=related_link\">",
"      Anal intraepithelial neoplasia: Diagnosis, screening, prevention, and treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?34/32/35337?source=related_link\">",
"      Cervical cancer screening tests: Techniques and test characteristics of cervical cytology and human papillomavirus testing",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/11/7351?source=related_link\">",
"      Clinical features and diagnosis of cutaneous squamous cell carcinoma (SCC)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/54/38762?source=related_link\">",
"      Clinical features, staging, and treatment of anal cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/10/13480?source=related_link\">",
"      Clinical trials of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/7/25722?source=related_link\">",
"      Colorectal cancer surveillance in inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/36/27206?source=related_link\">",
"      HIV infection and malignancy: Epidemiology and pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/31/30202?source=related_link\">",
"      HIV infection and malignancy: Management considerations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/55/887?source=related_link\">",
"      Human papillomavirus associated head and neck cancer",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/61/26585?source=related_link\">",
"      Initial surgical management of melanoma of the skin and unusual sites",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/47/27386?source=related_link\">",
"      Major side effects of systemic glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/32/22018?source=related_link\">",
"      Patient information: Anal cancer (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/17/19738?source=related_link\">",
"      Recommendations for the use of human papillomavirus vaccines",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/58/15270?source=related_link\">",
"      Second primary malignancies in patients with head and neck cancers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?25/53/26455?source=related_link\">",
"      Virology of human papillomavirus infections and the link to cancer",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12762="Chapter 11A: Renal hydrogen excretion";
var content_f12_29_12762=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Chapter 11A: Renal hydrogen excretion",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Burton D Rose, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?12/29/12762/contributors\">",
"     Theodore W Post, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?12/29/12762/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Aug 2, 2005.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"   </p>",
"   <p>",
"    Acid-base homeostasis can be easily understood if viewed in terms of the",
"    <span class=\"nowrap\">",
"     HCO3-/CO2",
"    </span>",
"    buffering system:",
"   </p>",
"   <p>",
"    (Eq. 1) &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HCO3- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; H2CO3 &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; H2O &nbsp;+ &nbsp;CO2",
"   </p>",
"   <p>",
"    At equilibrium, the relationship between the reactants can be expressed by the law of mass action. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=see_link&amp;anchor=H3#H3\">",
"     \"Chapter 10A: Acids and bases\", section on 'Law of mass action'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;PCO2",
"    <br/>",
"    (Eq. 2) &nbsp; &nbsp;[H+] &nbsp; = &nbsp; &nbsp; 24 &nbsp;x &nbsp;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HCO3-]",
"   </p>",
"   <p>",
"    or by the Henderson-Hasselbalch equation",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-]",
"    <br/>",
"    (Eq. 3) &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; 6.10 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;0.03 PCO2",
"   </p>",
"   <p>",
"    This system plays a central role in the maintenance of acid-base balance, because the HCO3- concentration and the PCO2 can be regulated independently, the former by changes in renal H+ excretion and the latter by changes in the rate of alveolar ventilation.",
"   </p>",
"   <p>",
"    These processes are extremely important, since acids and to a lesser degree bases are continually being added to the body from endogenous metabolic processes. For example, the metabolism of carbohydrates and fats (primarily derived from the diet) results in the production of approximately 15,000 mmol of CO2 per day. Since CO2 combines with H2O to form H2CO3, severe acidemia would ensue if this CO2 were not excreted by the lungs.",
"   </p>",
"   <p>",
"    In addition, the metabolism of proteins and other substances results in the generation of noncarbonic acids and bases [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ]. The H+ ions are derived mostly from the oxidation of sulfur-containing (methionine and cysteine) and cationic (arginine and lysine) amino acids, and the hydrolysis of that component of dietary phosphate that exists as H2PO4-:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Methionine &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;glucose &nbsp;+ &nbsp;urea &nbsp;+ &nbsp;SO4(2-) &nbsp;+ &nbsp;2 H+",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;Arginine+ &nbsp; &mdash;&gt; &nbsp; &nbsp; &nbsp;glucose (or CO2) &nbsp;+ &nbsp;urea &nbsp;+ &nbsp;H+",
"   </p>",
"   <p>",
"    &nbsp; &nbsp;R-H2PO4 &nbsp;+ &nbsp;H2O &nbsp; &nbsp; &mdash;&gt; &nbsp; &nbsp;ROH &nbsp;+ &nbsp;0.8 HPO42-",
"    <span class=\"nowrap\">",
"     /",
"    </span>",
"    0.2 H2PO4- &nbsp; + &nbsp; 1.8 H+",
"   </p>",
"   <p>",
"    The major sources of alkali, on the other hand, are the metabolism of anionic amino acids (glutamate and aspartate) and the oxidation or utilization for gluconeogenesis of organic anions (such as citrate and lactate):",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Glutamate- &nbsp;+ &nbsp;H+ &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;glucose &nbsp;+ &nbsp;urea",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Citrate- &nbsp;+ &nbsp;4.5 O2 &nbsp; &nbsp;&mdash;&gt; &nbsp; 5 CO2 &nbsp;+ &nbsp;3 H2O &nbsp;+ &nbsp;HCO3-",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Lactate- &nbsp;+ &nbsp;H+ &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;glucose &nbsp;+ &nbsp;CO2",
"   </p>",
"   <p>",
"    (The consumption of H+ ions in the first and third reactions is equivalent to the generation of new HCO3- ions in the body). On a normal western diet, the net effect is the production of 50 to 100 meq of H+ per day in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The homeostatic response to these acid and base loads occurs in three stages:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Chemical buffering by the extracellular and intracellular buffers (see Chap. 12).",
"     </li>",
"     <li>",
"      Changes in alveolar ventilation to control the PCO2.",
"     </li>",
"     <li>",
"      Alterations in renal H+ excretion to regulate the plasma HCO3- concentration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    For example, the H2SO4 &nbsp;produced from the oxidation of sulfur-containing amino acids is initially buffered in the extracellular fluid by HCO3-:",
"   </p>",
"   <p>",
"    (Eq. 4) &nbsp; &nbsp; &nbsp;H2SO4 &nbsp;+ &nbsp;2 NaHCO3 &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;Na2SO4 &nbsp;+ &nbsp;2 H2CO3",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &mdash;&gt; &nbsp; &nbsp; 2 H2O &nbsp;+ &nbsp;CO2",
"   </p>",
"   <p>",
"    Although this reaction minimizes the increase in the extracellular H+ concentration, the excess H+ ions must still be excreted by the kidney to prevent progressive depletion of HCO3- and the other body buffers and the development of metabolic acidosis. The CO2 generated by this reaction is excreted by the lungs.",
"   </p>",
"   <p>",
"    Under normal conditions, the steady state is preserved as renal H+ excretion varies directly with the rate of H+ production (",
"    <a class=\"graphic graphic_figure graphicRef71069 \" href=\"UTD.htm?10/62/11245\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/1,3\">",
"     1,3",
"    </a>",
"    ]. If acid generation is enhanced, for example, some of the excess H+ is initially retained, resulting in a slight reduction in the plasma HCO3- concentration (that may be less than 1",
"    <span class=\"nowrap\">",
"     meq/L)",
"    </span>",
"    and in the systemic pH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/3\">",
"     3",
"    </a>",
"    ]. This minimal degree of acidemia, which may be too small to be detected clinically, is at least part the stimulus to increase net renal acid excretion to a level similar to the new higher rate of acid generation.",
"   </p>",
"   <p>",
"    The net effect is that the plasma H+ concentration and pH are maintained within narrow limits. The normal values for these parameters are shown in this figure (",
"    <a class=\"graphic graphic_figure graphicRef65831 \" href=\"UTD.htm?39/51/40765\">",
"     figure 2",
"    </a>",
"    ). The decrease in pH (and increase in H+ concentration) in venous blood is due to the uptake of metabolically produced CO2 in the capillary circulation.",
"   </p>",
"   <p>",
"    The remainder of this chapter will mostly discuss the general mechanisms involved in renal H+ excretion and the factors responsible for the regulation of these processes. It is useful to summarize the steps involved in this complex process in advance:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The kidneys must excrete the 50 to 100 meq of noncarbonic acid generated each day.",
"     </li>",
"     <li>",
"      This is achieved by H+ secretion, although the mechanisms are different in the proximal tubule and thick ascending limb of the loop of Henle (Na+-H+ exchange) and in the collecting tubules (active H+-ATPase pump).",
"     </li>",
"     <li>",
"      The daily acid load cannot be excreted as free H+ ions, since the free H+ concentration in the urine is extremely low (&lt;.05",
"      <span class=\"nowrap\">",
"       meq/L)",
"      </span>",
"      in the physiologic pH range.",
"     </li>",
"     <li>",
"      The daily acid load also cannot be excreted unless virtually all of the filtered HCO3- has been reabsorbed, because HCO3- loss in the urine is equivalent to adding H+ ions to the body.",
"     </li>",
"     <li>",
"      Secreted H+ ions are excreted by binding to either filtered buffers, such as HPO42- and creatinine, or to NH3 to form NH4+. NH4+ is generated from the metabolism of glutamine in the proximal tubule; the rate at which this occurs can be varied according to physiologic needs.",
"     </li>",
"     <li>",
"      The extracellular pH is the primary physiologic regulator of net acid excretion. In pathophysiologic states, however, the effective circulating volume, aldosterone, and the plasma K+ concentration all can affect acid excretion, independent of the systemic pH.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     RENAL HYDROGEN EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The kidneys contribute to acid-base balance by regulating H+ excretion so that the plasma HCO3- concentration remains within appropriate limits. This involves two basic steps: (1) reabsorption of the filtered HCO3-; and (2) excretion of the 50 to 100 meq of H+ produced per day.",
"   </p>",
"   <p>",
"    It is essential to appreciate that loss of filtered HCO3- in the urine is equivalent to the addition of H+ to the body, since both are derived from the dissociation of H2CO3. As a result, virtually all of the filtered HCO3- must be reabsorbed before the dietary H+ load can be excreted. The quantitative importance of this process should not be underestimated. A normal subject with a glomerular filtration rate (GFR) of 180",
"    <span class=\"nowrap\">",
"     L/day",
"    </span>",
"    (125",
"    <span class=\"nowrap\">",
"     mL/min)",
"    </span>",
"    and a plasma HCO3- concentration of 24",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    filters and then must reabsorb approximately 4300 meq of HCO3- each day.",
"   </p>",
"   <p>",
"    The second step in renal acid-base regulation, excretion of the 50 to 100 meq daily H+ load, is accomplished by the combination of H+ ions either with urinary buffers such as HPO42- (referred to as titratable acidity) or with ammonia to form ammonium &mdash; NH3 &nbsp; + &nbsp; H+ &nbsp; &nbsp; &mdash;&gt; &nbsp; NH4+. These processes are important, because the excretion of free H+ ions is minimal. The lowest urine pH that can be achieved in humans is 4.5. Although this is almost 1000 times (3 log units) more acid than the extracellular pH, it still represents an extremely low free H+ concentration of less than 0.04",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    Remember that the free H+ concentration at an extracellular pH of 7.40 is only 40",
"    <span class=\"nowrap\">",
"     nanomol/L,",
"    </span>",
"    one-millionth the size of the daily acid load.",
"   </p>",
"   <p>",
"    The reabsorption of HCO3- and the formation of titratable acidity and NH4+ all involve H+ secretion from the tubular cell into the lumen (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef80603 \" href=\"UTD.htm?37/55/38781\">",
"     figure 4",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef70913 \" href=\"UTD.htm?16/18/16686\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. Three initial points need to be emphasized:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      The secreted H+ ions are generated within the tubular cell from the dissociation of H2O. This process also results in the equimolar production of OH- ions.",
"     </li>",
"     <li>",
"      These OH- ions bind to the active zinc-containing site of intracellular carbonic anhydrase; they then combine with CO2 to form HCO3- ions which are released into the cytosol and returned to the systemic circulation across the basolateral membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/4,6\">",
"       4,6",
"      </a>",
"      ]. The net effect is that the",
"      <strong>",
"       secretion of each H+ ion is associated with the generation of one HCO3- ion in the plasma.",
"      </strong>",
"      If the secreted H+ combines with filtered HCO3-, the result is HCO3- reabsorption (",
"      <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"       figure 3",
"      </a>",
"      ). This maintains the plasma HCO3- concentration by preventing HCO3- loss in the urine. If, however, the secreted H+ combines with HPO42- or NH3, a new HCO3- is added to the peritubular capillary (",
"      <a class=\"graphic graphic_figure graphicRef80603 \" href=\"UTD.htm?37/55/38781\">",
"       figure 4",
"      </a>",
"      and",
"      <a class=\"graphic graphic_figure graphicRef70913 \" href=\"UTD.htm?16/18/16686\">",
"       figure 5",
"      </a>",
"      ). This results in an increase in the plasma HCO3- concentration to",
"      <strong>",
"       replace the HCO3- lost in buffering the daily H+ load",
"      </strong>",
"      (Eq. 4).",
"     </li>",
"     <li>",
"      Different mechanisms are involved in proximal and distal acidification (see below).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Net acid excretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the urinary concentration of free H+ is negligible, the net quantity of H+ excreted in the urine is equal to the amount of H+ excreted as titratable acidity and NH4+ minus any H+ added to the body because of urinary HCO3- loss:",
"   </p>",
"   <p>",
"    (Eq. 5) &nbsp; &nbsp; &nbsp;Net acid excretion &nbsp; = &nbsp; titratable acidity &nbsp;+ &nbsp;NH4+ &nbsp;- &nbsp;urinary HCO3-",
"   </p>",
"   <p>",
"    In the steady state, the net amount of H+ excreted is roughly equal to the normal H+ load of 50 to 100",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (",
"    <a class=\"graphic graphic_figure graphicRef71069 \" href=\"UTD.htm?10/62/11245\">",
"     figure 1",
"    </a>",
"    ). However, this value can exceed 300",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    (primarily due to enhanced NH4+ excretion) if acid production is increased (see below). Net H+ excretion also can have a negative value if a large amount of HCO3- is lost in the urine. This may appropriately occur after the ingestion of citrate-containing fruit juices, since the metabolism of citrate results in the generation of HCO3-. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Proximal acidification",
"    </span>",
"    &nbsp;&mdash;&nbsp;The primary step in proximal acidification is secretion of H+ by the Na+-H+ exchanger (or antiporter) in the luminal membrane&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/7-10\">",
"     7-10",
"    </a>",
"    ]. This transport protein, which also appears to mediate most of HCO3- reabsorption in the thick ascending limb of the loop of Henle [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/11,12\">",
"     11,12",
"    </a>",
"    ], preferentially binds filtered Na+ at its external site and intracellular H+ at its internal site (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A H+-ATPase pump, similar to that in the distal nephron, is also present in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/8,13\">",
"     8,13",
"    </a>",
"    ]. Via the use of different experimental methodologies including genetic deletion, the Na+-H+ exchanger appears to be responsible for approximately two-thirds of proximal H+ secretion, with the H+-ATPase pump being responsible for most of the remainder [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/9,14,15\">",
"     9,14,15",
"    </a>",
"    ]. Preliminary evidence suggests that another Na+-H+ exchanger, NHE8, may also have a role in proximal H+ secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/15\">",
"     15",
"    </a>",
"    ]. Over eight such Na+-H+ exchangers have thus far been identified in mammalian systems, which differ in part by anatomic location and physiologic regulation.",
"   </p>",
"   <p>",
"    The energy for Na+-H+ exchange is indirectly provided by the Na+-K+-ATPase pump in the basolateral membrane. This pump transports reabsorbed Na+ into the peritubular capillary and maintains the effective cell Na+ concentration at a relatively low level (10 to 30",
"    <span class=\"nowrap\">",
"     meq/L).",
"    </span>",
"    The low cell Na+ concentration creates a favorable gradient for the passive diffusion of luminal Na+ into the cell that is large enough to drive active H+ secretion via",
"    <strong>",
"     electroneutral",
"    </strong>",
"    Na+-H+ exchange.",
"   </p>",
"   <p>",
"    The action of the Na+-H+ antiporters may also be mediated by changes in intracellular pH. Changes in intracellular pH result in binding of charged ions to this antiporter, which elicit a conformational change that allows ion exchange [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Proximal acidification also requires that the HCO3- formed within the cell be returned to the systemic circulation. As depicted in this figure (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    ), this is primarily achieved by a Na+-3HCO3- cotransporter in the basolateral membrane, although a Cl--HCO3- exchanger also is present, particularly in the S3 segment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/17-19\">",
"     17-19",
"    </a>",
"    ]. The Na+-3HCO3- transporter (which may actually function as Na+:CO3(2-):HCO3- carrier) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/19\">",
"     19",
"    </a>",
"    ] results in the net movement of negative charge. The energy for this process is provided by the electronegative potential within the cell that is created in part by the 3Na+ out-to-2K+ in stoichiometry of the Na+-K+-ATPase pump [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Distal acidification",
"    </span>",
"    &nbsp;&mdash;&nbsp;H+ secretion in the distal nephron primarily occurs in the intercalated cells in the cortical collecting tubule and in the cells in the outer and inner medullary collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/21-25\">",
"     21-25",
"    </a>",
"    ]; the distal tubule also may contribute but appears to be quantitatively less important [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/26\">",
"     26",
"    </a>",
"    ]. As illustrated in this figure (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    ), there are three main characteristics of distal acidification, which are somewhat different from acid secretion in the proximal tubule:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      H+ secretion is mediated by active secretory pumps in the luminal membrane [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/27-31\">",
"       27-31",
"      </a>",
"      ]. Both H+-ATPase and H+-K+-ATPase pumps are present [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/27,32,33\">",
"       27,32,33",
"      </a>",
"      ]. The latter is an exchange pump, leading to H+ secretion and K+ reabsorption; its main role may be in minimizing K+ loss during hypokalemia rather than in regulating acid-base balance [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/27,30,34\">",
"       27,30,34",
"      </a>",
"      ]. Following appropriate stimuli, such as systemic acidemia, cytoplasmic vesicles containing the H+-ATPase pumps move to fuse with the luminal membrane, resulting in H+ secretion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/35,36\">",
"       35,36",
"      </a>",
"      ]. Electroneutrality is maintained in this setting by concurrent secretion of Cl- via voltage-dependent mechanisms [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/21,28\">",
"       21,28",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp;Note that the Na+-H+ antiporter would not be an efficient mechanism of distal acidification, since the activity of this carrier is limited by the transcellular Na+ gradient that provides the energy for H+ secretion. This gradient is diminished in the collecting tubules due to the reduction in the tubular fluid Na+ concentration that can fall below 30",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    in the cortical collecting tubule. Furthermore, the gradient against which H+ must be secreted is markedly increased in these segments. A urine pH of 4.8, for example, represents a H+ concentration that is 400 times (2.6 log units) greater than that in the extracellular fluid. The net effect is that H+ secretion by Na+-H+ exchange would require a nonphysiologic cell Na+ concentration well below 1",
"    <span class=\"nowrap\">",
"     meq/L.",
"    </span>",
"    (There is evidence of a basolateral Na+-H+ exchanger in the medullary collecting duct; it is likely, however, that this transporter is primarily involved in the regulation of cell pH rather than systemic acid-base balance [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/37,38\">",
"     37,38",
"    </a>",
"    ]).",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The H+ secretory cells in the distal nephron do not transport Na+, since they have few if any of the luminal membrane Na+ channels or transporters that are required for the entry of luminal Na+ into the cell [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/21,39\">",
"       21,39",
"      </a>",
"      ]. Distal H+ secretion is, however, indirectly influenced by Na+ reabsorption in the principal cells in the cortical collecting tubule. The transport of cationic Na+ through Na+ channels in the luminal membrane, makes the tubular fluid relatively electronegative. This electrical gradient can affect acid handling in two ways: it promotes H+ accumulation in the lumen by minimizing the degree of back diffusion [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/40,41\">",
"       40,41",
"      </a>",
"      ]; and it facilitates the passive reabsorption of HCO3- [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/26\">",
"       26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Bicarbonate exit is mediated by a",
"      <span class=\"nowrap\">",
"       Cl-/HCO3-",
"      </span>",
"      exchanger in the basolateral membrane, thereby returning HCO3- to the systemic circulation [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/19,42\">",
"       19,42",
"      </a>",
"      ]. This protein is a truncated form of the Cl-",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      HCO3- exchanger in red cells (which is also called band 3 protein) [",
"      <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/43\">",
"       43",
"      </a>",
"      ]. The energy for Cl-",
"      <span class=\"nowrap\">",
"       /",
"      </span>",
"      HCO3- exchange is provided by the inward gradient for Cl- entry, since the Cl- concentration in the cells is relatively low&dagger;.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Regulation of the H+-ATPase secretory pumps appears to be mediated by a process of membrane insertion and recycling that is similar to the effect of antidiuretic hormone on luminal membrane water channels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/35,44\">",
"     35,44",
"    </a>",
"    ]. In the medullary collecting tubule and many of the intercalated cells in the cortical collecting tubule, cytoplasmic H+ pumps are inserted into the luminal membrane with an acid load, thereby facilitating excretion of the excess acid. On the other hand, an alkaline load results in recycling of these transporters from the luminal membrane to cytoplasmic vesicles [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/44\">",
"     44",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The net effect of H+ secretion in the collecting tubules is illustrated in this figure (",
"    <a class=\"graphic graphic_figure graphicRef55950 \" href=\"UTD.htm?0/24/398\">",
"     figure 6",
"    </a>",
"    ). The tubular fluid pH falls by about 0.6 units in the proximal tubule, is relatively stable in the loop of Henle and distal tubule which do not play a major role in urinary acidification, and then falls to its lowest level in the collecting tubules (represented in the previous figure as the difference between the distal tubule and the final urine) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/45\">",
"     45",
"    </a>",
"    ] .",
"   </p>",
"   <p>",
"    Impairment in this distal H+ secretory process results in a reduced net acid excretion, metabolic acidosis, and urine pH that is inappropriately high; this disorder is called type 1 (distal) renal tubular acidosis. A number of different defects can directly or indirectly cause this problem. As an example, patients with Sj&ouml;gren's syndrome have been described in whom there is complete absence of H+-ATPase pumps in the intercalated cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/46,47\">",
"     46,47",
"    </a>",
"    ]. How immunologic injury leads to this change is not known. Another mechanism is a mutation in the basolateral",
"    <span class=\"nowrap\">",
"     Cl-/HCO3-",
"    </span>",
"    exchanger [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/48\">",
"     48",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The preceding discussion has emphasized the function of the type A intercalated cells. There is also a second type of intercalated cell (type B) in the cortical collecting tubule that can insert the H+ pumps into the luminal membrane with an acid load or into the basolateral membrane with an alkaline load [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/44\">",
"     44",
"    </a>",
"    ]. The latter process allows HCO3- to be appropriately secreted rather than reabsorbed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h1\">",
"     BICARBONATE REABSORPTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately 90 percent of the filtered HCO3- is reabsorbed in the proximal tubule, most of which occurs in the first 1 to 2 mm of this segment [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/49,50\">",
"     49,50",
"    </a>",
"    ]. The marked reabsorptive capacity of the early proximal tubule appears to be mediated by an increased number of Na+-H+ exchangers and enhanced permeability to HCO3-&dagger; [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/51\">",
"     51",
"    </a>",
"    ]. The remaining 10 percent of the filtered HCO3- is reabsorbed in the more distal segments [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/4\">",
"     4",
"    </a>",
"    ], most of which occurs in the thick ascending limb (primarily by Na+-H+ exchange) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/11,12\">",
"     11,12",
"    </a>",
"    ] and in the outer medullary collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/21-23\">",
"     21-23",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Carbonic anhydrase and disequilibrium pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;Carbonic anhydrase within the tubular cells plays a central role in HCO3- reabsorption by facilitating the formation of HCO3- from the combination of OH- ions with CO2 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/6,52-55\">",
"     6,52-55",
"    </a>",
"    ]. The role of luminal carbonic anhydrase in the proximal tubule is less well appreciated. As H+ ions are secreted, two separate reactions occur in the tubular lumen (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    ): (1) the combination of H+ with filtered HCO3- to form H2CO3, and (2) the dehydration of H2CO3 into CO2 &nbsp;+ &nbsp;H2O, which are then reabsorbed:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;1 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;2",
"    <br/>",
"    (Eq. 1) &nbsp; &nbsp; &nbsp;H+ &nbsp;+ &nbsp;HCO3- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;H2CO3 &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp;CO2 &nbsp;+ &nbsp;H2O",
"   </p>",
"   <p>",
"    Step 2, the dehydration of H2CO3 into CO2 + H2O,normally proceeds relatively slowly. However, this reaction is accelerated in the early proximal tubule because the brush border of the tubular cells contains carbonic anhydrase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. Consequently, there is no accumulation of H2CO3 in the proximal tubular fluid. From the law of mass action, the maintenance of a low H2CO3 concentration drives reaction 1 in Eq. 1 to the right, thereby keeping the free H+ concentration at a relatively low level. In general, the tubular fluid pH falls only 0.6 pH units (from 7.40 in the filtrate to about 6.80 by the end of the proximal convoluted tubule), despite the reabsorption of the majority of the filtered HCO3- (",
"    <a class=\"graphic graphic_figure graphicRef55950 \" href=\"UTD.htm?0/24/398\">",
"     figure 6",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This response is extremely important since, as noted above, the gradient against which H+ is secreted by the Na+-H+ antiporter cannot exceed the favorable inward gradient for Na+. By minimizing the increase in the tubular fluid H+ concentration, luminal carbonic anhydrase minimizes the gradient against which H+ is secreted, thereby allowing continued H+ secretion and HCO3- reabsorption.",
"   </p>",
"   <p>",
"    The contribution of this system can be appreciated from the response to the administration of a carbonic anhydrase inhibitor that enters the cells to a limited degree and therefore inhibits the luminal but not the intracellular enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/52,53\">",
"     52,53",
"    </a>",
"    ]. In this setting, the dehydration of H2CO3 in the lumen is slowed, resulting in increases in the H2CO3 and H+ concentrations, thereby reducing proximal HCO3- reabsorption by up to 80 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/53\">",
"     53",
"    </a>",
"    ]. This ability to induce a HCO3- diuresis&dagger; makes a carbonic anhydrase inhibitor useful in the treatment of some patients with metabolic alkalosis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=see_link\">",
"     \"Treatment of metabolic alkalosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The role of luminal carbonic anhydrase can also be appreciated by comparing the function of the middle (S2) and late (S3) segments of the proximal tubule (",
"    <a class=\"graphic graphic_figure graphicRef58220 \" href=\"UTD.htm?22/29/23006\">",
"     figure 7",
"    </a>",
"    ). Luminal carbonic anhydrase is present in the former, but absent in the latter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/55,56\">",
"     55,56",
"    </a>",
"    ]. As shown in the tubular perfusion experiments in the following figure (",
"    <a class=\"graphic graphic_figure graphicRef62053 \" href=\"UTD.htm?9/60/10190\">",
"     figure 8",
"    </a>",
"    ), both segments can lower the tubular fluid pH by 0.6 to 0.8 units. This is associated with a marked reduction in the luminal HCO3- concentration in the early proximal tubule, due to a relatively high rate of HCO3- reabsorption. In comparison, there is relatively little HCO3- transport in the S3 segment since, in the absence of luminal carbonic anhydrase, secreted H+ ions and H2CO3 accumulate in the tubular fluid, producing a rapid fall in luminal pH that limits further H+ secretion.",
"   </p>",
"   <p>",
"    It is also possible to demonstrate a disequilibrium pH in those segments that lack luminal carbonic anhydrase (the S3 segment, the cortical collecting tubule, and most of the medullary collecting tubule) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/52,56-58\">",
"     52,56-58",
"    </a>",
"    ]. If, for example, the tubular fluid PCO2 and HCO3- are measured in the late proximal tubule, the pH can be calculated from the Henderson-Hasselbalch equation. However, the measured pH is almost 0.5 pH units below the calculated value (6.89 versus 7.35 in the S3 segment), a difference that is referred to as a disequilibrium pH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/52,56\">",
"     52,56",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The error in the calculated pH results from the fact that the pK'a of 6.10 can be applied to",
"    <span class=\"nowrap\">",
"     HCO3-/CO2",
"    </span>",
"    buffer system only when the H2CO3 concentration is relatively low in relation to the dissolved CO2 and HCO3- concentrations. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=see_link&amp;anchor=H2#H2\">",
"     \"Chapter 10B: Buffers\", section on 'Bicarbonate/carbon dioxide buffer system'",
"    </a>",
"    .) The 0.5 unit pH difference in this setting is presumably due to the accumulation of excess acid as H2CO3. The disequilibrium pH can be dissipated by the addition of carbonic anhydrase to the tubular fluid and is absent in those segments that contain this enzyme [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/56,58\">",
"     56,58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The uneven distribution of luminal carbonic anhydrase may play an important role in urinary acidification. The early proximal tubule has this enzyme and is able to reabsorb about 90 percent of the filtered HCO3-. The mid-part of the outer medullary collecting tubule also contains luminal carbonic anhydrase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/58\">",
"     58",
"    </a>",
"    ] and is the most important distal site of HCO3- reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/23\">",
"     23",
"    </a>",
"    ]. The other distal segments, in comparison, lack luminal carbonic anhydrase and are less able to reabsorb HCO3-; however, they play an essential role in NH4+ excretion, since the exaggerated reduction in tubular fluid pH promotes the diffusion of NH3 into the lumen, where it combines with the excess H+ and is trapped as NH4+ (see",
"    <a class=\"local\" href=\"#H10\">",
"     'Ammonium excretion'",
"    </a>",
"    below)&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/5,56-58\">",
"     5,56-58",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Bicarbonate secretion",
"    </span>",
"    &nbsp;&mdash;&nbsp;Virtually all of the filtered HCO3- is reabsorbed in normal subjects in whom there is a requirement to excrete the daily acid load. However, the loss of HCO3- in the urine is an appropriate response in patients with metabolic alkalosis (high arterial pH, high plasma HCO3- concentration). Although this HCO3- diuresis can be achieved by reabsorbing less of the filtered HCO3-, it appears that HCO3- secretion by a second population of intercalated cells in the cortical collecting tubule also contributes to this response [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/22,44,59-61\">",
"     22,44,59-61",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These cells differ from the HCO3--reabsorbing intercalated cells in that the polarity of the membrane transporters can be reversed. H+ and HCO3- ions are still produced within the cell; however, the H+ ions are secreted into the peritubular capillary by the H+-ATPase pump that is now inserted in the basolateral, rather than the luminal, membrane (",
"    <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"     figure 9",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/44,60\">",
"     44,60",
"    </a>",
"    ]. The HCO3- ions, in comparison, are secreted into the tubular lumen by an anion exchanger in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/59,60\">",
"     59,60",
"    </a>",
"    ]. However, the identity of this transporter is uncertain. It is electroneutral and is dependent upon luminal Cl- [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/59\">",
"     59",
"    </a>",
"    ], but does not appear to represent the same Cl--HCO3- exchanger that is present in the basolateral membrane of the HCO3--reabsorbing intercalated cells (",
"    <a class=\"graphic graphic_figure graphicRef60730 \" href=\"UTD.htm?8/8/8335\">",
"     figure 3",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/62,63\">",
"     62,63",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h1\">",
"     TITRATABLE ACIDITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Several weak acids are filtered at the glomerulus and may act as buffers in the urine. Their ability to do so is proportional to the quantity of the buffer present and to its pKa. The latter is important, since maximum buffering occurs at &plusmn; 1.0 pH unit from the pKa (",
"    <a class=\"graphic graphic_figure graphicRef74250 \" href=\"UTD.htm?21/11/21693\">",
"     figure 10",
"    </a>",
"    ). Because of its favorable pKa of 6.80 and its relatively high rate of urinary excretion, HPO4(2-)is the major urinary buffer (",
"    <a class=\"graphic graphic_figure graphicRef80603 \" href=\"UTD.htm?37/55/38781\">",
"     figure 4",
"    </a>",
"    ), with lesser contributions from other weak acids, such as creatinine (pKa &nbsp;= &nbsp;4.97) and uric acid (pKa &nbsp;= &nbsp;5.75).",
"   </p>",
"   <p>",
"    This process is referred to as titratable acidity, since it is measured by the amount of NaOH that must be added to a 24-h urine collection to titrate the urine pH back the same pH as that in the plasma (approximately 7.40 in normal subjects). Under normal conditions, 10 to 40",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    of H+ is buffered by these weak acids.",
"   </p>",
"   <p>",
"    The ability of phosphate to buffer H+ can be illustrated by the following example (",
"    <a class=\"graphic graphic_table graphicRef70080 \" href=\"UTD.htm?10/26/10667\">",
"     table 1",
"    </a>",
"    ). From the Henderson-Hasselbalch equation for the",
"    <span class=\"nowrap\">",
"     HPO4(2-)/",
"    </span>",
"    H2PO4- system,",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; [HPO4(2-)]",
"    <br/>",
"    (Eq. 2) &nbsp; &nbsp;pH &nbsp; = &nbsp; &nbsp; 6.80 &nbsp;+ &nbsp;log &nbsp;&mdash;&mdash;&mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H2PO4-]",
"   </p>",
"   <p>",
"    the ratio of HPO4(2-) to H2PO4- is 4:1 at an arterial pH of 7.40. If 50 mmol of phosphate is excreted in the urine (the remainder of the filtered phosphate being reabsorbed), then 40 mmol exists as HPO4(2-)and 10 mmol as H2PO4- in the glomerular filtrate. If the tubular fluid pH is lowered to 6.8 in the proximal tubule by H+ secretion, then, from Eq. 2, the ratio of HPO4(2-) to H2PO4- will fall to 1:1.",
"   </p>",
"   <p>",
"    As a result, there will now be 25 mmol each of HPO4(2-) and H2PO4- in the tubule. This represents the buffering of 15 mmol (or 15 million nanomol) of H+ by HPO4(2-) with an increase in the free H+ concentration from 40",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    (pH of 7.40) to only 160",
"    <span class=\"nowrap\">",
"     nanomol/L",
"    </span>",
"    (pH of 6.80). Thus, over 99.99 percent of the secreted H+ has been buffered. If the tubular fluid pH is lowered further to 4.8 (H+ concentration of 0.016",
"    <span class=\"nowrap\">",
"     mmol/L)",
"    </span>",
"    in the collecting tubules, essentially all the HPO4(2-) will be converted to H2PO4-, as a total of 39.5 mmol of H+ will have been buffered by the conversion of HPO4(2-) to H2PO4- (",
"    <a class=\"graphic graphic_table graphicRef70080 \" href=\"UTD.htm?10/26/10667\">",
"     table 1",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In summary, the amount of H+ buffered by HPO4(2-) increases as the tubular fluid pH is reduced. However, once the urine pH falls below 5.5, virtually all of the urinary phosphate exists as H2PO4- and further buffering cannot occur unless there is an increase in phosphate excretion. To some degree, acid loading decreases proximal phosphate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/64\">",
"     64",
"    </a>",
"    ] by decreasing the activity of the Na+-phosphate cotransporter that is responsible for the entry of luminal phosphate into the cell [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/65,66\">",
"     65,66",
"    </a>",
"    ]. This effect may be mediated both by decreased affinity for the interaction with Na+ [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/66\">",
"     66",
"    </a>",
"    ] and by conversion of HPO4(2-) to H2PO4-, which binds less avidly to the cotransporter [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/67\">",
"     67",
"    </a>",
"    ]. In addition, some of the excess H+ ions may compete for the Na+ site on the cotransporter, further decreasing phosphate reabsorption [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/65\">",
"     65",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Nevertheless, the ability to enhance net acid excretion by acidemia-induced phosphaturia is usually limited, and it is increased NH4+ excretion that generally constitutes the major adaptation to an acid load. One important exception occurs in diabetic ketoacidosis, where large amounts of &szlig;-hydroxybutyrate (pKa &nbsp;= &nbsp;4.8) are excreted in the urine. These ketoacid anions can act as urinary buffers, augmenting titratable acid excretion by as much as 50",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/68\">",
"     68",
"    </a>",
"    ]. This effect is due both to the high concentration of ketoacid anions present and to the proximity of the pKa of &szlig;-hydroxybutyrate to the acid urine pH.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     AMMONIUM EXCRETION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The ability to excrete H+ ions as ammonium adds an important degree of flexibility to renal acid-base regulation, because the rate of NH4+ production and excretion can be varied according to physiologic needs. The mechanism by which this process occurs has been considered to begin with ammonia (NH3) production by the tubular cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/69\">",
"     69",
"    </a>",
"    ]. Some of the excess NH3 then freely diffuses into the tubular lumen, where it combines with secreted H+ ions to form NH4+:",
"   </p>",
"   <p>",
"    (Eq. 3) &nbsp; &nbsp; &nbsp;NH3 &nbsp;+ &nbsp;H+ &nbsp; &nbsp;&mdash;&gt; &nbsp; &nbsp;NH4+",
"   </p>",
"   <p>",
"    These NH4+ ions are lipid-insoluble and are therefore \"trapped\" in the lumen, since back-diffusion cannot occur.",
"   </p>",
"   <p>",
"    This sequence also explains how NH3 can act as an effective buffer, even though the pKa of this system is 9.0, well above that of the plasma or urine. At a urine pH of 6.0, for example, the ratio of NH3 to NH4+ is 1:1000. The combination of this small amount of NH3 with secreted H+ ions should rapidly utilize all of the available buffer. This does not occur, however, since the ensuing reduction in the tubular fluid NH3 concentration results in the diffusion of more NH3 into the lumen. This ability to replenish the quantity of buffer is not present with titratable acidity; once HPO4(2-) has been converted to H2PO4-, further buffering by this system cannot occur.",
"   </p>",
"   <p>",
"    It is now clear that this model represents an oversimplification and that NH4+ excretion can be viewed as occurring in 3 major steps: (1) NH4+ is produced, primarily in the early proximal tubular cells; (2) luminal NH4+ is partially reabsorbed in the thick ascending limb and the NH3 then recycled within the renal medulla; and (3) the medullary interstitial NH3 reaches high concentrations that allow NH3 to diffuse into the tubular lumen in the medullary collecting tubule, where it is trapped as NH4+ by secreted H+, as predicted from the classic theory [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/69,70\">",
"     69,70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     NH4+ production",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial step in NH4+ excretion is the generation of NH4+ within the tubular cells from the metabolism of amino acids, particularly but not solely glutamine&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/2,69,71\">",
"     2,69,71",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    Glutamine &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp; NH4+ &nbsp;+ &nbsp;glutamate- &nbsp; &nbsp;&lt;&mdash;&gt; &nbsp; &nbsp;NH4+ &nbsp;+ &nbsp;alpha-ketoglutarate(2-)",
"   </p>",
"   <p>",
"    The first of these reactions is catalyzed by phosphate-dependent glutaminase and the second by glutamate dehydrogenase [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/72\">",
"     72",
"    </a>",
"    ]. The subsequent metabolism of alpha-ketoglutarate results in the generation of 2 HCO3- ions [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/2\">",
"     2",
"    </a>",
"    ] that are then returned to the systemic circulation by the Na+-3HCO3- cotransporter in the basolateral membrane (",
"    <a class=\"graphic graphic_figure graphicRef70913 \" href=\"UTD.htm?16/18/16686\">",
"     figure 5",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    Notice that it is primarily NH4+, not NH3, that is produced by these reactions, which occur mostly in the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. Lipid-soluble NH3 can freely diffuse out of the cell across both the luminal and basolateral membranes [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/75\">",
"     75",
"    </a>",
"    ]. In comparison, lipid-insoluble NH4+ can only be secreted into the tubular lumen, since the required transmembrane transporters are present only in the luminal membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/75\">",
"     75",
"    </a>",
"    ]. This process of NH4+ secretion appears to be mediated at least in part by the Na+-H+ antiporter, which can also function as a Na+-NH4+ exchanger (",
"    <a class=\"graphic graphic_figure graphicRef70913 \" href=\"UTD.htm?16/18/16686\">",
"     figure 5",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/75-77\">",
"     75-77",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Medullary recycling",
"    </span>",
"    &nbsp;&mdash;&nbsp;The NH4+ that is produced within the proximal tubule and secreted into the lumen exists in equilibrium with a much lesser quantity of NH3. This NH3 is capable of diffusing out of the lumen into the peritubular capillary, thereby reducing net acid excretion. This effect is minimized by the low urine pH that can lower urinary NH3 levels well below that in the plasma. As depicted in this figure (",
"    <a class=\"graphic graphic_figure graphicRef55950 \" href=\"UTD.htm?0/24/398\">",
"     figure 6",
"    </a>",
"    ), however, the urine does not become maximally acidified until the end of the collecting tubules. It is therefore possible that significant quantities of NH3 could be lost from the lumen, particularly in the medullary collecting tubule where progressive higher luminal concentrations of NH4+ and NH3 are achieved.",
"   </p>",
"   <p>",
"    These potential losses of luminal NH3 are minimized because more than 75 percent of the tubular fluid NH4+ is recycled within the medulla, thereby maintaining a high interstitial NH3 concentration (",
"    <a class=\"graphic graphic_figure graphicRef69352 \" href=\"UTD.htm?2/32/2574\">",
"     figure 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/70,74,78\">",
"     70,74,78",
"    </a>",
"    ]. The primary step in this process is reabsorption in the thick ascending limb by substitution of NH4+ for K+ both on the Na+-K+-2Cl- carrier and, to a much lesser degree, through the K+ channels in the luminal membrane (",
"    <a class=\"graphic graphic_figure graphicRef75301 \" href=\"UTD.htm?30/62/31725\">",
"     figure 12",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/70,79\">",
"     70,79",
"    </a>",
"    ]. The movement of reabsorbed NH4+ into the less acid tubular cell drives Eq. 3 to the left, resulting in the formation of NH3 and H+. The H+ ions are then resecreted into the lumen via a Na+-H+ exchanger, where they promote HCO3- reabsorption by combining with HCO3- that is delivered out of the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/80,81\">",
"     80,81",
"    </a>",
"    ]",
"   </p>",
"   <p>",
"    In comparison, the luminal membrane has the unusual characteristic of being impermeable to NH3 [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/81\">",
"     81",
"    </a>",
"    ]. As a result, the NH3 formed within the cell will diffuse out across the basolateral membrane into the medullary interstitium, and then into those compartments that have the lowest NH3 concentration, which in the tubules is a function of both delivery and the tubular fluid pH. As described above, a relatively small amount of H+ secretion can lead to a large reduction in pH (and the generation of a disequilibrium pH) in those nephron segments that lack luminal carbonic anhydrase (",
"    <a class=\"graphic graphic_figure graphicRef62053 \" href=\"UTD.htm?9/60/10190\">",
"     figure 8",
"    </a>",
"    ). Thus, some of the NH3 will diffuse into the S3 segment of the proximal tubule and then be recycled again in the thick ascending limb [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/56,79\">",
"     56,79",
"    </a>",
"    ]. The net effect is the maintenance of a high medullary interstitial NH3 concentration which promotes secretion into the medullary collecting tubule.",
"   </p>",
"   <p>",
"    Ammonium reabsorption in the thick limb is reduced by hyperkalemia (probably due to competition for the reabsorptive site on the Na+-K+-2Cl- cotransporter) and is enhanced by chronic metabolic acidosis due to increased NH4+ production in and delivery out of the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/78,82\">",
"     78,82",
"    </a>",
"    ]. The latter represents an appropriate response, since the ensuing increase in ammonia recycling will facilitate NH4+ excretion and therefore excretion of the acid load.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     NH3 secretion into the cortical and medullary collecting tubule",
"    </span>",
"    &nbsp;&mdash;&nbsp;The fluid entering the collecting tubules has a relatively low NH3 concentration, because of removal in the loop of Henle. Furthermore, there is no luminal carbonic anhydrase in most of the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/31,58\">",
"     31,58",
"    </a>",
"    ]. As a result, continued H+ secretion (by the H+-ATPase pump) in this segment produces a maximally acid urine that further reduces the tubular fluid NH3 levels. The net effect is that there is a relatively large gradient favoring the free diffusion of interstitial NH3 into the tubular lumen, where it forms NH4+ (",
"    <a class=\"graphic graphic_figure graphicRef69352 \" href=\"UTD.htm?2/32/2574\">",
"     figure 11",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/5,74\">",
"     5,74",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For luminal NH4+ accumulation to occur with maximum efficiency, the NH3 and NH4+ permeabilities must be different from those in the loop of Henle. In the latter segment, the luminal membrane is permeable to NH4+ but not to NH3; these characteristics permit luminal NH4+ to be reabsorbed without NH3 back-diffusion into the lumen. In contrast, the cell membranes in the collecting tubules are highly permeable to NH3 but have only a negligible permeability to NH4+ [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/83\">",
"     83",
"    </a>",
"    ]. As a result, interstitial NH3 can passively diffuse into the tubular lumen where it is then trapped as NH4+.",
"   </p>",
"   <p>",
"    The net effect is that NH3 is secreted into the lumen throughout the collecting tubules [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/70\">",
"     70",
"    </a>",
"    ]. The gradient is greatest in the inner medulla where the interstitial concentration is highest. However, there is a roughly equivalent degree of NH3 secretion in the cortex and outer medulla which have a higher NH3 permeability, due both to an increase in unit permeability and to a greater luminal surface area [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/70,83\">",
"     70,83",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Response to changes in pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;According to this model, NH4+ excretion can be increased in 1 of 2 ways: by increasing proximal NH4+ production from glutamine; and by lowering the urine pH, which will increase NH3 diffusion into the lumen in the medullary collecting tubule (",
"    <a class=\"graphic graphic_figure graphicRef50826 \" href=\"UTD.htm?19/53/20317\">",
"     figure 13",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/70\">",
"     70",
"    </a>",
"    ]. In humans given an acid load, for example, NH4+ excretion begins to increase within 2 h, due mostly to the formation of a more acid urine which increases the efficiency of NH3 secretion into the medullary collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/84\">",
"     84",
"    </a>",
"    ]. Total NH4+ excretion reaches its maximum level at 5 to 6 days, a time at which there is an elevation in both glutamine uptake by the kidney and tubular NH4+ production (",
"    <a class=\"graphic graphic_figure graphicRef80366 \" href=\"UTD.htm?7/46/7917\">",
"     figure 14",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/5,84-86\">",
"     5,84-86",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal models provide confirmation of this sequence. Phosphate-dependent glutaminase activity increases on the first day and glutamate dehydrogenase activity by day 2 to 3 after an acid load [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. However, NH4+ excretion begins to rise on the first day and is much greater than can be explained by the increase in enzyme activity; this response may reflect enhanced efficiency of NH4+ trapping or increased glutamine uptake by the cells [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/87,88\">",
"     87,88",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The adaptive increase in glutamine metabolism with acidemia begins with increased uptake by the proximal tubular cells&dagger;. Under normal conditions, most of the filtered glutamine is reabsorbed by cotransport with Na+, being driven by the favorable electrochemical gradient for passive Na+ entry into the cells. In the presence of acidemia, however, Na+-dependent glutamine uptake also occurs from the peritubular capillary across the basolateral membrane [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/89,90\">",
"     89,90",
"    </a>",
"    ]. It is uncertain if this response involves insertion of new transporters into the membrane or activation of previously inactive carriers. The peritubular capillary is a fertile source of glutamine, since only 20 percent of the renal plasma flow and therefore only 20 percent of the glutamine presented to the kidney normally undergoes glomerular filtration.",
"   </p>",
"   <p>",
"    &nbsp;&dagger;The increment in renal glutamine uptake leads to an initial reduction in circulating glutamine levels [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/85\">",
"     85",
"    </a>",
"    ]. This is then followed by increased glutamine release from skeletal muscle, due in part to activation of glutamine synthetase. How this occurs is not known, but the signal may derive in part from the kidney, since glutamine release from muscle can, in experimental animals, be diminished by nephrectomy [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/85\">",
"     85",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Once within the tubular cells, the proximal metabolism of glutamine is pH-dependent, appropriately increasing with acidemia and decreasing with alkalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/73,74\">",
"     73,74",
"    </a>",
"    ]. How this occurs is incompletely understood as several factors may play an important role. With acidemia, for example, the rise in NH4+ production may be largely mediated by enhanced activity of the enzymes involved in NH4+ production, including phosphate-dependent glutaminase (promoting the metabolism of glutamine to glutamate), glutamate dehydrogenase (promoting the metabolism of glutamate to alpha-ketoglutarate), and alpha-ketoglutarate dehydrogenase (promoting the metabolism of alpha-ketoglutarate) [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/71,88\">",
"     71,88",
"    </a>",
"    ]. These changes in enzyme activity are limited to the proximal tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/88\">",
"     88",
"    </a>",
"    ], which is consistent with this segment being the site of increased NH4+ production in acidemic states [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    It is presumed that proximal glutamine metabolism responds to alterations in cell pH that parallel those in the extracellular fluid. In particular, it may be an alteration in the pH gradient between the cytosol and the mitochondria that constitutes the signal to change the rate of NH4+ production [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/71,91\">",
"     71,91",
"    </a>",
"    ]. Other, most unidentified circulating factors may also contribute, including increased release of glucocorticoids [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/92,93\">",
"     92,93",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Regardless of the exact mechanisms involved, the net effect is that NH4+ excretion can increase from its normal value of 30 to 40",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    to over 300",
"    <span class=\"nowrap\">",
"     meq/day",
"    </span>",
"    with severe metabolic acidosis [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/68,94\">",
"     68,94",
"    </a>",
"    ]. This response, which is in marked contrast to the limited ability to enhance titratable acid excretion, is appropriate; each NH4+ produced results in the equimolar generation of HCO3- from the metabolism of alpha-ketoglutarate [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/2\">",
"     2",
"    </a>",
"    ]. Return of this HCO3- to the systemic circulation then raises the plasma HCO3- concentration toward normal.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Urine pH",
"    </span>",
"    &nbsp;&mdash;&nbsp;As depicted in this figure (",
"    <a class=\"graphic graphic_figure graphicRef62465 \" href=\"UTD.htm?17/31/17917\">",
"     figure 9",
"    </a>",
"    ), the tubular fluid pH falls progressively, reaching its lowest level in the medullary collecting tubule. In humans, the minimum urine pH that can be achieved is 4.5 to 5.0; this represents a maximum plasma-to-tubular fluid H+ gradient of almost 1:1000 (3 log units). The inability to make the urine more acid may reflect a limit on the strength of the H+-ATPase pump or on the impermeability of the tubular epithelium, which is required to prevent the passive backflux of secreted H+ ions out of the lumen.",
"   </p>",
"   <p>",
"    This ability to lower the urine pH is important, because the formation of titratable acidity and NH4+ are pH-dependent, both increasing as the urine is made more acid (",
"    <a class=\"graphic graphic_table graphicRef70080 \" href=\"UTD.htm?10/26/10667\">",
"     table 1",
"    </a>",
"    and",
"    <a class=\"graphic graphic_figure graphicRef50826 \" href=\"UTD.htm?19/53/20317\">",
"     figure 13",
"    </a>",
"    ). If the minimum urine pH were higher at 5.5 to 6.0 (which is still less than that of the plasma), titratable acid and NH4+ excretion would fall and excretion of the daily H+ load might be prevented. This appears to be the mechanism responsible for the acidemia in patients with type 1 (distal) renal tubular acidosis.",
"   </p>",
"   <p>",
"    The pH-dependence of titratable acidity and NH4+ formation also means that these processes (as well as HCO3- reabsorption) occur throughout the nephron as the urine is made more acid. The sites at which they are most likely to occur can be appreciated from the isohydric principle, which states that all three buffer systems must be in equilibrium:",
"   </p>",
"   <p>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HCO3-] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[HPO4(2-)] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[NH3 ]",
"    <br/>",
"    &nbsp;pH &nbsp;= &nbsp;6.1 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp;= &nbsp;6.8 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;&mdash;&mdash;&mdash;&mdash; &nbsp; = &nbsp;9.0 &nbsp;+ &nbsp;log &mdash;&mdash;&mdash;",
"    <br/>",
"    &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; 0.03PCO2 &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[H2PO4-] &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp; &nbsp;[NH4+]",
"   </p>",
"   <p>",
"    Thus, a secreted H+ ion will preferentially be buffered by that system with the highest concentration",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    the pKa closest to the tubular fluid pH [",
"    <a class=\"abstract\" href=\"UTD.htm?12/29/12762/abstract/74\">",
"     74",
"    </a>",
"    ]. In the proximal tubule, most secreted H+ ions are utilized for HCO3- reabsorption, because of the high concentration of HCO3- and the ability to minimize the reduction in pH by the action of luminal carbonic anhydrase. This segment also represents the site in which most NH4+ is secreted into the lumen and in which about one-half of the available HPO4(2-) is buffered (",
"    <a class=\"graphic graphic_table graphicRef70080 \" href=\"UTD.htm?10/26/10667\">",
"     table 1",
"    </a>",
"    ). In contrast, most H+ ions secreted in the medullary collecting tubule (where the urine pH is reduced to its lowest value) combine with secreted NH3, since virtually all the HCO3- has been reabsorbed and most of the HPO4(2-) has already been buffered (which occurs when the urine pH is below 5.8, that is, more than 1 pH unit from the pKa of 6.8).",
"   </p>",
"   <p>",
"    This discussion is continued elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=see_link\">",
"     \"Chapter 11B: Regulation of renal hydrogen excretion\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    (From Rose, BD, Post, TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York, 2001.)",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/1\">",
"      Lennon EJ, Lemann J Jr, Litzow JR. The effects of diet and stool composition on the net external acid balance of normal subjects. J Clin Invest 1966; 45:1601.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/2\">",
"      Halperin ML, Jungas RL. Metabolic production and renal disposal of hydrogen ions. Kidney Int 1983; 24:709.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/3\">",
"      Kurtz I, Maher T, Hulter HN, et al. Effect of diet on plasma acid-base composition in normal humans. Kidney Int 1983; 24:670.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/4\">",
"      DuBose TD Jr, Good DW. Effects of diuretics on renal acid-base transport. Semin Nephrol 1988; 8:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/5\">",
"      Hamm LL, Simon EE. Roles and mechanisms of urinary buffer excretion. Am J Physiol 1987; 253:F595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/6\">",
"      Soleimani M, Aronson PS. Effects of acetazolamide on Na+-HCO-3 cotransport in basolateral membrane vesicles isolated from rabbit renal cortex. J Clin Invest 1989; 83:945.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/7\">",
"      Malnic G. Robert F. Pitts memorial lecture. H+ secretion in renal cortical tubules: kinetic aspects. Kidney Int 1987; 32:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/8\">",
"      Kinsella JL, Aronson PS. Properties of the Na+-H+ exchanger in renal microvillus membrane vesicles. Am J Physiol 1980; 238:F461.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/9\">",
"      Preisig PA, Ives HE, Cragoe EJ Jr, et al. Role of the Na+/H+ antiporter in rat proximal tubule bicarbonate absorption. J Clin Invest 1987; 80:970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/10\">",
"      Goldfarb D, Nord EP. Asymmetric affinity of Na+-H+ antiporter for Na+ at the cytoplasmic versus external transport site. Am J Physiol 1987; 253:F959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/11\">",
"      Good DW. Regulation of bicarbonate and ammonium absorption in the thick ascending limb of the rat. Kidney Int Suppl 1991; 33:S36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/12\">",
"      Capasso G, Unwin R, Agulian S, Giebisch G. Bicarbonate transport along the loop of Henle. I. Microperfusion studies of load and inhibitor sensitivity. J Clin Invest 1991; 88:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/13\">",
"      Maddox DA, Barnes WD, Gennari FJ. Effect of acute increases in filtered HCO3- on renal hydrogen transporters: II. H(+)-ATPase. Kidney Int 1997; 52:446.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/14\">",
"      Schultheis PJ, Clarke LL, Meneton P, et al. Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger. Nat Genet 1998; 19:282.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/15\">",
"      Goyal S, Vanden Heuvel G, Aronson PS. Renal expression of novel Na+/H+ exchanger isoform NHE8. Am J Physiol Renal Physiol 2003; 284:F467.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/16\">",
"      Hunte C, Screpanti E, Venturi M, et al. Structure of a Na+/H+ antiporter and insights into mechanism of action and regulation by pH. Nature 2005; 435:1197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/17\">",
"      Soleimani M, Grassi SM, Aronson PS. Stoichiometry of Na+-HCO-3 cotransport in basolateral membrane vesicles isolated from rabbit renal cortex. J Clin Invest 1987; 79:1276.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/18\">",
"      Kurtz I. Basolateral membrane Na+/H+ antiport, Na+/base cotransport, and Na+-independent Cl-/base exchange in the rabbit S3 proximal tubule. J Clin Invest 1989; 83:616.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/19\">",
"      Preisig PA, Alpern RJ. Basolateral membrane H/HCO3 transport in renal tubules. Kidney Int 1991; 39:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/20\">",
"      Greger R, G&ouml;gelein H. Role of K+ conductive pathways in the nephron. Kidney Int 1987; 31:1055.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/21\">",
"      Levine DZ, Jacobson HR. The regulation of renal acid secretion: new observations from studies of distal nephron segments. Kidney Int 1986; 29:1099.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/22\">",
"      Jacobson HR, Furuya H, Breyer MD. Mechanism and regulation of proton transport in the outer medullary collecting duct. Kidney Int Suppl 1991; 33:S51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/23\">",
"      Lombard WE, Kokko JP, Jacobson HR. Bicarbonate transport in cortical and outer medullary collecting tubules. Am J Physiol 1983; 244:F289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/24\">",
"      Wall SM, Sands JM, Flessner MF, et al. Net acid transport by isolated perfused inner medullary collecting ducts. Am J Physiol 1990; 258:F75.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/25\">",
"      Tsuruoka S, Schwartz GJ. Metabolic acidosis stimulates H+ secretion in the rabbit outer medullary collecting duct (inner stripe) of the kidney. J Clin Invest 1997; 99:1420.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/26\">",
"      Chan YL, Malnic G, Giebisch G. Renal bicarbonate reabsorption in the rat. III. Distal tubule perfusion study of load dependence and bicarbonate permeability. J Clin Invest 1989; 84:931.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/27\">",
"      Garg LC. Respective roles of H-ATPase and H-K-ATPase in ion transport in the kidney. J Am Soc Nephrol 1991; 2:949.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/28\">",
"      Stone DK, Xie XS. Proton translocating ATPases: issues in structure and function. Kidney Int 1988; 33:767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/29\">",
"      Brown D, Hirsch S, Gluck S. Localization of a proton-pumping ATPase in rat kidney. J Clin Invest 1988; 82:2114.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/30\">",
"      Cheval L, Barlet-Bas C, Khadouri C, et al. K(+)-ATPase-mediated Rb+ transport in rat collecting tubule: modulation during K+ deprivation. Am J Physiol 1991; 260:F800.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/31\">",
"      Selvaggio AM, Schwartz JH, Bengele HH, et al. Mechanisms of H+ secretion by inner medullary collecting duct cells. Am J Physiol 1988; 254:F391.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/32\">",
"      Armitage FE, Wingo CS. Luminal acidification in K-replete OMCDi: contributions of H-K-ATPase and bafilomycin-A1-sensitive H-ATPase. Am J Physiol 1994; 267:F450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/33\">",
"      Wingo CS, Smolka AJ. Function and structure of H-K-ATPase in the kidney. Am J Physiol 1995; 269:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/34\">",
"      Kraut JA, Hiura J, Besancon M, et al. Effect of hypokalemia on the abundance of HK alpha 1 and HK alpha 2 protein in the rat kidney. Am J Physiol 1997; 272:F744.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/35\">",
"      Brown D. Membrane recycling and epithelial cell function. Am J Physiol 1989; 256:F1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/36\">",
"      Saboli I, Brown D, Gluck SL, Alper SL. Regulation of AE1 anion exchanger and H(+)-ATPase in rat cortex by acute metabolic acidosis and alkalosis. Kidney Int 1997; 51:125.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/37\">",
"      Hays SR, Alpern RJ. Apical and basolateral membrane H+ extrusion mechanisms in inner stripe of rabbit outer medullary collecting duct. Am J Physiol 1990; 259:F628.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/38\">",
"      Hering-Smith KS, Cragoe EJ Jr, Weiner D, Hamm LL. Inner medullary collecting duct Na(+)-H+ exchanger. Am J Physiol 1991; 260:C1300.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/39\">",
"      Sauer M, Flemmer A, Thurau K, Beck FX. Sodium entry routes in principal and intercalated cells of the isolated perfused cortical collecting duct. Pflugers Arch 1990; 416:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/40\">",
"      Batlle DC. Segmental characterization of defects in collecting tubule acidification. Kidney Int 1986; 30:546.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/41\">",
"      Harrington JT, Hulter HN, Cohen JJ, Madias NE. Mineralocorticoid-stimulated renal acidification: the critical role of dietary sodium. Kidney Int 1986; 30:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/42\">",
"      Star RA. Basolateral membrane sodium-independent Cl-/HCO3- exchanger in rat inner medullary collecting duct cell. J Clin Invest 1990; 85:1959.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/43\">",
"      Kollert-J&ouml;ns A, Wagner S, H&uuml;bner S, et al. Anion exchanger 1 in human kidney and oncocytoma differs from erythroid AE1 in its NH2 terminus. Am J Physiol 1993; 265:F813.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/44\">",
"      Bastani B, Purcell H, Hemken P, et al. Expression and distribution of renal vacuolar proton-translocating adenosine triphosphatase in response to chronic acid and alkali loads in the rat. J Clin Invest 1991; 88:126.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/45\">",
"      DuBose TD Jr, Lucci MS, Hogg RJ, et al. Comparison of acidification parameters in superficial and deep nephrons of the rat. Am J Physiol 1983; 244:F497.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/46\">",
"      Cohen EP, Bastani B, Cohen MR, et al. Absence of H(+)-ATPase in cortical collecting tubules of a patient with Sjogren's syndrome and distal renal tubular acidosis. J Am Soc Nephrol 1992; 3:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/47\">",
"      Bastani B, Haragsim L, Gluck S, Siamopoulos KC. Lack of H-ATPase in distal nephron causing hypokalaemic distal RTA in a patient with Sj&ouml;gren's syndrome. Nephrol Dial Transplant 1995; 10:908.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/48\">",
"      Karet FE, Gainza FJ, Gy&ouml;ry AZ, et al. Mutations in the chloride-bicarbonate exchanger gene AE1 cause autosomal dominant but not autosomal recessive distal renal tubular acidosis. Proc Natl Acad Sci U S A 1998; 95:6337.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/49\">",
"      Liu FY, Cogan MG, Rector FC Jr. Axial heterogeneity in the rat proximal convoluted tubule. II. Osmolality and osmotic water permeability. Am J Physiol 1984; 247:F822.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/50\">",
"      Maddox DA, Gennari FJ. The early proximal tubule: a high-capacity delivery-responsive reabsorptive site. Am J Physiol 1987; 252:F573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/51\">",
"      Liu FY, Cogan MG. Kinetics of bicarbonate transport in the early proximal convoluted tubule. Am J Physiol 1987; 253:F912.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/52\">",
"      Lucci MS, Pucacco LR, DuBose TD Jr, et al. Direct evaluation of acidification by rat proximal tubule: role of carbonic anhydrase. Am J Physiol 1980; 238:F372.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/53\">",
"      Lucci MS, Tinker JP, Weiner IM, DuBose TD Jr. Function of proximal tubule carbonic anhydrase defined by selective inhibition. Am J Physiol 1983; 245:F443.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/54\">",
"      Sasaki S, Marumo F. Effects of carbonic anhydrase inhibitors on basolateral base transport of rabbit proximal straight tubule. Am J Physiol 1989; 257:F947.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/55\">",
"      L&ouml;nnerholm G, Wistrand PJ. Carbonic anhydrase in the human kidney: a histochemical and immunocytochemical study. Kidney Int 1984; 25:886.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/56\">",
"      Kurtz I, Star R, Balaban RS, et al. Spontaneous luminal disequilibrium pH in S3 proximal tubules. Role in ammonia and bicarbonate transport. J Clin Invest 1986; 78:989.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/57\">",
"      Star RA, Kurtz I, Mejia R, et al. Disequilibrium pH and ammonia transport in isolated perfused cortical collecting ducts. Am J Physiol 1987; 253:F1232.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/58\">",
"      Star RA, Burg MB, Knepper MA. Luminal disequilibrium pH and ammonia transport in outer medullary collecting duct [corrected and issued with original paging in Am J Physiol 1987 Aug;253(2 Pt 2)]. Am J Physiol 1987; 252:F1148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/59\">",
"      Star RA, Burg MB, Knepper MA. Bicarbonate secretion and chloride absorption by rabbit cortical collecting ducts. Role of chloride/bicarbonate exchange. J Clin Invest 1985; 76:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/60\">",
"      Schuster VL. Cortical collecting duct bicarbonate secretion. Kidney Int Suppl 1991; 33:S47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/61\">",
"      Levine DZ, Iacovitti M, Harrison V. Bicarbonate secretion in vivo by rat distal tubules during alkalosis induced by dietary chloride restriction and alkali loading. J Clin Invest 1991; 87:1513.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/62\">",
"      Verlander JW, Madsen KM, Tisher CC. Effect of acute respiratory acidosis on two populations of intercalated cells in rat cortical collecting duct. Am J Physiol 1987; 253:F1142.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/63\">",
"      Verlander JW, Madsen KM, Low PS, et al. Immunocytochemical localization of band 3 protein in the rat collecting duct. Am J Physiol 1988; 255:F115.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/64\">",
"      Kempson SA. Effect of metabolic acidosis on renal brushborder membrane adaptation to low phosphorus diet. Kidney Int 1982; 22:225.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/65\">",
"      Murer H. Homer Smith Award. Cellular mechanisms in proximal tubular Pi reabsorption: some answers and more questions. J Am Soc Nephrol 1992; 2:1649.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/66\">",
"      Busch A, Waldegger S, Herzer T, et al. Electrophysiological analysis of Na+/Pi cotransport mediated by a transporter cloned from rat kidney and expressed in Xenopus oocytes. Proc Natl Acad Sci U S A 1994; 91:8205.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/67\">",
"      Quamme GA. Effect of pH on Na(+)-dependent phosphate transport in renal outer cortical and outer medullary BBMV. Am J Physiol 1990; 258:F356.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/68\">",
"      Owen OE, Licht JH, Sapir DG. Renal function and effects of partial rehydration during diabetic ketoacidosis. Diabetes 1981; 30:510.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/69\">",
"      Knepper MA. NH4+ transport in the kidney. Kidney Int Suppl 1991; 33:S95.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/70\">",
"      DuBose TD Jr, Good DW, Hamm LL, Wall SM. Ammonium transport in the kidney: new physiological concepts and their clinical implications. J Am Soc Nephrol 1991; 1:1193.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/71\">",
"      Schoolwerth AC. Regulation of renal ammoniagenesis in metabolic acidosis. Kidney Int 1991; 40:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/72\">",
"      Wright PA, Knepper MA. Glutamate dehydrogenase activities in microdissected rat nephron segments: effects of acid-base loading. Am J Physiol 1990; 259:F53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/73\">",
"      Good DW, Burg MB. Ammonia production by individual segments of the rat nephron. J Clin Invest 1984; 73:602.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/74\">",
"      Buerkert J, Martin D, Trigg D. Segmental analysis of the renal tubule in buffer production and net acid formation. Am J Physiol 1983; 244:F442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/75\">",
"      Preisig PA, Alpern RJ. Pathways for apical and basolateral membrane NH3 and NH4+ movement in rat proximal tubule. Am J Physiol 1990; 259:F587.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/76\">",
"      Simon EE, Merli C, Herndon J, et al. Effects of barium and 5-(N-ethyl-N-isopropyl)-amiloride on proximal tubule ammonia transport. Am J Physiol 1992; 262:F36.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/77\">",
"      Knepper MA, Packer R, Good DW. Ammonium transport in the kidney. Physiol Rev 1989; 69:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/78\">",
"      Packer RK, Desai SS, Hornbuckle K, Knepper MA. Role of countercurrent multiplication in renal ammonium handling: regulation of medullary ammonium accumulation. J Am Soc Nephrol 1991; 2:77.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/79\">",
"      Garvin JL, Burg MB, Knepper MA. Active NH4+ absorption by the thick ascending limb. Am J Physiol 1988; 255:F57.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/80\">",
"      Halperin ML. How much \"new\" bicarbonate is formed in the distal nephron in the process of net acid excretion? Kidney Int 1989; 35:1277.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/81\">",
"      Kikeri D, Sun A, Zeidel ML, Hebert SC. Cell membranes impermeable to NH3. Nature 1989; 339:478.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/82\">",
"      Good DW. Adaptation of HCO-3 and NH+4 transport in rat MTAL: effects of chronic metabolic acidosis and Na+ intake. Am J Physiol 1990; 258:F1345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/83\">",
"      Flessner MF, Wall SM, Knepper MA. Permeabilities of rat collecting duct segments to NH3 and NH4+. Am J Physiol 1991; 260:F264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/84\">",
"      Tizianello A, Deferrari G, Garibotto G, et al. Renal ammoniagenesis in an early stage of metabolic acidosis in man. J Clin Invest 1982; 69:240.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/85\">",
"      Welbourne TC. Interorgan glutamine flow in metabolic acidosis. Am J Physiol 1987; 253:F1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/86\">",
"      Welbourne T, Weber M, Bank N. The effect of glutamine administration on urinary ammonium excretion in normal subjects and patients with renal disease. J Clin Invest 1972; 51:1852.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/87\">",
"      DiGiovanni SR, Madsen KM, Luther AD, Knepper MA. Dissociation of ammoniagenic enzyme adaptation in rat S1 proximal tubules and ammonium excretion response. Am J Physiol 1994; 267:F407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/88\">",
"      Wright PA, Packer RK, Garcia-Perez A, Knepper MA. Time course of renal glutamate dehydrogenase induction during NH4Cl loading in rats. Am J Physiol 1992; 262:F999.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/89\">",
"      Windus DW, Cohn DE, Klahr S, Hammerman MR. Glutamine transport in renal basolateral vesicles from dogs with metabolic acidosis. Am J Physiol 1984; 246:F78.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/90\">",
"      Windus DW, Klahr S, Hammerman MR. Glutamine transport in basolateral vesicles from dogs with acute respiratory acidosis. Am J Physiol 1984; 247:F403.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/91\">",
"      Simpson DP, Hager SR. Bicarbonate-carbon dioxide buffer system: a determinant of the mitochondrial pH gradient. Am J Physiol 1984; 247:F440.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/92\">",
"      Welbourne TC, Givens G, Joshi S. Renal ammoniagenic response to chronic acid loading: role of glucocorticoids. Am J Physiol 1988; 254:F134.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/93\">",
"      Kinsella J, Cujdik T, Sacktor B. Na+-H+ exchange activity in renal brush border membrane vesicles in response to metabolic acidosis: The role of glucocorticoids. Proc Natl Acad Sci U S A 1984; 81:630.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?12/29/12762/abstract/94\">",
"      CLARKE E, EVANS BM, MACINTYRE I, MILNE MD. Acidosis in experimental electrolyte depletion. Clin Sci (Lond) 1955; 14:421.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 7273 Version 3.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-61.55.141.10-11D65C23BF-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12762=[""].join("\n");
var outline_f12_29_12762=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      RENAL HYDROGEN EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Net acid excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Proximal acidification",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Distal acidification",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      BICARBONATE REABSORPTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Carbonic anhydrase and disequilibrium pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Bicarbonate secretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      TITRATABLE ACIDITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      AMMONIUM EXCRETION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      NH4+ production",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Medullary recycling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      NH3 secretion into the cortical and medullary collecting tubule",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Response to changes in pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Urine pH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/7273\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7273|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?10/62/11245\" title=\"figure 1\">",
"      Acid production and excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?39/51/40765\" title=\"figure 2\">",
"      NI AB values",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?8/8/8335\" title=\"figure 3\">",
"      Mechanism of HCO3 reabsorption",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?37/55/38781\" title=\"figure 4\">",
"      Titratable acid excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?16/18/16686\" title=\"figure 5\">",
"      NH4 excretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?0/24/398\" title=\"figure 6\">",
"      Segmental changes in urine pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?22/29/23006\" title=\"figure 7\">",
"      Proximal tubule segments",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?9/60/10190\" title=\"figure 8\">",
"      Disequilibrium pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?17/31/17917\" title=\"figure 9\">",
"      Distal HCO3 secretion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?21/11/21693\" title=\"figure 10\">",
"      Buffering by phosphate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?2/32/2574\" title=\"figure 11\">",
"      Mechanism of NH4 recycling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?30/62/31725\" title=\"figure 12\">",
"      Loop of Henle transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?19/53/20317\" title=\"figure 13\">",
"      NH4 excretion and urine pH",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?7/46/7917\" title=\"figure 14\">",
"      Acid load and NH4 excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/7273|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?10/26/10667\" title=\"table 1\">",
"      Titratable acid and pH",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?8/61/9173?source=related_link\">",
"      Chapter 10A: Acids and bases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?22/43/23224?source=related_link\">",
"      Chapter 10B: Buffers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/54/10089?source=related_link\">",
"      Chapter 11B: Regulation of renal hydrogen excretion",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?14/14/14568?source=related_link\">",
"      Treatment of metabolic alkalosis",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f12_29_12763="Na balance in cirrhotic ascites";
var content_f12_29_12763=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F53969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F53969&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Estimation of sodium balance in patients with cirrhosis and ascites",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"sublist1_start\">",
"        The following calculations can be used to estimate sodium balance in a patient with ascites and advanced cirrhosis",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Mean serum sodium concentration = ascitic fluid sodium concentration = 130 meq/L",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Daily net positive balance is 78 meq if intake is 88 meq, excretion is close to zero, and nonurinary losses are 10 meq",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Total sodium accumulation over 14 days is 1092 meq (78 x 14)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"sublist1\">",
"        Increase in extracellular fluid volume (most of which will accumulate as ascites) is 8.4 liters (1092 meq &divide; 130 meq/L)",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Thus, if a patient is complying with dietary sodium",
"excretion, an 8.4 liter paracentesis will remove 14 days of accumulated",
"sodium. Paracentesis can be performed less often in compliant patients",
"who still have some urinary sodium excretion.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12763=[""].join("\n");
var outline_f12_29_12763=null;
var title_f12_29_12764="Tips for using compression stockings PI";
var content_f12_29_12764=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PI%2F57705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PI%2F57705&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Tips for using compression stockings",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td>",
"        Here are tips for using compression stockings:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Wash new compression stockings before wearing them to reduce their stiffness and to make them easier to put on.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Put on stockings as early as possible in the morning after you bandage any sores you have because swelling is less in the morning. If you do not put the stockings on early, raise your legs for 20 to 30 minutes before putting the stockings on.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; When putting on stockings, sit on a chair with firm back support (not on the bed).",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Knee-high stockings can be put on using the \"heel-pocket-out method.\" The heel-pocket-out method to put on compression stockings is as follows:",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        1. Turn the leg part of the stocking inside-out down to the heel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        2. Put your foot into the stocking, hold onto the folded edge, and pull the stocking onto your foot and over the heel.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent2\">",
"        3. Gently work the stocking up your leg by turning it right-side out.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Some people find it helpful to wear rubber gloves to put their stockings on. This can make it easier to slide the stockings up the legs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Heavy compression stockings may go on more easily if light silk pantyhose are worn under the compression stockings, or if you first put powder on your legs.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"indent1\">",
"        &bull; Skin moisturizers and treatments that are used to treat open sores can make the stockings dirty and wear them out. Wash the stockings each day after wearing them if possible. Stockings can be washed in cold water by hand. You can also wash them with cold water and a small amount of mild detergent in a washing machine. Hang the stockings up to dry, and do not dry them in a machine. Buying at least two pairs of stockings at a time will let you wear one pair while the other pair is drying.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you have an allergy to rubber (latex), you can buy compression stockings without elastic.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        If you are not able to pull on your stockings, talk with your doctor or nurse. There are different stockings you can use or devices that can help you put on stockings.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12764=[""].join("\n");
var outline_f12_29_12764=null;
var title_f12_29_12765="Protein kinase and phosphatase";
var content_f12_29_12765=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F78694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F78694&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Action of protein kinases",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 389px; height: 194px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Schematic representation of the action of protein kinases. Phosphates are transferred from ATP molecules onto target molecules by protein kinases; these phosphates are then removed by protein phosphatases.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12765=[""].join("\n");
var outline_f12_29_12765=null;
var title_f12_29_12766="Rivaroxaban drug interactions";
var content_f12_29_12766=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F73141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F73141&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Rivaroxaban pharmacokinetic interactions",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <colgroup span=\"4\" width=\"25%\">",
"     </colgroup>",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Selected interacting drugs and drug classes",
"       </td>",
"       <td class=\"subtitle1\">",
"        Effect",
"       </td>",
"       <td class=\"subtitle1\">",
"        Management suggestions",
"       </td>",
"       <td class=\"subtitle1\">",
"        Recommendations found in licensed product information*",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Combined P-gp and strong CYP3A4 inhibitors (eg, boceprevir",
"        <sup>",
"         &bull;",
"        </sup>",
"        , clarithromycin, cobicistat containing coformulations, conivaptan",
"        <sup>",
"         &bull;",
"        </sup>",
"        , delavirdine",
"        <sup>",
"         &bull;",
"        </sup>",
"        ,",
"        <strong>",
"         all",
"        </strong>",
"        HIV protease inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        [eg, ritonavir], imatinib",
"        <sup>",
"         &bull;",
"        </sup>",
"        , itraconazole, ketoconazole, nefazodone",
"        <sup>",
"         &bull;",
"        </sup>",
"        , posaconazole",
"        <sup>",
"         &bull;",
"        </sup>",
"        , telaprevir, telithromycin",
"        <sup>",
"         &bull;",
"        </sup>",
"        , voriconazole",
"        <sup>",
"         &bull;",
"        </sup>",
"        )",
"       </td>",
"       <td>",
"        Increased rivaroxaban concentration (significant effect)",
"       </td>",
"       <td>",
"        <p>",
"         Avoid concurrent use with agents known to strongly inhibit both CYP3A4 and P-gp. Bleeding risk is further increased in patients with renal insufficiency.",
"        </p>",
"        <p>",
"         If co-administration cannot be avoided, there is no specific dose adjustment available. Closely monitor for signs of excessive anticoagulation.",
"        </p>",
"        The efficacy of routine coagulation testing to evaluate the degree of anticoagulation with rivaroxaban is limited and is discussed in the text.",
"       </td>",
"       <td>",
"        <p>",
"         US: Avoid use with combined P-gp and strong CYP3A4 inhibitors (including ketoconazole, itraconazole, ritonavir, conivaptan).",
"        </p>",
"        <p>",
"         CAN: Use with strong inhibitors of both P-gp and CYP3A4 contraindicated (including ketoconazole, itraconazole, voriconazole, posaconazole, or ritonavir).",
"        </p>",
"        EMA, UK: Use with strong inhibitors of both P-gp and CYP3A4 (including ketoconazole, itraconazole, posaconazole, voriconazole, or HIV protease inhibitors",
"        <sup>",
"         &Delta;",
"        </sup>",
"        ) is not recommended.",
"       </td>",
"      </tr>",
"      <tr class=\"divider_bottom\">",
"       <td>",
"        Combined inhibitors of P-gp and/or moderate inhibitors of CYP3A4 (eg, amiodarone, azithromycin, chloramphenicol, cimetidine, erythromycin, cyclosporine, diltiazem, dronedarone, felodipine, fluconazole",
"        <sup>",
"         &bull;",
"        </sup>",
"        , grapefruit and grapefruit juice",
"        <sup>",
"         &loz;",
"        </sup>",
"        , lapatinib, mifepristone, naproxen",
"        <sup>",
"         &bull;",
"        </sup>",
"        , nicardipine, quinidine, ranolazine, tamoxifen, verapamil)",
"       </td>",
"       <td>",
"        Increased rivaroxaban concentration (moderate effect in patients with normal renal function; significant effect in patients having renal insufficiency)",
"       </td>",
"       <td>",
"        <p>",
"         Use with caution; if co-administration cannot be avoided, there is no specific dose adjustment available.",
"        </p>",
"        Avoid concurrent use if possible in patients with renal insufficiency (CrCl 15 to 50 mL/minute).",
"       </td>",
"       <td>",
"        <p>",
"         US: If receiving rivaroxaban for VTE prophylaxis no additional precautions generally required (eg, with clarithromycin or erythromycin). However, caution is advised with combined P-gp and weak or moderate inhibitors of CYP3A4 in patients with renal insufficiency (CrCl 15 to 50 mL/minute).",
"        </p>",
"        <p>",
"         CAN: In general, interactions that inhibit only one elimination pathway (CYP3A4 or P-gp) are not expected to be clinically relevant (eg, erythromycin or grapefruit juice). However, caution is required with fluconazole and clarithromycin.",
"        </p>",
"        EMA, UK: In general, interactions which inhibit only one elimination pathway led to mean increases in exposure of 1.3 to 1.5 fold that are not expected to be clinically relevant (eg, clarithromycin, erythromycin, fluconazole). Avoid coadministration with dronedarone due to limited clinical data.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        <p>",
"         <strong>",
"          Combined P-gp and strong inducers of 3A4",
"         </strong>",
"         (eg, carbamazepine, dexamethasone, rifampin",
"         <sup>",
"          &sect;",
"         </sup>",
"         )",
"        </p>",
"        <p>",
"         <strong>",
"          Inducers of P-gp",
"         </strong>",
"         (eg, doxorubicin, nefazodone, prazosin, St. John's wort, tipranavir, trazodone, vinblastine)",
"        </p>",
"        <strong>",
"         Strong inducers of CYP3A4",
"        </strong>",
"        (eg, aminoglutethimide, barbiturates, bosentan, efavirenz, etravirine, fosphenytoin, nafcillin, nevirapine, oxcarbazepine, pentobarbital, phenobarbital, phenytoin, primidone, rifabutin, rifapentine)",
"       </td>",
"       <td>",
"        Decreased rivaroxaban concentration (significant effect)",
"       </td>",
"       <td>",
"        <p>",
"         Avoid concurrent use with agents known to strongly induce CYP3A4 and/or P-gp.",
"        </p>",
"        Effect on rivaroxaban may persist for several weeks following discontinuation of a strong inducer of P-gp and/or 3A4.",
"       </td>",
"       <td>",
"        <p>",
"         US: Avoid concomitant use of rivaroxaban with strong inducers of CYP3A4 and P-gp (including rifampin",
"         <sup>",
"          &sect;",
"         </sup>",
"         , carbamazepine, phenytoin, St John's wort).",
"        </p>",
"        <p>",
"         CAN: Avoid strong CYP3A4 inducers (including rifampin",
"         <sup>",
"          &sect;",
"         </sup>",
"         , phenytoin, carbamazepine, phenobarbital, St. John's wort).",
"        </p>",
"        UK, EMA: Use caution with strong inducers of CYP3A4 (rifampin",
"        <sup>",
"         &sect;",
"        </sup>",
"        , phenytoin, carbamazepine, phenobarbital, St John's wort).",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Interaction data and recommendations refer to systemic drug forms. For additional information see Lexi-Interact drug interactions program provided with UpToDate.",
"    <div class=\"footnotes\">",
"     CYP3A4: cytochrome P450 3A4; P-gp: P-glycoprotein efflux transporters; VTE: venous thromboembolism; CrCl: creatinine clearance; US: United States Prescribing Information; CAN: Canadian Product Monograph; EMA: European Medicines Agency Summary of Product Characteristics; UK: United Kingdom Summary of Product Characteristics.",
"     <br/>",
"     *",
"     <strong>",
"      Drug interactions, management recommendations, and contraindicated drug combinations listed in licensed product information vary by country. Consult official product information for details before using this agent.",
"     </strong>",
"     <br/>",
"     <span class=\"bullet\">",
"      &bull;",
"     </span>",
"     Limited or conflicting data concerning relevance of P-gp inhibition.",
"     <br/>",
"     &Delta; Atazanavir, darunavir, fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir, and tipranavir.",
"     <br/>",
"     <span class=\"lozenge\">",
"      &loz;",
"     </span>",
"     Avoidance of grapefruit and grapefruit juice in large quantities advised due to lack of predictability of its effect.",
"     <br/>",
"     &sect; Rifampicin is international nonproprietary (generic) name.",
"    </div>",
"    <div class=\"reference\">",
"     Data accessed September 28, 2012:",
"     <br/>",
"     <ol>",
"      <li>",
"       Xarelto (rivaroxaban) US prescribing information revised December 2011 available at:",
"       <a href=\"file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610\" target=\"_blank\">",
"        file://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=10db92f9-2300-4a80-836b-673e1ae91610",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       Canada Product Monograph Xarelto rivaroxaban revision July 18, 2012 available at:",
"       <a href=\"file://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng\" target=\"_blank\">",
"        file://webprod3.hc-sc.gc.ca/dpd-bdpp/dispatch-repartition.do?lang=eng",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       European Medicines Agency Summary of Product Characteristics Xarelto (rivaroxaban) updated January 20, 2012 available at:",
"       <a href=\"file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&amp;mid=WC0b01ac058001d124\" target=\"_blank\">",
"        file://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/000944/human_med_001155.jsp&amp;mid=WC0b01ac058001d124",
"       </a>",
"       .",
"      </li>",
"      <li>",
"       UK Summary of Product Characteristics Xarelto updated on eMC May, 2012:",
"       <a href=\"file://www.medicines.org.uk/EMC/medicine/21265/SPC/Xarelto+10+mg+film-coated+tablets\" target=\"_blank\">",
"        file://www.medicines.org.uk/EMC/medicine/21265/SPC/Xarelto+10+mg+film-coated+tablets",
"       </a>",
"       .",
"      </li>",
"     </ol>",
"     <br/>",
"     Additional data from:",
"     <br/>",
"     <ol>",
"      <li>",
"       Lexicomp online Lexi-Interact Copyright &copy; 1978-2013 by Lexicomp, Inc. All rights reserved.",
"      </li>",
"      <li>",
"       Hansten PD, Horn JR. Top 100 drug interactions: guide to patient management, 12th ed, H&amp;H Publications, 2012.",
"      </li>",
"      <li>",
"       Kwong LM, Tong LM. Drug interactions with rivaroxaban following total joint replacement surgery; Ann Pharmacother 2012; 46:1232.",
"      </li>",
"     </ol>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12766=[""].join("\n");
var outline_f12_29_12766=null;
var title_f12_29_12767="Omphalocele 3D ultrasound";
var content_f12_29_12767=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F62449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F62449&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Omphalocele 3D ultrasound",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 286px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    This is a 3-dimensional ultrasound examination of a fetus with an omphalocele at 15 weeks gestation. The omphalocele sac is seen anterior to the fetal body. Note the smoothness of the outer contour of the sac.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Ana Monteagudo, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f12_29_12767=[""].join("\n");
var outline_f12_29_12767=null;
